fludarabine has been researched along with Leukemia, Lymphocytic, Chronic, B-Cell in 1136 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.09) | 18.7374 |
| 1990's | 219 (19.28) | 18.2507 |
| 2000's | 454 (39.96) | 29.6817 |
| 2010's | 414 (36.44) | 24.3611 |
| 2020's | 48 (4.23) | 2.80 |
| Authors | Studies |
|---|---|
| Castro, JE; Choi, MY; Molinski, TF; Stout, EP | 1 |
| Aboraia, AS; Brancale, A; DeLuca, HF; Ferla, S; Ochalek, JT; Pepper, CJ; Simons, C; Zhu, J | 1 |
| Brunhofer-Bolzer, G; Dyckmanns, N; Erker, T; Freund, P; Jäger, U; Knaus, HA; Le, T; Pausz, C; Vanura, K | 1 |
| Adams, JM; Anderson, MA; Blombery, P; Carney, DA; Chen, X; Dengler, MA; Handunnetti, SM; Huang, DCS; Lew, TE; Lin, VS; Nguyen, T; Panigrahi, A; Roberts, AW; Seymour, JF; Tam, CS; Thompson, ER; Wei, AH; Westerman, DA | 1 |
| Alcoceba, M; Andreu, MÁ; Anguita, E; Collado, R; Córdoba, R; de la Serna, J; de Oteyza, JP; Deben, G; Fernández, MC; Fernández-Cuevas, B; Fernández-Zarzoso, M; García-Malo, MD; García-Marco, JA; Garcia-Vela, JA; Gómez, S; González, M; González-Barca, E; González-Rincón, J; López-Jiménez, J; Navarro-Matilla, B; Nova-Gurumeta, S; Paz-Arias, R; Peñalver, FJ; Pérez-Persona, E; Pérez-Sanz, N; Recasens, V; Ruíz-Guinaldo, MÁ; Sánchez-Beato, M; Yáñez, L | 1 |
| Bağrıaçık, EÜ; Gökçen, S; Kayhan, H; Yağcı, M | 1 |
| Armand, P; Arnason, J; Brown, JR; Davids, MS; Fernandes, SM; Fisher, DC; Gadi, D; Griffith, A; Lederer, JA; Lee, B; Lehmberg, TZ; Machado, JH; Martindale, SP; Odejide, O; Rai, V; Thrash, E; Tyekucheva, S; Vartanov, A; Wang, Z | 1 |
| Allsup, DJ; Bloor, A; Cairns, D; Clifford, R; Craig, Z; Gattei, V; Hillmen, P; Hockaday, A; Howard, D; Munir, T; Pepper, C; Rawstron, A; Robbe, P; Schuh, A; Soe, Z; Zucchetto, A | 1 |
| Ling, Y; Qi, Y; Xu, W; Xu, X; Yang, S; Ye, H; Zhao, Y | 1 |
| Aviv, A; Bairey, O; Bomben, R; Braester, A; Bronstein, Y; Chiarenza, A; Coscia, M; Cuneo, A; Del Poeta, G; Del Principe, MI; Fineman, R; Foà, R; Gaidano, G; Gattei, V; Gentile, M; Goldschmidt, N; Gutwein, O; Herishanu, Y; Laurenti, L; Levi, S; Loseto, G; Mauro, FR; Morabito, F; Murru, R; Neri, A; Olivieri, J; Perry, C; Pietrasanta, D; Reda, G; Rossi, D; Ruchlemer, R; Shvidel, L; Sportoletti, P; Tadmor, T; Trentin, L; Varettoni, M; Visentin, A; Ziv-Baran, T; Zucchetto, A | 1 |
| Böttcher, S; Decker, T; Eichhorst, B; Fink, AM; Fischer, K; Hallek, M; Heinisch, K; Holmes, EE; Kreuzer, KA; Kutsch, N; Müller-Hagen, S; Ritgen, M; Robrecht, S; Schüler, G; Stilgenbauer, S; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Do Nascimento, J; Domingo-Domenech, E; Encuentra, M; Ferrá, C; Gallardo, D; González-Barca, E; López, P; Oliveira, AC; Ribera, JM; Rodriguez-Luaces, M; Roncero, JM; Sarrá, J; Sureda, A | 1 |
| Bahlo, J; Baumann, M; Brüggemann, M; Christiansen, I; da Cunha-Bang, C; De Silva, N; Eichhorst, B; Enggaard, L; Fink, AM; Fischer, K; Frederiksen, H; Fürstenau, M; Gaska, T; Geisler, C; Goede, J; Gregor, M; Hallek, M; Hebart, H; Hoogendoorn, M; Illmer, T; Jäger, U; Janssens, A; Juliusson, G; Kater, AP; Koene, H; Kreuzer, KA; Levin, MD; Leys, MBL; Lindström, V; Lotfi, K; Niemann, CU; Nösslinger, T; Poulsen, CB; Regelink, JC; Ritgen, M; Robrecht, S; Schneider, C; Schöttker, B; Simon, F; Staber, PB; Stilgenbauer, S; Tadmor, T; Tausch, E; Thornton, P; van der Klift, M; van Oers, M; von Tresckow, J; Wendtner, CM; Widmer, A; Zhang, C | 1 |
| Dai, L; Ding, C; Fan, L; Jiang, R; Li, J; Miao, Y; Qin, S; Qiu, J; Qiu, T; Sha, Y; Shen, H; Wu, W; Wu, Y; Xia, Y; Xu, W; Yang, Y; Zhu, H | 1 |
| Bazinet, A; Keating, MJ; O'Brien, SM; Peterson, CB; Plunkett, W; Saha, S; Tam, CS; Thompson, PA; Wierda, WG | 1 |
| Boubaya, M; Bravetti, C; Chapiro, E; Davi, F; Dehgane, L; Doualle, C; Garnier, D; Grange, B; Jondreville, L; Lerner, LK; Nguyen-Khac, F; Roos-Weil, D; Smagghe, L; Susin, SA; Tournilhac, O | 1 |
| Stirrups, R | 1 |
| Bijou, F; Durrieu, F; Filleron, T; Gauthier, M; Martin, E; Obéric, L; Peres, M; Quillet Mary, A; Vergez, F; Ysebaert, L | 1 |
| Bosch, F; Böttcher, S; Cantin, G; Cortelezzi, A; Foà, R; Gresko, E; Knauf, W; Leblond, V; Merot, JL; Robson, S; Stilgenbauer, S; Tausch, E; Tiab, M; Trunzer, K; Turgut, M; Zaritskey, A | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Hether, T; Jain, N; Jorgensen, JL; Keating, MJ; O'Brien, SM; Peterson, C; Srivastava, J; Strati, P; Thompson, PA; Wierda, WG | 1 |
| Smolej, L | 2 |
| Abrams, ZB; Abruzzo, LV; Bahlo, J; Barron, LL; Benner, A; Bloehdorn, J; Bondaruk, JE; Coombes, KR; Czerniak, BA; Ferrajoli, A; Fischer, K; Hallek, M; Herling, CD; Keating, MJ; Majewski, T; Oakes, CC; Stilgenbauer, S | 1 |
| Shen, YF; Sun, HL; Zhou, X; Zou, ZJ | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Danilewicz, M; Franiak-Pietryga, I; Jander, M; Kuncman, W; Sikorska, H; Ziemba, B | 1 |
| Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R | 1 |
| Anagnostopoulos, A; Bhoi, S; Duran-Ferrer, M; Ghia, P; Kollia, P; Ljungström, V; Malousi, A; Mansouri, L; Martin-Subero, JI; Moysiadis, T; Oscier, D; Papakonstantinou, N; Plevova, K; Pospisilova, S; Pott, C; Queirós, AC; Ritgen, M; Rosenquist, R; Stamatopoulos, K; Stavroyianni, N; Trentin, L; Tsagiopoulou, M | 1 |
| Govindaraju, S; Grosicki, S; Kryachok, I; Lewerin, C; Mazur, G; Middeke, JM; Miklos, U; Montillo, M; Österborg, A; Rekhtman, G; Stefanelli, T; Steurer, M; Strugov, V; Vincent, G | 1 |
| Antoniou, P; Blakemore, SJ; Bryant, D; Carr, L; Catovsky, D; Chan, J; Clifford, R; Colins, A; Cragg, MS; Davis, Z; Else, M; Forster, J; Kadalyayil, L; Larrayoz, M; McCarthy, H; Morilla, R; Oscier, DG; Parker, H; Robbe, P; Rose-Zerilli, MJJ; Schuh, A; Speight, G; Stankovic, T; Stec-Dziedzic, E; Steele, AJ; Strefford, JC; Vavoulis, D; Walewska, RJ | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Busch, R; Cazin, B; Cymbalista, F; Döhner, H; Dreyfus, B; Eichhorst, B; Fink, AM; Fischer, K; Groß-Ophoff-Müller, C; Hallek, M; Herling, CD; Hoechstetter, MA; Ibach, S; Kaiser, F; Kneba, M; Langerbeins, P; Leblond, V; Leprêtre, S; Letestu, R; Levy, V; Porcher, R; Robrecht, S; Stilgenbauer, S; Wentner, CM | 1 |
| Banerjee, H; Blonski, J; Govind Babu, K; Grosicki, S; Homenda, W; Kriachok, I; Kłoczko, J; Lech-Maranda, E; Litvinskaya, E; Loscertales, J; Rekhtman, G; Robak, T; Rybka, J; Stefanelli, T; Vincent, G | 1 |
| Al Tourah, AJ; Bruyere, H; Dueck, G; Galbraith, P; Gerrie, AS; Hardy, E; Hrynchak, M; Huang, SJ; Noble, MC; Ramadan, KM; Sehn, L; Toze, CL; Tsang, P; Tucker, T; Young, S | 1 |
| Chevassut, T; Milne, K; Sturrock, B | 1 |
| Gordiienko, I; Ivanivska, T; Shcherbina, V; Shlapatska, L; Sidorenko, S | 1 |
| Suzumiya, J; Takizawa, J | 1 |
| Bloehdorn, J; Döhner, H; Lichter, P; Mertens, D; Stilgenbauer, S; Yosifov, DY | 1 |
| Bernardi, R; Bongiovanni, L; Coltella, N; Ghia, P; Magliulo, D; Ponzoni, M; Scarfò, L; Valsecchi, R | 1 |
| Allain, EP; Bat, V; Caron, P; Demirtas, D; Droit, A; Guillemette, C; Hubmann, R; Jäger, U; Joly-Beauparlant, C; Labriet, A; Le, T; Lévesque, E; Rouleau, M; Schnabl, S; Shehata, M; Staber, PB; Tremblay, S; Turcotte, V; Vaillancourt, J; Vanura, K; Villeneuve, L | 1 |
| Cheah, R; Dendle, C; Gregory, G; Mohan, B; Tey, A | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Danilewicz, M; Franiak-Pietryga, I; Jander, M; Kuncman, W; Lewkowicz, P; Ostrowska, K; Sikorska, H; Ziemba, B | 1 |
| Ahn, IE; Fleisher, T; Gaglione, E; Lotter, J; Maric, I; Mu, R; Pittaluga, S; Pleyer, C; Rampertaap, S; Rosenzweig, S; Soto, S; Stetler-Stevenson, M; Sun, C; Superata, J; Tian, X; Wiestner, A; Yuan, CM | 1 |
| Armand, P; Arnason, J; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hanna, J; Lee, B; McDonough, M; Montegaard, J; Odejide, O; Tyekucheva, S | 1 |
| An, Y; Gao, X; Jingquan, G; Xiao, K; Xie, W; Yang, L | 1 |
| Aanei, C; Baseggio, L; Béné, MC; Boubaya, M; Campos, L; Cartron, G; Chatelain, B; Cymbalista, F; Dahmani, A; Dartigeas, C; Debliquis, A; Delepine, R; Drénou, B; Feugier, P; Jacob, MC; Katsahian, S; Le Garff-Tavernier, M; Leblond, V; Legac, E; Leprêtre, S; Letestu, R; Lévy, V; Lhoumeau, AC; Quiney, C; Robillard, N; Rouillé, V; Ticchioni, M; Van Den Neste, E; Vaudaux, S | 1 |
| Bar, M; Bezerra, ED; Cassaday, RD; Chapuis, AG; Chou, CK; Cowan, AJ; Fiorenza, S; Gauthier, J; Green, DJ; Hawkins, RM; Hirayama, AV; Jamieson, AW; Kiem, HP; Kimble, EL; Maloney, DG; Milano, F; Pender, BS; Phi, TD; Riddell, SR; Shadman, M; Sheih, A; Steinmetz, RN; Till, BG; Turtle, CJ; Vakil, A | 1 |
| Cao, L; Du, XY; Fan, L; Li, JY; Wang, F; Wang, L; Xu, W; Zhu, HY | 1 |
| Bejar, J; Garty-Ofir, M; Kreiniz, N; Polliack, A; Tadmor, T | 1 |
| Albano, F; Angelucci, E; Battistini, R; Coscia, M; Cuneo, A; De Propris, MS; Del Giudice, I; Del Poeta, G; Della Starza, I; Foà, R; Gozzetti, A; Guarini, AR; Ilariucci, F; Liberati, AM; Mauro, FR; Molica, S; Musolino, C; Nanni, M; Neri, A; Piciocchi, A; Pietrasanta, D; Raponi, S; Re, F; Reda, G; Soddu, S; Tedeschi, A; Vignetti, M; Zaja, F | 1 |
| Fukuhara, S; Izutsu, K; Kinoshita, T; Ohashi, Y; Suzumiya, J; Takizawa, J; Tobinai, K; Yamamoto, G | 1 |
| Moreno, C | 1 |
| Andersen, MA; da Cunha-Bang, C; Frederiksen, H; Grønbaek, K; Hjalgrim, H; Niemann, CU; Rostgaard, K; Rotbain, EC | 1 |
| Chamo, M; Gazit, R; Goldstein, O; Ilic, S; Keinan, N; Scharff, Y | 1 |
| Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M | 1 |
| Ayala, A; Borthakur, G; Bose, P; Burger, J; Estrov, Z; Ferrajoli, A; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Lopez, W; O'Brien, S; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Takahashi, K; Thompson, P; Wang, S; Wang, W; Wang, X; Wierda, WG | 1 |
| Allsup, D; Bloor, A; Emmerson, J; Hillmen, P; Hockaday, A; Howard, D; Munir, T; Nathwani, A; Oughton, JB; Paneesha, S; Phillips, D; Rawstron, A; Turner, D | 1 |
| Allsup, D; Baird, DM; Bomben, R; Bulian, P; Catovsky, D; Fegan, CD; Gattei, V; Hillmen, P; Hockaday, A; Norris, K; Ow, PL; Pepper, AGS; Pepper, C; Polesel, J; Rawstron, A; Soe, Z; Tissino, E; Zucchetto, A | 1 |
| Illés, Á; Szász, R; Telek, B | 1 |
| Amini, R; Ashofteh, N; Baazm, M; Karami, H; Molaee, N | 1 |
| Barr, PM; Barrientos, JC; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Kay, NE; Leis, JF; Lesnick, CE; Litzow, MR; Mato, AR; Mullane, MP; O'Brien, S; Paietta, EM; Shanafelt, TD; Singh, AK; Stone, R; Tallman, MS; Tschumper, RC; Wang, XV; Zhang, CC | 1 |
| Becker, U; Miguel, LS; Paquete, AT; Pereira, C; Pinto, CG | 1 |
| Go, RS; Kay, NE; Winters, JL | 1 |
| Baculea, S; Cote, S; Diels, J; Van Sanden, S | 1 |
| Chauffaille, MLLF; Fonseca, ARBMD; Goncalves, MV; Guedes, NR; Lacerda, MP; Pereira, AD; Rodrigues, CA; Yamakawa, PE; Yamamoto, M | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Jander, M; Maciejewski, H; Robak, T; Treliński, J; Voit, B; Ziemba, B | 1 |
| Abenhardt, W; Bahlo, J; Bentz, M; Blau, I; Bühler, A; Busch, R; Döhner, H; Eckart, MJ; Eichhorst, B; Emmerich, B; Fischer, K; Freier, W; Fuss, H; Goebeler, M; Hallek, M; Hartmann, F; Hoechstetter, MA; Hopfinger, G; Hurtz, HJ; Jäger, U; Müller, L; Schimke, H; Stilgenbauer, S; Vehling-Kaiser, U; Wendtner, CM; Winkler, D | 1 |
| Appleby, N; Cahill, MR; Crotty, G; Enright, H; Hayat, A; Hennessy, B; Hodgson, A; Kelly, J; Leahy, M; O'Brien, D; O'Dwyer, M; O'Leary, H; Parker, I; Quinn, FM; Scott, K; Smyth, L; Vandenberghe, EA | 1 |
| Brown, JR; Chai-Adisaksopha, C | 1 |
| Aurran-Schleinitz, T; Benchikh, R; Cymbalista, F; Defoi, Y; Feugier, P; Godmer, P; Guillermin, Y; Herbaux, C; Jardel, H; Laribi, K; Leblond, V; Leprêtre, S; Letestu, R; Lévy, V; Michallet, AS; Orsini, F; Pegourié, B; Salles, G; Subtil, F; Vallais, F; Vaudaux, S | 1 |
| Brown, JR; Kay, NE | 1 |
| Hawkes, EA; Opat, S | 1 |
| Gladstone, DE; Gocke, CD | 1 |
| Baculea, S; Côté, S; Diels, J; Dorman, E; Fahrbach, K; Sanden, SV; Xu, Y | 1 |
| Albano, F; Chiurazzi, F; Cimmino, C; Fiume, G; Frieri, C; Golino, G; Iaccino, E; Mallardo, M; Mimmi, S; Pastore, A; Pisano, A; Quinto, I; Scala, G; Vecchio, E | 1 |
| Li, H; Li, ZJ; Liu, HM; Lü, R; Qiu, LG; Wang, TY; Xiong, WJ; Yi, SH; Yu, Z | 1 |
| Cherry, MA; Crew, RM; Kim, YM; Li, S; Liu, G; Liu, Y; Lu, X; Wang, X; Wen, Z | 1 |
| Aurran, T; Banos, A; Cartron, G; Dartigeas, C; de Guibert, S; Delmer, A; Dupuis, J; Ferrant, E; Feugier, P; Gagez, AL; Guiu, B; Leblond, V; Leprêtre, S; Letestu, R; Letuan, P; Mahé, B; Orsini-Piocelle, F; Rouillé, V; Ternant, D; Tournilhac, O; Tout, M; Villemagne, B | 1 |
| Abuelgasim, KA; Al Atwi, N; Al Balwi, M; Almughairi, A; Alshieban, S; Alsubaie, M; Rehan, H | 1 |
| Aurran, T; Béné, MC; Casasnovas, O; Cazin, B; Chevret, S; Corront, B; Cymbalista, F; Delépine, R; Delmer, A; Feugier, P; Leblond, V; Leprêtre, S; Letestu, R; Mahé, B; Maisonneuve, H; Nguyen-Khac, F; Ross-Weil, D; Royer, B; Tournilhac, O; Van Den Neste, E; Vaudaux, S | 1 |
| Bancaud, A; Bradbury, A; Cazaux, C; Filleron, T; Fournié, JJ; Gilhodes, J; Grgurevic, S; Hoffmann, JS; Laurent, G; Montilla-Perez, P; Pelofy, S; Queille, S; Quillet-Mary, A; Récher, C; Ysebaert, L | 1 |
| Borthakur, G; Burger, JA; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Jabbour, E; Jain, N; Jorgensen, J; Kadia, TM; Keating, MJ; O'Brien, SM; Peterson, CB; Strati, P; Thompson, PA; Wierda, WG | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Girschikofsky, M; Greil, R; Hartmann, TN; Lang, A; Melchardt, T; Petzer, A; Pleyer, L; Steurer, M; Thaler, J; Voskova, D; Weiss, L; Zaborsky, N | 1 |
| Tam, CS; Thompson, PA | 1 |
| Arad, A; Aviv, A; Bairey, O; Braester, A; Fineman, R; Goldschmidt, N; Greenbaum, U; Herishanu, Y; Joffe, E; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T | 1 |
| Aktan, M; Bosch, F; Dartigeas, C; Ferra Coll, CM; Foà, R; Gresko, E; Kisro, J; Leblond, V; Merot, JL; Montillo, M; Raposo, J; Robson, S; Stilgenbauer, S | 1 |
| Arigoni, M; Benes, V; Brychtova, Y; Calogero, RA; Cerna, K; Chochola, V; Doubek, M; Mayer, J; Mraz, M; Musilova, K; Oppelt, J; Pavlasova, G; Pospisilova, S; Radova, L; Seda, V; Trbusek, M | 1 |
| Arroyo, DS; Bussi, C; Heller, V; Iribarren, P; Rodriguez, CM; Sastre, D; Slavutsky, I; Stanganelli, C | 1 |
| Crispino, JD; Fu, C; Gong, Y; Marinaccio, C; Shi, H; Shi, X; Sun, Z; Wan, Y; Wang, Z; Xu, K | 1 |
| Andersson, PO; Asklid, A; Bjellvi, J; Hansson, L; Johansson, H; Karlsson, C; Karlsson, K; Kimby, E; Klintman, J; Lauri, B; Mattsson, M; Norin, S; Österborg, A; Sandstedt, AB; Strandberg, M; Sylvan, SE; Tolvgård, S | 1 |
| Jain, N | 1 |
| Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; McIver, T; Morariu-Zamfir, R; O'Brien, S; Pagel, JM | 1 |
| Baird, DM; Fegan, CD; Hillmen, P; Hills, R; Norris, K; Pepper, C; Rawstron, A | 1 |
| Li, Y; Wang, X; Xu, Y; Zhang, Y; Zhou, X | 1 |
| Aviv, A; Bairey, O; Braester, A; Fineman, R; Herishanu, Y; Levi, I; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T; Yuklea, M | 1 |
| Araujo, C; Banos, A; Compaci, G; Despas, F; Larcher, M; Laurent, G; Oberic, L; Sahnes, L; Sommet, A; Ysebaert, L | 1 |
| Antic, D; Dencic-Fekete, M; Djurasinovic, V; Karan-Djurasevic, T; Kostic, T; Marjanovic, I; Mihaljevic, B; Pavlovic, S; Tosic, N; Vukovic, V | 1 |
| Ariznavarreta, GD; Carbonell, F; Champ, D; Costa, MAA; De La Serna Torroba, J; De Marcos, NS; De Oteyza, JP; De Paz Arias, R; Díaz, MG; Fernández, IP; Ferrer, S; García-Marco, JA; García-Vela, JA; González-Barca, E; Guinaldo, MAR; Jarque, I; Jiménez, JL; Llanos, EB; Malo, MDG; Martin, EMD; Martinez, RM; Parraga, FJP; Persona, EP; Ramírez, MJ; Recasens, V; Suarez, JG; Tatay, AC; Valle, MDCF; Yañez, L; Zarzoso, MF | 1 |
| Brychtova, Y; Brzobohata, A; Doubek, M; Mayer, J; Mraz, M; Panovska, A; Pavlova, S; Pospisilova, S; Skuhrova Francova, H; Spunarova, M; Tom, N; Trbusek, M | 1 |
| Wierda, WG | 1 |
| Wendtner, CM | 1 |
| Chen, B; Fang, Q; He, Z; Li, P; Ma, D; Ren, M; Wang, J; Zhe, N; Zhong, Q; Zhou, Z | 1 |
| Burgess, M; Cheung, C; Gill, D; McMillan, NA; Mollee, P; Saunders, NA; Tate, C | 1 |
| Barr, PM; Barrientos, J; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Jelinek, DF; Kay, NE; Leis, JF; Little, RF; Litzow, M; Mato, AR; Mullane, MP; O'Brien, S; Shanafelt, TD; Singh, AK; Stone, RM; Tallman, M; Wang, XV; Zhang, CC | 1 |
| Facco, M; Frezzato, F; Gurrieri, C; Imbergamo, S; Martini, V; Pagnin, E; Piazza, F; Pravato, S; Raggi, F; Scomazzon, E; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A | 1 |
| Azoulay, E; Darmon, M; Epelboin, L; Levy, V; Malphettes, M; Schnell, D; Vincent, F; Xhaard, A | 1 |
| Schmutz, JL; Trechot, P | 1 |
| Bogusz, J; Cebula-Obrzut, B; Majchrzak, A; Mędra, A; Robak, T; Smolewski, P | 1 |
| Fahrmann, JF; Hardman, WE | 1 |
| Brychtová, Y; Doubek, M; Lindtnerová, M; Lysák, D; Malčíková, J; Mayer, J; Motyčková, M; Panovská, A; Pospíšilová, Š; Šimkovič, M; Smolej, L; Trbušek, M; Vodárek, P | 1 |
| Fan, L; Fang, C; Li, JY; Liu, L; Xu, W; Zhang, LN; Zhu, HJ; Zou, ZJ | 1 |
| Qin, Q; Xie, Z; Zhu, Y | 1 |
| Bertoni, F; Cavalli, F; Lobetti-Bodoni, C; Stussi, G; Zucca, E | 1 |
| Bahlo, J; Böttcher, S; Busch, R; Cramer, P; Döhner, H; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Goede, V; Hallek, M; Kneba, M; Langerbeins, P; Mayer, J; Pflug, N; Schubert, F; Stilgenbauer, S; Wendtner, CM | 1 |
| Almasan, A; Hill, BT; Kalaycio, M; Mazumder, S; Sharma, A; Singh, K | 1 |
| Li, F; Li, ZJ; Qi, JY; Qiu, LG; Xing, LJ; Xu, Y; Yi, SH; Yu, Z; Zhao, YZ | 1 |
| Beum, PV; Lee, E; Lindorfer, MA; Marti, G; Mo, CC; Njuguna, N; Taylor, RP; Vire, B; Wiestner, A; Wilson, WH | 1 |
| Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Kotkowska, A; Robak, T; Rogalińska, M; Smolewski, P; Wawrzyniak, E; Żołnierczyk, JD | 1 |
| Kalaycio, M; Lukenbill, J | 1 |
| Böttcher, S; Bühler, A; Busch, R; Döhner, H; Eichhorst, B; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, M; Hensel, M; Hopfinger, G; Kneba, M; Mayer, J; Pflug, N; Ritgen, M; Staib, P; Stilgenbauer, S; Wendtner, CM; Wenger, M; Winkler, D; Zenz, T | 1 |
| Jaskova, Z; Navrkalova, V; Sebejova, L; Trbusek, M; Zemanova, J | 1 |
| Faderl, S; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Strati, P; Wierda, W | 1 |
| Badoux, X; Jones, JA; Kantarjian, H; Keating, MJ; Kipps, TJ; O'Brien, S; Plunkett, W; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Bühler, A; Busch, R; Cazzola, M; Döhner, H; Döhner, K; Edelmann, J; Hallek, M; Kless, S; Mack, S; Mertens, D; Paschka, P; Rossi, M; Schnaiter, A; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Burke, RT; Druker, BJ; Loriaux, MM; Prins, RC; Spurgeon, SE; Tyner, JW | 1 |
| Burger, J; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Strati, P; Tam, C; Wierda, W | 1 |
| Agrwal, N; Blair, JE; Carey, EJ; De Petris, G; Kusne, S; Ronan, BA; Seville, MT; Vikram, HR | 1 |
| Catovsky, D; Dearden, CE; Else, M; Hillmen, P; Richards, S | 1 |
| Gibson, SB; Graham, BA; Ishdorj, G; Johnston, JB; Yoon, JY | 1 |
| Bouvet, E; Cazin, B; Coiffier, B; Laurent, G; Michallet, AS; Mosser, L; Oberic, L; Salles, G; Schlaifer, D; Ysebaert, L | 1 |
| Abella, E; Abrisqueta, P; Bobillo, S; Bosch, F; Calvo, X; Carbonell, F; Constants, M; Delgado, J; Escoda, L; Ferrà, C; Ferrer, S; García-Marco, JA; González, M; González, Y; González-Barca, E; Jarque, I; Montoro, JB; Montserrat, E; Monzó, E; Muntañola, A; Terol, MJ; Villamor, N | 1 |
| Carr, DF; Catovsky, D; Cox, TF; Eccles, R; Else, M; Gardiner, LJ; Gonzalez de Castro, D; Johnson, GG; Lin, K; Lloyd, B; Oates, M; Oscier, DG; Pettitt, AR; Pirmohamed, M; Sibson, DR; Strefford, JC | 1 |
| Caimi, P; Habecker, B; Hill, BT; Kalaycio, M; Kindwall-Keller, T | 1 |
| Jindra, P; Lysák, D | 1 |
| Bojarska-Junak, A; Chocholska, S; Dmoszyńska, A; Hus, I; Roliński, J; Tomczak, W; Woś, J | 1 |
| Eketorp Sylvan, S; Hansson, L; Karlsson, C; Lundin, J; Norin, S; Osterborg, A | 1 |
| Beckers, MM; Daenen, S; Doorduijn, JK; Doreen Te Raa, G; Eldering, E; Kater, AP; Lankheet, NA; Liu, RD; Luijks, DM; Slinger, E; Spiering, M; Tonino, SH; van Oers, MH | 1 |
| Amital, H; Davidson, T; Kneller, A; Schiby, G; Twig, G; Yaniv, G; Zavdy, O | 1 |
| Barth, MJ; Czuczman, MS | 1 |
| Autore, F; D'arena, G; De Padua, L; Efremov, DG; Falcucci, P; Innocenti, I; Laurenti, L; Marietti, S; Piccirillo, N; Sica, S; Vannata, B; Za, T | 1 |
| Albano, F; Angrilli, F; Brugiatelli, M; Carella, AM; Chiarenza, A; Chiaretti, S; Cortelezzi, A; Cuneo, A; De Propris, MS; Del Giudice, I; Della Starza, I; Fazi, P; Foà, R; Gentile, G; Guarini, A; Laurenti, L; Marasca, R; Marinelli, M; Mauro, FR; Molica, S; Musolino, C; Nanni, M; Nobile, F; Piciocchi, A; Vignetti, M; Zaja, F | 1 |
| Ahn, KW; Aljurf, MD; Alyea, EP; Arora, M; Brown, JR; Cortes, J; de Lima, M; Gale, RP; Holland, HK; Hsu, JW; Inamoto, Y; Kalaycio, ME; Kamble, RT; Laughlin, MJ; Lewis, ID; Maziarz, RT; Saber, W; Sabloff, M; Seftel, M; Sobecks, RM; Wirk, BM; Zhu, X | 1 |
| Geisler, CH | 1 |
| Streu, E | 2 |
| Dijkstra, FS; Janssen, JJ; Ossenkoppele, GJ; Visser, OJ; Witte, BI; Wondergem, MJ; Zweegman, S | 1 |
| Ambrosetti, A; Attolico, I; Barzan, A; Benedetti, F; Bergui, L; Billio, A; Carlo-Stella, C; Chiarenza, A; Devizzi, L; Di Nicola, M; Di Raimondo, F; Gianni, AM; Gueli, A; Guidetti, A; Intermesoli, T; Magni, M; Matteucci, P; Montanari, M; Mulè, A; Olivieri, A; Parvis, G; Patti, C; Rambaldi, A; Scimè, R; Tarella, C; Trentin, L; Valagussa, P; Viero, P; Viviani, S | 1 |
| Advani, P; Akhtar, D; Chanan-Khan, A; Chitta, K; Colon-Otero, G; Foran, J; Khan, AN; Masood, A; Miller, KC; Paulus, A; Rivera, C; Roy, V | 1 |
| Hafner, J; Kumar, K; Mulligan, S; Ng, K | 1 |
| Abbas, AY; Bradshaw, TD; Brennan, P; Fegan, C; Fischer, PM; Pepper, C; Pratt, G; Shao, H; Walsby, E; Wang, S | 1 |
| Brandberg, Y; Gill, D; Hammerström, J; Hertzberg, M; Johansson, H; Juliusson, G; Jønsson, V; Karlsson, K; Liliemark, J; McLennan, R; Mulligan, SP; Norman, J; Strömberg, M; Sundström, G; Uggla, B; Wallvik, J | 1 |
| Dave, SS; Kulbacki, E; McKinney, MS; Papalas, JA; Wang, E | 1 |
| Chae, YK; Estrov, Z; Jain, P; Keating, MJ; Rozovski, U; Trinh, L; Wang, X; Wierda, WG | 1 |
| Kawakami, T; Kitano, K; Mimura, Y; Nakazawa, H; Nakazawa, K; Nishina, S; Sakai, K; Senoo, Y | 1 |
| Aoki, S | 1 |
| Molica, S | 2 |
| Abrisqueta, P; Bosch, F; Calpe, E; Carabia, J; Carpio, C; Castellví, J; Crespo, M; Palacio, C; Purroy, N | 1 |
| Carey, P; Hurst, E; Jayakody Arachchillage, D; Keenan, F; Menne, T; Moses, S; O'Brien, SG; Wallis, JP | 1 |
| Hoang, KQ; Momin, F; Reyes, C; Satram-Hoang, S; Skettino, S | 1 |
| Burger, J; Challagundla, P; Estrov, Z; Faderl, SH; Ferrajoli, A; Jain, N; Jorgensen, J; Keating, MJ; O'Brien, SM; Strati, P; Tambaro, FP; Wierda, WG | 1 |
| Abenhardt, W; Dörfel, S; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Meyer, D; Münz, M | 1 |
| Abrahamse-Testroote, MC; Doorduijn, J; Geisler, CH; Ghidey Alemayehu, W; Itälä Remes, M; Jurlander, J; Kimby, E; Kozak, T; Polliack, A; Tjønnfjord, G; van Oers, MH; van T' Veer, MB; Walewski, J; Wittebol, S; Wu, KL | 1 |
| Ayres, ML; Baladandayuthapani, V; El-Mabhouh, AA; Gandhi, V; Keating, MJ; Shpall, EJ; Wierda, WG | 1 |
| Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; López-Otín, C; Matas-Céspedes, A; Montraveta, A; Pérez-Galán, P; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S | 1 |
| Brown, JR; O'Brien, SM; Porter, DL | 1 |
| Bence-Bruckler, I; Benner, A; Bloehdorn, J; Busch, R; Catalano, J; Dmoszynska, A; Döhner, H; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Fink, AM; Fischer, K; Geisler, CH; Hallek, M; Larratt, L; Loscertales, J; Montillo, M; Nguyen, TQ; Palermo, G; Robak, T; Rossiev, VA; Salogub, GN; Shi, X; Solal-Celigny, P; Stilgenbauer, S; Stinson, SY; Valente, N; Warzocha, K; Weisser, M; Wenger, MK; Yeh, RF; Yu, N | 1 |
| Amadori, S; Bo, MD; Bomben, R; Buccisano, F; Bulian, P; Capelli, G; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Gaidano, G; Gattei, V; Maurillo, L; Niscola, P; Pozzo, F; Ragusa, D; Rossi, D; Rossi, FM; Zucchetto, A | 1 |
| Giannopoulos, K; Jamroziak, K; Robak, T; Szemraj, J; Tukiendorf, A | 1 |
| Ando, T; Kamachi, K; Kimura, S; Kojima, K; Nishijima, A; Takeshita, M | 1 |
| Bartalucci, G; Bocchia, M; Candi, V; Cencini, E; Crupi, R; Defina, M; Fabbri, A; Frasconi, A; Gozzetti, A; Lauria, F; Papini, G; Raspadori, D; Schiattone, L | 1 |
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Ugarte-Berzal, E | 1 |
| Ali, S; Olszewski, AJ; Shafqat, H | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL | 1 |
| Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lee, HJ; O'Brien, S; Qiao, W; Wierda, W | 1 |
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Almasan, A; Erzurum, SC; Hill, BT; Janocha, AJ; Sharma, A; Smith, MR | 1 |
| Russo, GL; Russo, M; Spagnuolo, C | 1 |
| Castellano, G; Dominguez, N; Fernandez, I; Manzano, ML; Martin, A; Muñoz, R | 1 |
| Guzailinuer, W; Li, Y; Liu, H; Maimaitili, Y; Wang, X; Xiao, M | 1 |
| Awan, FT; Byrd, JC; Flinn, IW; Hellmann, A; Hillmen, P; Hughes, SG; Robak, T; Shannon, M; Trone, D | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Bassett, RL; Ciurea, S; Gulbis, A; Jabbour, E; Khouri, IF; Korbling, M; Oran, B; Popat, UR; Rondon, G; Turturro, F; Wei, W | 1 |
| Anheier, N; Bergmann, M; Busch, R; Cramer, P; Döhner, H; Dürig, J; Eichhorst, B; Fink, AM; Fischer, K; Goebeler, ME; Hallek, M; Hurtz, HJ; Langerbeins, P; Stauch, MB; Stilgenbauer, S; Wendtner, CM | 1 |
| Cortes, J; Do, KA; Ferrajoli, A; Kantarjian, H; Keating, MJ; Khouri, I; Lerner, S; O'Brien, S; Plunkett, W; Tam, CS; Wang, X; Wierda, W | 1 |
| Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lerner, S; O'Brien, S; Qiao, W; Strom, SS; Trinh, L; Wang, X; Wierda, W | 1 |
| Derks, IA; Eldering, E; Geisler, CH; Hüllein, J; Jethwa, A; Kater, AP; Lodén, M; Malcikova, J; Moerland, PD; Monsuur, H; Navrkalova, V; Oldreive, C; Pospisilova, S; Skowronska, A; Stankovic, T; Te Raa, GD; Trbusek, M; van Laar, J; van Oers, MH; Zenz, T | 1 |
| Becker, HJ; Beckmann, L; Brinkmann, K; Fandrey, J; Frenzel, LP; Hallek, M; Huelsemann, MF; Kashkar, H; Otto, T; Pallasch, CP; Patz, M; Reinhardt, HC; Theurich, S; von Bergwelt-Baildon, M; Wendtner, CM; Zahedi, RP | 1 |
| Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Guthrie, KA; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Rezvani, AR; Sandmaier, BM; Sorror, ML; Storb, RF; Storer, BE | 1 |
| Byrd, JC; Gordon, A; Guinn, D; Hertlein, E; Jaglowski, S; Johnson, AJ; Larson, R; Lin, TS; Maddocks, K; Marcucci, G; Ruppert, AS; Woyach, J | 1 |
| Aldrin, A; Andersson, PO; Björkstrand, B; Häggström, J; Hansson, L; Norin, S; Rommel, F; Timberg, L | 1 |
| Foltynski, P; Ladyzynski, P; Molik, M | 1 |
| Błoński, JZ; Góralski, P; Hartman, M; Kiliańska, ZM; Koceva-Chyła, A; Piekarski, H; Robak, P; Robak, T; Rogalińska, M; Rogalska, A; Wawrzyniak, E | 1 |
| Ariel, A; Bairey, O; Braester, A; Fineman, R; Goldschmidt, N; Herishanu, Y; Joffe, E; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shapiro, M; Shvidel, L; Tadmor, T | 1 |
| Li, BL; Li, J; Li, SX; Liu, Y; Wang, HT; Wang, TM; Zhai, B; Zhu, HL | 1 |
| Azzollini, K; Bejot, C; Bhattacharyya, PK; Chow, KF; Feldman, T; Foon, KA; Gadaleta, G; Goy, A; Howlett, C; Kdiry, S; Mato, AR; Mrkulic, M; Pascual, LN; Porter, D; Schuster, SJ; Strelec, L; Svoboda, J; Valentinetti, M; Yannotti, K; Zenreich, J | 1 |
| Bosman, WM; Langenberg, JC; Ritchie, ED; van den Bremer, J | 1 |
| Butler, AC; Chan, G; Fang, L; Jewell, RC; Kipps, TJ; Laubscher, KH; Lewis, E; Lindeman, R; Patton, WN; Sedoti, D; Witman, P; Zhou, YY | 1 |
| Appelbaum, FR; Bennett, JM; Byrd, JC; Claus, R; Dewald, GW; Flinn, IW; Grever, MR; Gribben, JG; Hussein, MA; Jelinek, DF; Larson, RA; Lozanski, A; Lozanski, G; Lucas, DM; Moore, DF; Neuberg, DS; Paietta, EM; Plass, C; Ruppert, AS; Tallman, MS | 1 |
| Dyer, MJ; Furman, RR; Goldstein, N; Gupta, IV; Hellmann, A; Hillmen, P; Jewell, RC; Kipps, TJ; Kozak, T; Lisby, S; Losic, N; Mayer, J; Österborg, A; Padmanabhan-Iyer, S; Phillips, JL; Piotrowska, M; Robak, T; Stilgenbauer, S; Struemper, H; Trnêný, M; Wierda, WG; Williams, CD | 1 |
| Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; Lymp, J; O'Brien, S; Pagel, JM | 1 |
| da Silva, AS; de Mello, LM; Koury, Cde N; Nunes, AA; Souza, KM | 1 |
| Andritsos, L; Brown, JR; Bühler, A; Byrd, JC; Caligaris-Cappio, F; Devin, J; Gabrilove, J; Ghia, P; Grever, MR; Hallek, M; Heerema, NA; Janssens, A; Johnson, AJ; Kipps, TJ; Lanasa, MC; Larson, RA; Leblond, V; Milligan, DW; Stilgenbauer, S | 1 |
| Best, OG; Crassini, K; Mulligan, SP; Stevenson, WS | 1 |
| Beck, C; Dreyfus, B; Dyer, MJ; Gupta, IV; Hellman, A; Hess, G; Hillmen, P; Jewell, RC; Kozlowski, P; Lisby, S; Mayer, J; Nebot, N; Österborg, A; Pfreundschuh, M; Phillips, JL; Rizzi, R; Schetelig, J; Schuh, A; Smolej, L; Spacek, M; Wierda, WG; Williams, V | 1 |
| Bergmann, M; Wendtner, CM | 1 |
| Tsukasaki, K | 1 |
| Amigo-Jiménez, I; García-Marco, JA; García-Pardo, A; Lozano-Santos, C; Nova-Gurumeta, S; Pérez-Sanz, N | 1 |
| Assouline, S; Badoux, X; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Hourcade-Potelleret, F; McIntyre, C; Sayyed, P | 1 |
| Hallek, M | 3 |
| Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
| Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L | 1 |
| Brown, JR | 2 |
| Mamorska-Dyga, A; Seiter, K | 1 |
| Bodzenta-Lukaszyk, A; Bolkun, L; Dabrowska, M; Eljaszewicz, A; Jasiewicz, M; Kaminski, K; Kloczko, J; Lapuc, I; Luksza, E; Miklasz, P; Moniuszko, M; Piszcz, J; Ptaszynska-Kopczynska, K; Rusak, M; Singh, P | 1 |
| Chocholska, S; Dmoszynska, A; Hus, M; Klimek, P; Kowal, M; Macheta, A; Podhorecka, M; Szymczyk, A | 1 |
| Hu, W; Huang, Q; Liu, J; Qiu, L; Wang, Z; Zhou, Y | 1 |
| Cassin, R; Cortelezzi, A; Gaidano, G; Giannarelli, D; Orofino, N; Reda, G; Rossi, D; Sciumè, M; Vincenti, D | 1 |
| Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Short, NJ; Smith, SC; Wierda, WG | 1 |
| Derks, IA; Eldering, E; Hoogendoorn, M; Kater, AP; Laddach, N; Leeksma, AC; Loden-van Straaten, M; Luijks, DM; Moerland, PD; Navrkalova, V; Skowronska, A; Stankovic, T; te Raa, GD; Trbusek, M; van Oers, MH; Yigittop, H; Zenz, T | 1 |
| Hirano, T; Tsuji, T; Tuda, H; Yamasaki, H | 1 |
| Chan, TY; Soon, AK | 1 |
| Bulian, P; Cerri, M; Chiarenza, A; Cortelezzi, A; Coscia, M; Cuneo, A; De Paoli, L; Del Giudice, I; Del Poeta, G; Foà, R; Forconi, F; Gaidano, G; Gattei, V; Gentile, M; Ghilardi, G; Laurenti, L; Marasca, R; Massaia, M; Mauro, FR; Montillo, M; Morabito, F; Moreno, C; Motta, M; Neri, A; Perbellini, O; Rigolin, GM; Rossi, D; Tedeschi, A; Terzi-di-Bergamo, L; Vincelli, I; Visco, C; Zaja, F; Zinzani, PL | 1 |
| Bahlo, J; Busch, R; Chataline, V; Goede, V; Hallek, M; Kremers, S; Müller, L; Reschke, D; Schlag, R; Schmidt, B; Stilgenbauer, S; Vehling-Kaiser, U; Wedding, U | 1 |
| Bucur, S; Cohen, JB; Colbert, A; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; King, N; Langston, AA; Lechowicz, MJ; Lonial, S; Sinha, R; Waller, EK; Winton, EF | 1 |
| Brannagan, TH; Leitch, MM; Sherman, WH | 1 |
| Buño, I; Martinez-Laperche, C; Muñoz-Calleja, C; Perez-Chacon, G; Rebolleda, N; Somovilla-Crespo, B; Zapata, JM | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Langerbeins, P | 1 |
| Brown, JR; Cohen, JB; Flowers, CR; Jaye, DL; Katzen, HI; Lakhanpal, S; Leis, JF; Rosenthal, H; Sinha, R; Stock, W; Waller, EK | 1 |
| Jallad, B; Mawri, S; Nabi, S; Won, J | 1 |
| Barrett, M; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Maisel, D; Nguyen, T; Palermo, G; Robak, T; Smith, H; Weisser, M; Yeh, RF | 1 |
| Catovsky, D; Else, M; Oscier, D; Wade, R | 1 |
| Bazargan, A; Carney, DA; Cheah, CY; Filshie, R; Januszewicz, EH; Lew, TE; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M | 1 |
| Bahlo, J; Böttcher, S; Cramer, P; Döhner, H; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Ghia, P; Goede, V; Hallek, M; Herling, CD; Herling, M; Kneba, M; Kovacs, G; Kreuzer, KA; Langerbeins, P; Marlton, P; Maurer, C; Seymour, JF; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Freireich, EJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Plunkett, W; Smith, SC; Stingo, F; Tam, CS; Thompson, PA; Wierda, WG | 1 |
| Ave, E; Castelli, M; Chiodin, G; Facco, M; Frezzato, F; Gattazzo, C; Giorgi, CA; Lessi, F; Martini, V; Piazza, F; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A; Zambello, R | 1 |
| Alomari, M; Best, OG; Christopherson, RI; Haynes, PA; Jenkins, Y; Kaufman, KL; Mactier, S; Mirzaei, M; Mulligan, SP; Pascovici, D | 1 |
| Amadori, S; Bittolo, T; Bomben, R; Buccisano, F; Cefalo, M; Dal Bo, M; de Fabritiis, P; De Santis, G; Del Poeta, G; Del Principe, MI; Gaidano, G; Gattei, V; Maurillo, L; Rossi, D; Rossi, FM; Venditti, A; Zucchetto, A | 1 |
| Bahlo, J; Borsi, L; Civello, D; Eichhorst, B; Fingerle-Rowson, G; Fischer, K; Hallek, M; Kaiser, P; Kellermann, L; Mensch, A; Müller, D; Reiser, M; Stock, S; Walshe, R | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L | 1 |
| Berrebi, A; Shvidel, L | 1 |
| Agathangelidis, A; Baliakas, P; Belessi, C; Blakemore, SJ; Chiorazzi, N; Clifford, R; Cortese, D; Davi, F; Gaidano, G; Ghia, P; Höglund, M; Juliusson, G; Kotaskova, J; Langerak, AW; Ljungström, V; Mansouri, L; Ntoufa, S; Oscier, D; Panagiotidis, P; Pandzic, T; Plevova, K; Pospisilova, S; Pott, C; Rosenquist, R; Rossi, D; Schuh, A; Sjöblom, T; Smedby, KE; Stamatopoulos, K; Stavroyianni, N; Strefford, JC; Sutton, LA; Trentin, L; Young, E | 1 |
| Ahmadzadeh, A; Khodadadi, A; Saki, G; Teimoori, A; Valizadeh, A | 1 |
| Breuer, A; Dürig, J; Gigel, C; Herling, M; Mayer, P; Möllmann, M; Stiefelhagen, M; Vasyutina, E | 1 |
| Andersson, PO; Chang, CN; Daly, S; Gorczyca, M; Grosicki, S; Gupta, I; Kaplan, P; Kryachok, I; Kulyaba, Y; Lisby, S; Mazur, G; Middeke, JM; Montillo, M; Österborg, A; Rekhtman, G; Schuh, A; Steurer, M; Udvardy, M; Zaritskey, A | 1 |
| Han, HJ; Lu, YW; Xia, RX | 1 |
| Calvieri, S; Cantisani, C; Giustini, S; Iacovino, C; Miraglia, E | 1 |
| Assouline, S; Badoux, X; Berthillon, N; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Li, S; McIntyre, C; Sayyed, P; Trneny, M | 1 |
| Akhtar-Ali, M; Ban, K; Baumann, T; Blakemore, SJ; Campo, E; Clifford, R; He, L; Hellström, AR; Hellström, M; Kundu, S; Larsson, J; Ljungström, V; Lopez-Guillermo, A; Mansouri, L; Pandzic, T; Rosenquist, R; Schuh, A; Sjöblom, T; Strefford, JC | 1 |
| Becker, U; Hautala, A; Kyttälä, M; Martikainen, J; Poikonen, E; Soini, E | 1 |
| Böhme, A; Dreyling, M; Fries, S; Höhler, T; Kellermann, L; Kiewe, P; Zoellner, AK | 1 |
| Castejon, R; Losada-Fernandez, I; Martinez, A; Morado, M; Perez-Aciego, P; Perez-Chacon, G; Rebolleda, N; Rosado, S; Vallejo-Cremades, MT; Vargas-Nuñez, JA | 1 |
| Bahlo, J; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kovacs, G; Langerbeins, P; Maurer, C; Müller, L; Pflug, N; Ritgen, M; Seiler, T; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Bahlo, J; Böttcher, S; Busch, R; Döhner, H; Eichhorst, B; Fink, AM; Fischer, K; Gregor, M; Hallek, M; Kiehl, M; Klapper, W; Kneba, M; Köchling, G; Köppler, H; Kovacs, G; Kreuzer, KA; Lange, E; Maurer, C; Plesner, T; Plöger, C; Schlag, R; Sökler, M; Stilgenbauer, S; Trneny, M; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Arana Echarri, A; Beyaert, M; Bol, V; Bontemps, F; Michaux, L; Saussoy, P; Smal, C; Starczewska, E; Van Den Neste, E; Vekemans, MC | 1 |
| Bendell, J; Brown, JR; Derks, IA; Eichhorst, B; Eldering, E; Fernandes, SM; Filvaroff, EH; Garrick, B; Hallek, M; Hege, K; Kater, AP; Kersten, MJ; Michot, JM; Reinhardt, HC; Rodríguez, MS; Ter Burg, J; Thijssen, R; Trowe, T; van Bochove, GG; van Kampen, RJ | 1 |
| Brown, JR; Hallek, MJ; Pagel, JM | 1 |
| Becker, U; Briggs, AH; Moreno, SG; Ngo, P; Ray, JA; Samanta, K | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Cebula-Obrzut, B; Franiak-Pietryga, I; Kaczmarek, A; Klajnert-Maculewicz, B; Maciejewski, H; Robak, T; Smolewski, P; Voit, B; Ziemba, B; Ziółkowska, E | 1 |
| Bahlo, J; Busch, R; Eichhorst, B; Fischer, K; Hallek, M; Hensel, M; Hess, G; Hopfinger, G; Kutsch, N; Maria Fink, A; Mayer, J; von Grünhagen, U; Wendtner, CM | 1 |
| Altenhofer, P; Andel, J; Burcoveanu, C; Burgstaller, S; Doubek, M; Egle, A; Flochová, E; Fridrik, M; Gercheva, L; Girschikofsky, M; Greil, R; Hrubiško, M; Jäger, U; Klingler, A; Kozák, T; Králiková, E; Ladická, M; Mayer, J; Melchardt, T; Mihaylov, G; Mikušková, E; Nösslinger, T; Obrtlíková, P; Oexle, H; Palášthy, S; Papajík, T; Pecherstorfer, M; Petzer, A; Pleyer, L; Raynov, J; Smolej, L; Spasov, E; Stehlíková, O; Steurer, M; Zabernigg, A | 1 |
| Vargas Núñez, JA | 1 |
| Borsky, M; Brychtova, Y; Bryja, V; Collakova, J; Dzimkova, M; Hylse, O; Janovska, P; Jaskova, Z; Kasparkova, M; Kohoutek, J; Oltova, A; Paruch, K; Trbusek, M; Verner, J; Vesely, P; Zaprazna, K; Zemanova, J | 1 |
| Cao, H; Chen, G; Ding, J; Li, J; Pang, N; Qu, J; Wang, L; Yuan, H; Zhang, R; Zhang, Z; Zhao, F | 1 |
| Ahmed, S; Alatrash, G; Anderlini, P; Bassett, RL; Burger, JA; Ciurea, SO; Ferrajoli, A; Gulbis, AM; Jabbour, EJ; Jorgensen, JL; Kadia, TM; Khouri, IF; Ledesma, C; Marin, D; Medeiros, LJ; Olson, A; Oran, B; Patel, KK; Popat, UR; Samuels, BI; Sui, D; Turturro, F | 1 |
| Allsup, D; Bloor, A; Collett, L; Hillmen, P; Hockaday, A; Howard, DR; Munir, T; Oughton, JB; Phillips, D; Rawstron, AC | 1 |
| Ayres, ML; Balakrishnan, K; Burger, JA; Cortes, JE; Ferrajoli, A; Gandhi, V; Jain, N; Kadia, TM; Keating, MJ; O'Brien, SM; Tambaro, FP; Wierda, WG | 1 |
| Chen, YY; Fan, L; Hong, M; Li, JY; Miao, KR; Miao, YQ; Qian, SX; Wang, L; Wu, W; Xia, Y; Xie, Y; Xu, W; Yu, H; Zhao, HH; Zhu, H; Zhu, HY; Zhu, Y | 1 |
| Abdulkadyrov, K; Błoński, JZ; Carey, JL; Chang, CN; Gorczyca, MM; Govind Babu, K; Grosicki, S; Gupta, IV; Homenda, W; Kryachok, I; Kuliczkowski, K; Kulyaba, Y; Kłoczko, J; Lisby, S; Loscertales, J; McKeown, A; Rekhtman, G; Robak, T; Warzocha, K | 1 |
| Babu, V; Biersack, B; Bloehdorn, J; Chessa, L; Crispatzu, G; Efremov, DG; Hallek, M; Herling, CD; Herling, M; Knittel, G; Lohmann, G; Mayer, P; Muenzner, JK; Prinz, C; Reinart, N; Reinhardt, HC; Schneider, JI; Schobert, R; Schumacher, B; Stilgenbauer, S; Vasyutina, E | 1 |
| Abdulkadyrov, K; Bal, V; Błoński, JZ; Chang, CN; Govind Babu, K; Grosicki, S; Gupta, IV; Homenda, W; Kryachok, I; Kuliczkowski, K; Kulyaba, Y; Kłoczko, J; Lisby, S; Loscertales, J; McKeown, A; Rekhtman, G; Robak, T; Warzocha, K | 1 |
| Aurran-Schleinitz, T; Birsen, R; Bonnet, C; Boubaya, M; Choquet, S; Cymbalista, F; Delarue, R; Dietrich, PY; Dupuis, J; Fahri, J; Lamy, T; Leblond, V; Lemal, R; Lepretre, S; Levy, V; Michallet, AS; Re, D; Troussard, X; Wanquet, A; Ysebaert, L | 1 |
| Belsito, V; Carella, AM; Cortellezzi, A; Cuneo, A; De Propris, MS; Ferretti, A; Foà, R; Guarini, AR; Liberati, AM; Marinelli, M; Mauro, FR; Molica, S; Nanni, M; Orlando, SM; Paoloni, F; Rizzi, R; Spriano, M; Tosi, P; Vignetti, M; Zaja, F | 1 |
| Appelhans, D; Bednarek, M; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Maciejewski, H; Misiewicz, M; Ostrowska, K; Ziemba, B | 1 |
| Bruzzese, D; Busiello, T; Cesaro, E; Chiurazzi, F; Ciano, M; Costanzo, P; Fiammetta Romano, M; Garofalo, O; Romano, S; Simeone, L; Sodaro, G | 1 |
| Bloor, A; Blundell, J; Fegan, C; Gribben, JG; Hamblin, M; Hillmen, P; Hockaday, A; Howard, DR; McParland, L; Munir, T; Pettitt, A; Phillips, D; Pocock, C; Rawstron, AC; Varghese, A | 1 |
| Hagist, S; Hallek, M; Krause, G; Pallasch, CP; Patz, M; Veldurthy, A; Wendtner, CM | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Chen, Z; Du, M; Feng, L; Huang, P; Keating, MJ; Pelicano, H; Plunkett, W; Trachootham, D; Wierda, WG; Zhang, H; Zhang, W; Zhou, Y | 1 |
| Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Innocenti, I; Laurenti, L; Leone, G; Piccirillo, N; Sica, S; Sorà, F; Tarnani, M; Zini, G | 1 |
| Nabhan, C | 1 |
| Austen, B; Brennan, P; Fegan, C; Hewamana, S; Hiller, L; Hills, R; Hooper, L; Lin, TT; Pepper, C; Pratt, G; Stankovic, T; Starczynski, J; Ward, R | 1 |
| Cass, CE; Dabbagh, L; Ghosh, S; King, K; Lai, R; Mackey, JR; Santos, C; Tsang, RY; Young, J | 1 |
| Andersen, MK; Christiansen, CB; Geisler, C; Hastrup, N; Jurlander, J; Madsen, HO; Pedersen, LB; Rath, J | 1 |
| Fabbri, A; Forconi, F; Gozzetti, A; Lauria, F; Lenoci, M; Raspadori, D; Sozzi, E; Tassi, M | 1 |
| Bednarek, JD; Blonski, JZ; Goralski, P; Hanausek, M; Kilianska, ZM; Piekarski, H; Robak, T; Rogalinska, M; Walaszek, Z; Wozniak, K | 1 |
| Cwynarski, K; Duke, VM; Hart, SM; Hoffbrand, AV; Howard-Reeves, JD; Kottaridis, PD; Nacheva, EP; Prentice, AG; Steele, AJ; Vassilev, LT; Wickremasinghe, RG; Yogashangary, BC | 1 |
| Becker, ST; Klapper, W; Repp, R; Sinis, N; Warnke, PH; Wiltfang, J | 1 |
| Lamanna, N; Weiss, MA | 1 |
| Chen, LJ; Gu, WJ; Hong, M; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Wu, YJ; Xu, W | 1 |
| Lamanna, N; Sauter, C; Weiss, MA | 1 |
| Bole, J; Castro, JE; Kipps, TJ; Rassenti, L; Sandoval-Sus, JD | 1 |
| Baldanti, F; Citro, A; Gatti, M; Lazzarino, M; Orlandi, EM; Pochintesta, L | 1 |
| Karasawa, M | 1 |
| Balakrishnan, K; Burger, JA; Gandhi, V; Wierda, WG | 1 |
| Campo, E; Casado, FJ; Colomer, D; López-Guerra, M; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M; Trigueros-Motos, L; Villamor, N | 1 |
| Dmoszynska, A; Halicka, HD; Klimek, P; Kowal, M; Podhorecka, M | 1 |
| Blum, KA; Brooker-McEldowney, M; Byrd, JC; Dalton, JT; Farley, KL; Fischer, B; Grever, MR; Heerema, NA; Hurh, E; Jarjoura, D; Johnson, AJ; Lin, TS; Mitchell, SM; Moran, ME; Phelps, MA; Rozewski, DM; Schaaf, LJ; Wu, D | 1 |
| Borchmann, P; Elter, T; Engert, A; Hallek, M; Kilp, J; Schulz, H | 1 |
| Bauduer, F | 1 |
| Berchem, G; Bouzar, AB; Boxus, M; Bron, D; Burny, A; Chatelain, B; Chatelain, C; Defoiche, J; Lagneaux, L; Macallan, D; Pettengell, R; Willems, L; Willis, F | 1 |
| Abenhardt, W; Busch, R; Eichhorst, BF; Hallek, M; Kneba, M; Ritgen, M; Schweighofer, CD; Wendtner, CM | 1 |
| Borsky, M; Brychtova, Y; Cejkova, S; Chumchalova, J; Doubek, M; Klabusay, M; Mayer, J; Novakova, V; Pospisilova, S; Potesil, D; Rocnova, L; Smardova, J; Trbusek, M; Zezulkova, D | 1 |
| Abruzzo, LV; Barron, LL; Coombes, KR; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Kipps, TJ; Lerner, S; Lin, KI; O'Brien, S; Rassenti, L; Schlette, E; Tam, CS; Wierda, WG | 1 |
| Bierman, P; Bociek, RG; Dickinson, JD; Emanuel, K; Hegde, GV; Joshi, AD; Joshi, SS; Kollessery, GJ; Mittal, AK; Peterson, KJ; Vose, JM; Weisenburger, DD | 1 |
| Ahmadi, T; Schuster, SJ | 1 |
| Boyiadzis, M; Butchko, A; Foon, KA; Laman, A; Land, SR; Lenzer, D; Marks, S; Meisner, D; Pietragallo, L; Raptis, A; Schaefer, P; Sulecki, M; Tarhini, A | 1 |
| Brentjens, RJ; Gencarelli, AN; Golde, DW; Heaney, ML; Jurcic, JG; Lamanna, N; Maslak, P; Noy, A; Panageas, KS; Scheinberg, DA; Weiss, MA; Zelenetz, AD | 1 |
| Brennan, P; Burnett, AK; Fegan, C; Hewamana, S; Jenkins, C; Jordan, CT; Lin, TT; Pepper, C; Rowntree, C | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Byrd, JC; Caligiuri, MA; Cheney, C; Heerema, N; Lin, TS; Lucas, DM; Lucas, MS; Moran, ME; Wei, L; Woyach, JA | 1 |
| Butters, TD; Ganeshaguru, K; Gerrard, G; Mehta, AB | 1 |
| Carney, DA; Mulligan, SP | 1 |
| Boelens, J; Bracke, M; Derycke, L; Janssens, A; Lust, S; Offner, F; Philippé, J; Van Bockstaele, F; Van Gele, M; Vanhoecke, B | 1 |
| Cazin, B; Chapiro, E; Davi, F; Delmer, A; Dreyfus, B; Leporrier, M; Leprêtre, S; Lesty, C; Mahe, B; Maloum, K; Merle-Béral, H; Nguyen-Khac, F; Settegrana, C; Tournilhac, O | 1 |
| Ferrajoli, A | 1 |
| Castejón, R; Citores, MJ; García-Marco, JA; Vargas, JA; Villarreal, M; Yebra, M | 1 |
| Brass, D; Cunningham, J; Gelly, K; Groves, M; MacCallum, S; Sales, M; Tauro, S | 1 |
| Keating, MJ; Tsimberidou, AM | 2 |
| Elliott, P; Haines, I; Stanley, R | 1 |
| Bojarska-Junak, A; Bullinger, L; Dmoszynska, A; Döhner, H; Giannopoulos, K; Kowal, M; Rolinski, J; Stilgenbauer, S; Wasik-Szczepanek, E | 1 |
| Brown, PV; Conneally, E; Delaney, E; Hayat, A; Lawler, M; Liptrot, S; McCann, SR; McGuckin, S; O'Brien, D; O'Rourke, P; Quinn, F; Vandenberghe, E | 1 |
| Ferrajoli, A; Motta, M; Wierda, WG | 1 |
| Alonso, R; Bantia, S; Bontemps, F; Campo, E; Colomer, D; López-Guerra, M; Manz, C; Mehrling, T; Montserrat, E; Smal, C; Upshaw, R; Villamor, N | 1 |
| Bartholomé, K; Buchner, M; Burger, M; Chevalier, N; Dierks, C; Fuchs, S; Gribben, JG; Jumaa, H; Pfeifer, D; Prinz, G; Timmer, J; Vallat, L; Veelken, H; Zirlik, K | 1 |
| Brent, S; Dyker, A; Erhorn, S; Ferrie, L; Horsley, W; Macfarlane, K; Palmer, S; Thomas, S; Walker, S; White, S | 1 |
| Bleakley, M; Hudecek, M; Kostic, A; Maloney, D; Nishida, T; Riddell, SR; Storb, R; Warren, EH | 1 |
| Bühler, A; Busch, R; Döhner, H; Dreger, P; Dührsen, U; Finke, J; Groner, S; Hallek, M; Hensel, M; Hohloch, K; Jäger, U; Kneba, M; Lengfelder, E; Schlag, R; Schlenk, RF; Söling, U; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Bergmann, MA; Brittinger, G; Burkhard, O; Busch, R; Döhner, H; Eichhorst, BF; Emmerich, B; Fink, AM; Fischer, K; Goede, V; Hallek, M; Kranzhöfer, N; Ritgen, M; Rohrberg, R; Schweighofer, CD; Söling, U; Stauch, M; Stilgenbauer, S; Wendtner, CM; Westermann, A | 1 |
| Kay, NE; Lamanna, N | 1 |
| Lin, TS; Maddocks, KJ | 1 |
| Chew, E; Fairlie, WD; Grigg, AP; Huang, DC; Khaw, SL; Lee, EF; Mason, KD; Rayeroux, KC; Roberts, AW; Seymour, JF; Szer, J | 1 |
| Bühler, A; Busch, R; Denzel, T; Döhner, H; Groner, S; Häbe, S; Hallek, M; Mertens, D; Mohr, J; Sarno, A; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Faderl, S; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Wierda, W | 1 |
| Stilgenbauer, S; Zenz, T | 1 |
| Błoński, JZ; Kiliańska, ZM; Robak, T; Wesierska-Gadek, J; Zolnierczyk, JD | 1 |
| Boyd, TE; Chanan-Khan, AA; Gribben, J; Itri, LM; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Rai, KR; Seymour, JF; Skotnicki, AB | 1 |
| Tam, CS | 2 |
| Brum, S; Carvalho, D; Carvalho, F; Ferreira, AC; Pataca, I; Santos, JR; Santos, MC | 1 |
| Beert, E; Bontemps, F; Connerotte, T; de Viron, E; Hermans, C; Knoops, L; Michaux, L; Saussoy, P; Smal, C; Van Den Neste, E; Vannuffel, P; Vekemans, MC | 1 |
| Desjardins, P; Duncan, AM; Fernandez, L; Kipps, T; Larratt, L; Li, D; Rassenti, L; Rizi, D; Rubin, S; Sadura, A; Shepherd, L; Shustik, C; Turner, AR | 1 |
| Browne, PV; Butini, S; Campiani, G; Catherwood, MA; Greene, LM; Hayat, A; Lawler, M; Maginn, EN; McElligott, AM; McGuckin, S; Vandenberghe, E; Williams, DC; Zisterer, DM | 1 |
| Buti, M; Esteban, R; Homs, M; Palacios, A; Rodriguez-Frias, F; Sanchez, MJ | 1 |
| Byrd, JC; Castro, J; Flinn, IW; Harris, S; Heerema, N; Hughes, S; Kipps, TJ; Leigh, B; Lin, TS; Molina, A; O'Brien, S; Tangri, S; Wierda, W; Woodworth, J; Wynne, D | 1 |
| Brejcha, M; Brychtova, Y; Cejkova, S; Doubek, M; Klabusay, M; Kuglik, P; Malcikova, J; Mayer, J; Pospisilova, S; Rocnova, L; Skuhrova Francova, H; Smardova, J; Svitakova, M; Tichy, B; Trbusek, M; Vranova, V | 1 |
| Brown, M; Gibson, SB; Hernandez, TA; Hu, X; Johnston, JB; Kumar, SA; Kuschak, B | 1 |
| Byrd, JC; Gockerman, J; Hohl, R; Hurd, D; Larson, RA; Nattam, S; Perry, MC; Peterson, BL; Rai, KR | 1 |
| Abruzzo, L; Admirand, J; Keating, MJ; Lerner, S; Lin, KI; O'Brien, S; Schlette, EJ; Tam, C; Wierda, W | 1 |
| Alatrash, G; Albitar, M; Burger, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Keating, MJ; Lerner, S; Manshouri, T; O'Brien, S; Wang, X; Wierda, WG | 1 |
| Kosseifi, SG; Krishnaswamy, G; Smith, S; Vyas, B; Vyas, H | 1 |
| Błoński, JZ; Góralski, P; Kiliańska, ZM; Komina, O; Piekarski, H; Robak, T; Rogalińska, M; Wesierska-Gadek, J; Zołnierczyk, JD | 1 |
| Eldering, E; Kater, AP; Tonino, SH; van Gelder, M; van Oers, MH | 1 |
| Celadin, M; Furlan, A; Pietrogrande, F; Sanzari, M; Vianello, F; Villanova, F | 1 |
| Bazargan, A; Tam, CS | 1 |
| Baiocchi, RA; Blum, KA; Byrd, JC; Fischer, DB; Grever, MR; Johnson, AJ; Kraut, EH; Lin, TS; Mitchell, SM; Moran, ME; Porcu, P; Ruppert, AS; Schaaf, LJ | 1 |
| Castejon, R; Citores, MJ; Garcia-Marco, JA; Rosado, S; Vargas, JA; Villarreal, M | 1 |
| Desmond, R; Farrell, M; Gleeson, M; Lynch, K; Murphy, P | 1 |
| Biagi, E; Brenner, MK; Carrum, G; Dotti, G; Foster, AE; Goodell, MA; Heslop, HE; Lu, A; Okur, FV; Savoldo, B; Yvon, E | 1 |
| Fan, L; Li, JY; Liu, P; Miao, KR; Qiao, C; Wu, YJ; Xu, W; Yao, L; Zhu, DX; Zhu, HY | 1 |
| Aractingi, S; Auffret, N; Bodemer, C; Brousse, N; Duong, T; Fraitag, S; Grange, F; Hermine, O | 1 |
| Fernández-Calotti, P; Pastor-Anglada, M | 1 |
| Afanasiev, BV; Catalano, J; Dartigeas, C; Dmoszynska, A; Ganly, PS; Geisler, CH; Larratt, L; Loscertales, J; Maurer, J; Mendila, M; Moiseev, SI; Montillo, M; Robak, T; Rosta, A; Saville, MW; Solal-Céligny, P; Valente, N; Warzocha, K; Wenger, MK; Zyuzgin, I | 1 |
| Chan, G; Davis, R; Dyer, MJ; Furman, RR; Hellmann, A; Hillmen, P; Kipps, TJ; Kozak, T; Losic, N; Mayer, J; Osterborg, A; Padmanabhan, S; Piotrowska, M; Robak, T; Russell, CA; Stilgenbauer, S; Trneny, M; Wierda, WG; Williams, CD; Wilms, J | 1 |
| Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszyñska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Hellmann, A; Jamroziak, K; Konopka, L; Kostyra, A; Lewandowski, K; Piotrowska, M; Piszcz, J; Potoczek, S; Robak, T; Seferynska, I; Stella-Holowiecka, B; Warzocha, K; Zawilska, K; Zdunczyk, A | 1 |
| Ali, MA; Balbaa, OA; Farahat, NM; Hussein, Ael-S; Shamaa, LA | 1 |
| Bot, FJ; Chaker, L; Maartense, E; Segeren, CM | 1 |
| Golubeva, ME; Isaeva, NV; Kudriavtseva, AV; Malykh, OV; Tkachenko, SB; Zagoskina, TP | 1 |
| Garratty, G | 1 |
| Lamanna, N | 1 |
| Balakrishnan, K; Bantia, S; Bickel, S; Chen, Y; Gandhi, V; Kantarjian, H; Keating, MJ; Kilpatrick, JM; O'Brien, S; Ravandi, F; Tyler, BF; Verma, D | 1 |
| Blanc, A; Corre, J; Fournié, JJ; Gross, E; Kühlein, E; Laurent, G; Quillet-Mary, A; Ysebaert, L | 1 |
| Aouali, N; Berchem, G; Bernardin, F; Cornillet-Lefebvre, P; Delmer, A; Duhem, C; El Khoury, V; Leners, B; Moussay, E; Muller, A; Palissot, V; Poirel, HA; Ries, F; Vallar, L; van Dyck, E; Van Moer, K; Wenner, T | 1 |
| Chocholska, S; Dmoszynska, A; Halicka, D; Klimek, P; Kowal, M; Podhorecka, M | 2 |
| Cavazzini, F; Ciccone, M; Cuneo, A; De Angeli, C; Ferracin, M; Grilli, A; Lupini, L; Negrini, M; Rizzotto, L; Saccenti, E; Veronese, A; Zagatti, B | 1 |
| Li, JY; Xu, W; Yao, L | 1 |
| Chiang, R; Earp, J; Gootenberg, JE; Keegan, P; Lemery, SJ; McDougal, A; Pazdur, R; Pilaro, A; Rothmann, MD; Yang, J; Zhang, J; Zhao, H | 1 |
| Keating, MJ; Tam, CS | 2 |
| Bond, KM; Cianciolo, GJ; Diehl, LF; Friedman, DR; Gockerman, JP; Kennedy, MN; Lanasa, MC; Moore, JO; Mowery, YM; Pizzo, SV; Weinberg, JB | 1 |
| Chiusolo, P; D'Arena, G; De Padua, L; Efremov, DG; Falcucci, P; Innocenti, I; Laurenti, L; Leone, G; Marietti, S; Piccirillo, N; Sica, S; Sora', F; Tarnani, M; Zini, G | 1 |
| Cao, X; Dong, HJ; Fang, C; Hong, M; Li, JY; Miao, KR; Wang, DM; Xu, W; Zhu, DX | 1 |
| Dong, HJ; Fang, C; Li, JY; Miao, KR; Qiao, C; Wang, DM; Wu, YJ; Xu, W; Zhu, DX; Zhu, HY | 1 |
| Gocke, CD; Hristov, AC; Nava, VE; Saladino, A | 1 |
| Allain, JP; Candotti, D; El Chaar, M; Power, JP; Spillane, D; Temple, J; Thomas, M | 1 |
| Mupo, A; Russo, GL; Russo, M; Spagnuolo, C; Tedesco, I; Volpe, S | 1 |
| Tsimberidou, AM | 1 |
| Atkins, JN; Bengtson, EM; Byrd, JC; Donohue, KA; Hoke, EE; Larson, RA; Lin, TS; Link, BK; Lucas, MS; Rai, KR | 1 |
| Bergmann, M; Bühler, A; Busch, R; Denzel, T; Döhner, H; Edelmann, J; Eichhorst, B; Häbe, S; Hallek, M; Hensel, M; Hopfinger, G; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Afanasiev, BV; Bence-Bruckler, I; Catalano, J; Dmoszynska, A; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Geisler, CH; Larratt, L; Loscertales, J; Moiseev, SI; Montillo, M; Robak, T; Rossiev, VA; Solal-Celigny, P; Spleiss, O; Warzocha, K; Weisser, M; Wenger, MK; Yeh, RF; Zhi, J | 1 |
| Brychtová, Y; Doubek, M; Mayer, J; Panovská, A | 1 |
| Bär, C; Brantner, P; Buchner, M; Burger, M; Dierks, C; Gribben, JG; Mertelsmann, R; Ott, A; Pfeifer, D; Prinz, G; Stickel, N; Veelken, H; Zirlik, K | 1 |
| Bulgar, AD; Donze, JR; Gerson, SL; Kirkland, EB; Li, L; Liu, L; Snell, M; Xu, Y; Yang, S | 1 |
| Brassac, M; Fournié, JJ; Gross, E; Kheirallah, S; L'Faqihi-Olive, FE; Laurent, G; Quillet-Mary, A; Struski, S; Ysebaert, L | 1 |
| Abramson, J; Brown, JR; Dalton, V; Freedman, AS; Hochberg, E; Kuang, Y; McDonough, SM; Mikler, E; Neuberg, D; Reynolds, H; Ritz, J; Thompson, C; Werner, L | 1 |
| Angchaisuksiri, P; Apilugsanachit, A; Atichartakarn, V; Boonsakan, P; Chuncharunee, S; Jootar, S; Kanoksil, W; Karntisaviwat, K; Niparuck, P; Nitiyanant, P; Rerkamnuatchoke, B; Ungkanont, A | 1 |
| Egle, A; Gassner, FJ; Geisberger, R; Greil, R; Hartmann, TN; Hofbauer, JP; Tinhofer, I; Weiss, L | 1 |
| Burchette, J; Foo, WC; Huang, Q; Hutchinson, CB; Sebastian, S; Wang, E | 1 |
| Hillmen, P | 2 |
| Bergmann, M; Berrebi, A; Böttcher, S; Bühler, A; Busch, R; Caligaris-Cappio, F; Catalano, J; Cazin, B; Döhner, H; Eichhorst, BF; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, M; Hensel, M; Hess, G; Hopfinger, G; Jäger, U; Kneba, M; Mayer, J; Mendila, M; Ritgen, M; Seymour, JF; Staib, P; Stilgenbauer, S; Trneny, M; von Grünhagen, U; Wendtner, CM; Westermann, A; Winkler, D; Zenz, T; Zinzani, PL | 1 |
| Eldering, E; Kater, AP; Tonino, SH; van Laar, J; van Oers, MH; Wang, JY | 1 |
| Lech-Maranda, E; Robak, P; Robak, T | 1 |
| Holmes, NE; Kelman, A; Korman, TM; Opat, S | 1 |
| Main, C; Moxham, T; Pitt, M; Stein, K | 1 |
| Best, G; Buggins, AG; Devereux, S; Dyer, MJ; Fegan, C; Fishlock, K; Hewamana, S; Hills, R; Kennedy, BJ; Lin, TT; Majid, A; Miall, F; Oscier, DG; Pepper, C; Pratt, G; Wagner, S; Yallop, D | 1 |
| Ascaso, FJ; Fuertes, MA; Jimenez, B; Keane, PA; Sadda, S | 1 |
| Aloyz, R; Amrein, L; Assouline, S; Caplan, S; Desjardins, P; Egorin, MJ; Hebb, J; Panasci, L; Rousseau, C | 1 |
| Doorduijn, JK; Lam, KH; van de Langerijt, B; van den Bent, MJ | 1 |
| Abadie, E; Ersbøll, J; Gravanis, I; Marty, M; Pignatti, F; Skovlund, E | 1 |
| Amsailale, R; Arts, A; Bastin-Coyette, L; Bontemps, F; Cardoen, S; de Viron, E; Smal, C; Van Den Neste, E | 1 |
| Casak, SJ; Davis, G; Jarral, V; Keegan, P; Khandelwal, A; Lemery, SJ; Pazdur, R; Rothmann, MD; Shen, YL; Zhao, H | 1 |
| Booth, GA; Brown, J; Cocks, K; Cohen, DR; Dearden, C; Ezekwisili, R; Fegan, C; Hillmen, P; Kennedy, DB; Mercieca, J; Milligan, DW; Pettitt, A; Pocock, C; Radford, J; Rawstron, AC; Sayala, HA; Smith, AF; Varghese, AM | 1 |
| Badoux, XC; Burger, J; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, SM; Wang, X; Wierda, WG | 2 |
| Bakun, AV; Fedosenko, VV; Khlebko, PV; Kustanovich, AM; Serhiyenka, TF; Svirnovski, AI; Taras, IB | 1 |
| Delioukina, ML; Forman, SJ; Krishnan, A; Palmer, JM; Stiller, T; Thomas, SH | 1 |
| Schnaiter, A; Stilgenbauer, S | 1 |
| Byrd, JC; Gribben, JG; Heerema, NA; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Ruppert, AS; Woyach, JA | 1 |
| Abrisqueta, P; Bosch, F; Crespo, M | 1 |
| Castillo, JJ; Reagan, JL | 1 |
| Cervigón, I; Palomo, A; Solano, F; Torres-Iglesias, LM; Zapata, AM | 1 |
| Hattori, H; Karasuno, T; Kotake, T; Kuwayama, M | 1 |
| Fan, L; Fang, C; Hong, M; Li, JY; Liu, P; Miao, KR; Qiao, C; Wu, YJ; Xu, M; Xu, W; Zhu, DX; Zhu, HY; Zhuang, Y | 1 |
| Ba, LA; Doering, M; Hallek, M; Herling, M; Jacob, C; Lilienthal, N; Peer-Zada, AA; Prinz, C | 1 |
| Catovsky, D; Dearden, CE; Gonzalez, D; Hockley, S; Martinez, P; Matutes, E; Morgan, GJ; Oscier, D; Richards, SM; Wade, R | 1 |
| Chan, G; Chang, CN; Dürig, J; Gorczyca, M; Griniute, R; Griskevicius, L; Gupta, I; Hernandez-Ilizaliturri, FJ; Hess, G; Kipps, TJ; Mayer, J; Nielsen, TG; Padmanabhan, S; Russell, CA; Smolej, L; Stilgenbauer, S; Wierda, WG | 1 |
| Cencini, E; Fabbri, A; Forconi, F; Lauria, F; Raspadori, D; Sicuranza, A; Sozzi, E | 1 |
| Crathorne, L; Garside, R; Hoyle, M; Hyde, C | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M | 1 |
| Einberger, C; Fleiss, K; Fonatsch, C; Gaiger, A; Gruber, M; Hauswirth, AW; Heintel, D; Jäger, U; Porpaczy, E; Shehata, M; Skrabs, C; Thalhammer, R; Vanura, K | 1 |
| Chen, R; Ewald, B; Plunkett, W; Sampath, D; Wierda, W; Zecevic, A | 1 |
| Barbour, SJ; Beaulieu, MC; Magil, AB; Zalunardo, NY | 1 |
| Argentieri, D; Bartomioli, M; Bezares, RF; Diaz, A; Garay, G; Milone, G; Ryser, R; Stemelin, G; Zubiaur, EL | 1 |
| James, DF; Kipps, TJ | 1 |
| Arampatzis, S; Eleftheriadis, T; Giannakoulas, N; Karasavvidou, F; Kourti, P; Liakopoulos, V; Matsouka, P; Stefanidis, I | 1 |
| Bergmann, L; Chow, KU; Cordes, HJ; Kim, SZ; Schlegelberger, B; Stilgenbauer, S; von Neuhoff, N; Wunderle, L | 1 |
| Badoux, X; Burger, J; Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Parikh, SA; Wang, X; Wierda, WG | 1 |
| Connors, JM; Gerrie, AS; Li, CH; Ramadan, KM; Sutherland, J; Toze, CL; Yee, A | 1 |
| Attolico, I; Crugnola, M; De Blasio, A; Ilariucci, F; Montillo, M; Morra, E; Petrizzi, VB; Ricci, F; Spedini, P; Spriano, M; Tedeschi, A; Uziel, L; Vismara, E; Zaccaria, A | 1 |
| Colović, M; Colović, N; Fekete, MD; Janković, G; Palibrk, V; Suvajdžić, N; Tomin, D | 1 |
| Appelbaum, FR; Bennett, JM; Byrd, JC; Dewald, G; Flinn, IW; Grever, MR; Hussein, MA; Larson, RA; Lazarus, HM; Litzow, MR; Neuberg, D; Paietta, EM; Rowe, JM; Smith, MR; Tallman, MS | 1 |
| Bergmann, M; Buske, C; Dreyling, M; Egensperger, R; Franke, D; Herold, T; Mumm, FF; Schinwald, N; Seiler, T; Trumm, C | 1 |
| Friedmann, M; Gutierrez, H; Han, L; Hornberger, J; Keating, MJ; Lerner, S; Reyes, C; Satram-Hoang, S; Shewade, A | 1 |
| Cook, H; Datto, M; Daugherty, FJ; Davis, PH; DeCastro, CM; Diehl, LF; Friedman, DR; Gockerman, JP; Lanasa, MC; Li, Z; Matta, KM; Moore, JO; Rehder, C; Rizzieri, D; Weinberg, JB | 1 |
| Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D | 1 |
| Aurran-Schleinitz, T; Dartigeas, C; Feugier, P; Leprêtre, S; Letestu, R; Van Den Neste, E; Ysebaert, L | 1 |
| Chan, GW; Gupta, IV; Lisby, S; Osterborg, A; Padmanabhan, S; Wierda, WG | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
| Fan, L; Li, JY; Liu, P; Miao, KR; Xu, M; Xu, W | 1 |
| Bezares, RF; Bitsmans, A; Borge, M; Galmarini, CM; Gamberale, R; Giordano, M; González, M; Jancic, C; Morande, PE; Nannini, P; Rodríguez, AL; Zanetti, SR | 1 |
| Baldini, L; Cortelezzi, A; Gritti, G; Maura, F; Molica, S; Neri, A; Piciocchi, A; Reda, G | 1 |
| Asmar, L; Boehm, KA; Di Bella, N; Hyman, W; Lyons, RM; Reynolds, C; Richards, DA; Robbins, GJ; Vellek, M; Zhan, F | 1 |
| Arnoulet, C; Béné, MC; Brumpt, C; Capiod, JC; de Carvalho Bittencourt, M; Degenne, M; Durrieu, F; Eghbali, H; Feugier, P; Feuillard, J; Garand, R; Geneviève, F; Kara-Terki, A; Kulhein, E; Maynadié, M; Ochoa-Noguera, ME; Plesa, A; Roussel, M; Truchan-Graczyk, M | 1 |
| Kalk, E; Karanth, M; Khan, N; McLarnon, A; Moss, PA; Murray, J; Piper, KP; Pratt, G | 1 |
| Jäger, U; Janssens, A; Leblond, V; Lepretre, S; Nikitin, E; Robak, T; Wendtner, CM | 1 |
| Elter, T; Engert, A; Gercheva-Kyuchukova, L; Hallek, M; Jaksic, B; Kyrcz-Krzemień, S; Pylylpenko, H; Rekhtman, G; Robak, T; Sirard, C; Vatutin, M; Wu, J | 1 |
| Amadori, S; Biagi, A; Bomben, R; Bruno, A; Buccisano, F; Bulian, P; Coletta, AM; Dal Bo, M; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Gattei, V; Luciano, F; Maurillo, L; Neri, B; Rossi, FM; Simotti, C; Venditti, A; Zucchetto, A | 1 |
| Aguilar, J; Al-Katib, A; del Busto, R; Johnson, LB; Obeid, KM; Sharma, M; Szpunar, S | 1 |
| Cesano, A; Evensen, E; Fantl, WJ; Huang, YW; Nolan, GP; Palazzo, AL | 1 |
| Fournié, JJ; Laurent, G; Liffraud, C; Quillet-Mary, A; Ysebaert, L | 1 |
| Hollweg, A; Rai, KR | 1 |
| Bertoni, F; Bruscaggin, A; Cerri, M; Chiaretti, S; Cresta, S; Dalla-Favera, R; Deaglio, S; Deambrogi, C; Del Giudice, I; Fangazio, M; Foà, R; Forconi, F; Gaidano, G; Gargiulo, E; Gattei, V; Guarini, A; Khiabanian, H; Messina, M; Monti, S; Pasqualucci, L; Rabadan, R; Rasi, S; Rossi, D; Spina, V; Vaisitti, T | 1 |
| Bergier, G; Glass, F; McCardle, T; Moscinski, L; Naghashpour, M; Setoodeh, R; Sokol, L | 1 |
| Spaner, DE | 1 |
| Dietrich, S; Dreger, P; Giese, T; Hahn, E; Hess, M; Ho, AD; Hüllein, J; Krämer, OH; Luft, T; Rieger, M; Schäfer, C; Tretter, T; Zenz, T | 1 |
| Schuh, A | 1 |
| Keating, MJ; McDonnell, TJ; Medeiros, LJ; Tang, G; Wang, SA; Wierda, WG; Zhou, Y | 1 |
| Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Komina, O; Robak, P; Smolewski, P; Węsierska-Gądek, J; Żołnierczyk, JD | 1 |
| Beaumont, T; Breij, EC; Eldering, E; Elias, JA; Geest, CR; Kater, AP; Luijks, DM; Tromp, JM; van Laar, J; van Oers, MH | 1 |
| Best, G; Christopherson, RI; Crossett, B; Henrich, S; Mactier, S; Mulligan, SP | 1 |
| Byrd, JC; Woyach, JA | 1 |
| Best, OG; Che, Y; Christopherson, RI; Forsyth, C; Mulligan, SP; Singh, N | 1 |
| Catovsky, D; Cocks, K; Crofts, S; Else, M; Richards, SM; Smith, AG; Wade, R | 1 |
| Colomer, D; Fernández-Calotti, PX; Lopez-Guerra, M; Pastor-Anglada, M | 1 |
| Bonacorsi, G; Bulgarelli, J; Castelli, I; Coluccio, V; Deaglio, S; Debbia, G; Fiorcari, S; Fontana, M; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Narni, F; Torelli, G; Zucchini, P | 1 |
| Breikša, B; Chapenko, S; Feldmane, L; Garcia-Cabeza, M; Gomez-Roman, J; Jaunmuktane, Z; Lejniece, S; Lejnieks, A; Murovska, M; Ziediņa, I | 1 |
| Dmoszynska, A; Joshi, A; Li, J; Mangat, R; Robak, T; Valente, N; Visich, J; Wenger, M; Zhi, J | 1 |
| Fan, H; Guo, B; Li, SX; Lin, J; Lu, XC; Ran, HH; Yang, Y; Zhai, B; Zhu, HL | 1 |
| Feliu, J; García-Muñoz, R; Olavarría, E; Zabalza, A | 1 |
| Bertoni, F; Bruscaggin, A; Chiaretti, S; Cresta, S; Dalla-Favera, R; Daniele, G; Deaglio, S; Deambrogi, C; Del Giudice, I; Fabbri, G; Famà, R; Fangazio, M; Foà, R; Forconi, F; Gaidano, G; Gattei, V; Greco, M; Guarini, A; Marinelli, M; Monti, S; Pasqualucci, L; Rasi, S; Rossi, D; Spina, V; Vaisitti, T | 1 |
| Böttcher, S; Bühler, A; Busch, RM; Döhner, H; Eichhorst, BF; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, MJ; Kneba, M; Mendila, M; Ritgen, M; Stilgenbauer, S; Wendtner, CM; Wenger, MK; Zenz, T | 1 |
| Bauer, K; Elter, T; Engert, A; Hallek, M; Monsef, I; Roloff, V; Skoetz, N | 1 |
| Aurran, T; Béné, MC; Casasnovas, O; Cazin, B; Chevret, S; Corront, B; Cymbalista, F; Delépine, R; Delmer, A; Feugier, P; Leblond, V; Lepretre, S; Letestu, R; Mahé, B; Maisonneuve, H; Royer, B; Tournilhac, O; Van Den Neste, E; Vaudaux, S | 1 |
| Burger, JA; Chen, G; Croce, CM; Garcia-Prieto, C; Huang, P; Keating, MJ; Liu, J; Lu, W; Pelicano, H; Plunkett, W; Trachootham, D; Zhang, W | 1 |
| Beum, PV; Beurskens, FJ; Engelberts, P; Farooqui, M; Lindorfer, MA; Mackus, WJ; Parren, PW; Taylor, RP; Wiestner, A | 1 |
| Byrd, JC; Gordon, A; Gribben, JG; Heerema, NA; Larson, RA; Lozanski, A; Lozanski, G; Lucas, DM; Marcucci, G; Morrison, VA; Rai, KM; Ruppert, AS | 1 |
| Gan, SL; Ma, P; Sun, H; Wang, WM; Xie, XS | 1 |
| Döhner, H; Gribben, JG; Hallek, M; Keating, MJ; Stilgenbauer, S; Zenz, T | 1 |
| Blough, DK; Cheng, MM; Devine, EB; Goulart, B; Veenstra, DL | 1 |
| Boyiadzis, M; Foon, KA; Kropf, P; Lentzsch, S; Lenzner, D; Marks, S; Mehta, D; Pietragallo, L; Sulecki, M; Tarhini, A | 1 |
| Bono, M; Bruno, S; Casciaro, S; Decensi, A; Fais, F; Ghiotto, F; Luzzi, P; Mazzarello, AN; Morabito, F; Recchia, A; Tenca, C | 1 |
| Fathi, AT; Hasserjian, R; Sadrzadeh, H | 1 |
| Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Döhner, H; Elter, T; Engert, A; Fink, AM; Fischer, K; Gassmann, W; Hallek, M; Hasan, I; James, R; Kahl, C; Ritgen, M; Staib, P; Stauch, M; Stilgenbauer, S; Wendtner, CM; Winkler, D | 1 |
| Fan, L; Fang, C; Hong, M; Li, JY; Liu, P; Miao, KR; Wang, YH; Xu, W; Zhu, DX; Zhu, W; Zou, ZJ | 1 |
| Burnett, AK; Fegan, C; Pearce, L; Pepper, C; Walsby, E | 1 |
| Best, OG; Mulligan, SP | 1 |
| Borowiec, M; Błoński, JZ; Franiak-Pietryga, I; Korycka-Wołowiec, A; Maciejewski, H; Mirowski, M; Robak, T; Sałagacka, A | 1 |
| Adamson, J; Carter, A; Catovsky, D; Dearden, C; Gonzalez, D; Johnson, GG; Lin, K; Matutes, E; Oates, M; Oscier, DG; Pettitt, AR; Richards, S; Wade, R | 1 |
| Andritsos, L; Blum, KA; Byrd, JC; Flynn, JM; Grever, MR; Gupta, SV; Gurcan, M; Herman, SE; Johnson, AJ; Jones, JA; Kong, H; Lehman, A; Lucas, DM; Mahoney, E; Smith, LL; Wagner, AJ; Yeh, YY; Zhang, X | 1 |
| Denk, U; Egle, A; Greil, R; Hamacher, F; Hofbauer, JP; Kenner, L; Kocher, T; Melchardt, T; Merkel, O; Scheideler, M; Schlederer, M; Sifft, E; Steurer, M; Wacht, N | 1 |
| Ave, E; Brunati, AM; Cabrelle, A; Carraro, S; Facco, M; Frezzato, F; Gattazzo, C; Martini, V; Semenzato, G; Teramo, A; Tibaldi, E; Trentin, L; Trimarco, V; Zambello, R | 1 |
| Bosanquet, AG; Catovsky, D; Else, M; Matutes, E; Richards, SM; Wade, R | 1 |
| Canaani, J; Dezorella, N; Eshel, R; Gepstein, L; Herishanu, Y; Naparstek, E; Perry, C; Polliack, A; Rothman, R; Sarid, N; Shpringer, M; Solar, I | 1 |
| Almazi, JG; Christopherson, RI; Crossett, B; Kohnke, PL; Mactier, S | 1 |
| Peterson, A; Shah, BK; Uprety, D | 1 |
| Rossi, D | 1 |
| Appelbaum, FR; Belch, A; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Solh, M; Tallman, MS | 1 |
| Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M | 1 |
| Bosanquet, AG; Lin, K; Melarangi, T; Oates, M; Pettitt, AR; Rockliffe, N; Slupsky, JR; Zhuang, J | 1 |
| Chevrier, S; Houot, R; Lamy, T; Marchand, T; Poullot, E; Revest, M; Tattevin, P | 1 |
| Fan, L; Fang, C; Li, JY; Liu, L; Xu, W; Yang, S; Zhang, LN; Zou, ZJ | 1 |
| Bruyere, H; Chan, MJ; Dalal, CB; Gerrie, AS; Gillan, TL; Huang, SJ; Ramadan, KM; Toze, CL | 1 |
| Cacoub, P; Choquet, S; Decaux, O; Hermine, O; Jego, P; Karras, A; Pineton de Chambrun, M; Saadoun, D | 1 |
| Brychtova, Y; Chovancova, J; Doubek, M; Francova, HS; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Stehlikova, O; Tichy, B; Tomiska, M | 1 |
| Bozsó, T; Iványi, JL; Plander, M; Skrapits, J; Szendrei, T | 1 |
| Fan, L; Li, JY; Liu, L; Wang, DM; Xu, W; Yang, S; Zhang, LN; Zou, ZJ | 1 |
| Borel, C; Bouvet, E; Cazin, B; Compaci, G; Laurent, G; Michallet, AS; Obéric, L; Ysebaert, L | 1 |
| Ahmad, A; Becker, MW; Coppage, M; Iqbal, A | 1 |
| Catovsky, D; Collins, A; Cross, NC; Else, M; Forster, J; Gardiner, A; Gomez, B; Gonzalez de Castro, D; Oscier, DG; Parker, A; Parker, H; Rose-Zerilli, MJ; Strefford, JC; Winkelmann, N | 1 |
| Bay, JO; Blaise, D; Bordigoni, P; El-Cheikh, J; Labussière-Wallet, H; Michallet, M; Milpied, N; Mohty, M; Morisset, S; Sobh, M; Socié, G; Tabrizi, R | 1 |
| Ahmed, G; Davis, Z; Dyer, M; Gonzalez, D; Matutes, E; Moss, P; Oldreive, C; Oscier, D; Parker, A; Richards, S; Skowronska, A; Stankovic, T; Taylor, AM; Thomas, P | 1 |
| Bhadelia, N; Freedberg, DE; Oster, MW; Poneros, JM | 1 |
| Autore, F; Chiusolo, P; Innocenti, I; Laurenti, L; Leone, G; Sica, S; Sorà, F; Vannata, B | 1 |
| Bauer, K; Elter, T; Engert, A; Hallek, M; Rancea, M; Roloff, V; Skoetz, N | 1 |
| Bai, LY; Byrd, JC; Chan, KK; Cheney, C; Herman, SE; Jarjoura, D; Jin, Y; Lee, LJ; Lee, RJ; Mao, Y; Marcucci, G; Mo, X; Muthusamy, N; Ramanunni, A; Wang, X; Yu, B | 1 |
| Bellemare, J; Bilban, M; Fleiss, K; Gaiger, A; Gleiss, A; Gruber, M; Guillemette, C; Hoermann, G; Jaeger, U; Le, T; Lévesque, É; Mannhalter, C; Porpaczy, E; Shehata, M; Skrabs, C; Vanura, K; Zehetmayer, S | 1 |
| Giannakakis, C; Guido, G; Mosillo, G; Rocca, AR; Salviani, C; Serriello, I | 1 |
| Alhede, M; Bjarnsholt, T; Braendstrup, P; Clasen-Linde, E; Eickhardt, S; Høiby, N; Jensen, KE; Moser, C; Vindeløv, L | 1 |
| McCormack, C; McCurdy, O; Prince, HM; Ritchie, D | 1 |
| Baker, D; Betz, A; Burke, R; Coffey, G; DeGuzman, F; Druker, BJ; Fletcher, LB; Hollenbach, SJ; Loriaux, MM; Pak, Y; Pandey, A; Sinha, U; Spurgeon, SE; Tyner, JW | 1 |
| Apollonio, B; Caligaris-Cappio, F; Fazi, C; Fonte, E; Ghia, P; Muzio, M; Ranghetti, P; Scarfò, L | 1 |
| Appelbaum, FR; Belch, AR; Byrd, JC; Geyer, S; Kolitz, J; Larson, RA; Lin, TS; Morrison, VA; Rai, K; Ruppert, AS; Tallman, MS; Woyach, JA | 1 |
| Balleisen, L; Eimermacher, H; Freier, W; Heit, W; Hinke, A; Ibach, S; Knauf, W; Megdenberg, D; Niederle, N; Weiß, J | 1 |
| Ajana, F; Ettahar, N; Legout, L; Massongo, M; Patoz, P; Rose, C; Senneville, E | 1 |
| Cohen, HJ; Elias, L; Hines, J; Hurwitz, HI; Larson, RA; Martell, RE; Morrison, VA; Peterson, BL; Petros, WP; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Basmaji, N; Garg, MS; Garg, S | 1 |
| Batár, P; Kiss, A; Rák, K; Rejtó, L; Reményi, G; Telek, B; Udvardy, M | 1 |
| Bergmann, M; Busch, R; Emmerich, B; Franke, A; Hallek, M; Hiddemann, W; Hopfinger, G; Pasold, R; Schlag, R; Schmitt, B; Wendtner, CM | 1 |
| Andreeff, M; Cortes, JE; Faderl, S; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Tsimberidou, AM | 1 |
| Aivado, M; Burger, J; Finke, J; Haas, R; Henze, L; Schulte, K | 1 |
| Bellosillo, B; Bosch, F; Campo, E; Colomer, D; López-Guillermo, A; Marcé, S; Montserrat, E; Villamor, N | 1 |
| Montserrat, E | 2 |
| Champlin, RE; Keating, MJ; Khouri, IF; Saliba, RM | 1 |
| Cheson, BD; Hegde, UP; White, T; Wilson, WH | 1 |
| Belch, AR; Cass, CE; Coupland, R; Graham, KA; Mackey, JR; Reiman, T; Wong, J; Young, J | 1 |
| de Fabritiis, P; De Propris, MS; Foa, R; Gentile, M; Giammartini, E; Giannarelli, D; Mandelli, F; Mauro, FR; Meloni, G; Rapanotti, MC | 1 |
| Ales, NC; Byrd, JC; Helman, DL; Shorr, AF | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Brettman, L; Cooper, MR; Freter, CE; Mercier, RJ; Mitchell, BS; Rai, KR; Santábarbara, P; Stadtmauer, EA; Wacker, B | 1 |
| Field, K; Seymour, JF; Slavin, MA | 1 |
| Andreeff, M; Bennett, F; Charboneau, L; Kim, Y; Kipps, TJ; Kitada, S; Liotta, LD; Pedersen, IM; Rassenti, L; Reed, JC; Schimmer, A; Sporn, MB; Zapata, JM | 1 |
| Aulitzky, WE; Diehl, V; Engert, A; Hallek, M; Hensel, M; Herold, M; Hinke, A; Huhn, D; Klein, SK; Knauf, WU; Rehwald, U; Reiser, M; Schulz, H | 1 |
| Böck, HP; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M | 1 |
| Garzia, M; Laurenti, L; Leone, G; Piccioni, P; Sabatelli, M; Sora', F | 1 |
| Anxionnat, R; Grignon, Y; Hulin, C; Léonard, S; Taillandier, L; Vespignani, H | 1 |
| Altés, A; Bellosillo, B; Besalduch, J; Bosch, F; Cobo, F; Colomer, D; Esteve, J; Ferrer, A; Giné, E; López-Guillermo, A; Montserrat, E; Perales, M; Ribera, JM; Villamor, N | 1 |
| Giralt, S; Goldman, JM; Hale, G; Mackinnon, S; Slavin, S; Waldmann, H | 1 |
| Horie, T; Horikoshi, A; Hosokawa, Y; Sawada, S; Takei, K | 1 |
| Cavalli-Björkman, N; Gruber, A; Kalin, M; Lundin, J; Osby, E; Osterborg, A | 1 |
| Cragg, L; Feldman, EJ; Grant, S; Roberts, JD; Smith, MR | 1 |
| Byrd, JC; Larson, RA; Peterson, B; Piro, L; Saven, A; Schiffer, C; Vardiman, JW | 1 |
| Jeleń, M; Kuliczkowski, K; Kuliszkiewicz-Janus, M; Małecki, R | 1 |
| Balleari, E; Capaia, M; Clavio, M; de Totero, D; Foa, R; Gobbi, M; Montera, MP; Tazzari, PL | 1 |
| Fernandez, MJ; Grau, E; Llopis, I; Pastor, E; Real, E | 1 |
| Clouse, LH; Hussain, K; Mazza, JJ | 1 |
| Beyer, J; Bornhäuser, M; Ehninger, G; Fauser, AA; Hensel, M; Ho, AD; Kiehl, M; Kienast, J; Kröger, N; Neubauer, A; Scheffold, C; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zander, AR | 1 |
| Beyan, C; Cetin, T; Kaptan, K; Nevruz, O; Satar, B | 1 |
| Albitar, M; Alvarado, Y; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Thomas, DA; Tsimberidou, AM; Verstovsek, S; Wierda, W | 1 |
| Aliff, TB; Frankel, SR; Horgan, D; Jurcic, JG; Kossman, SE; Lamanna, N; Maslak, PG; Scheinberg, DA; Weiss, MA | 1 |
| Abebe, L; Adiga, GU; Wiernik, PH | 1 |
| Canelhas, A; Coelho, H; Guerra, M; Lima, M; Pinto Ribeiro, AC; Teixeira, Mdos A | 1 |
| Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Kontoyiannis, D; Lerner, S; O'Brien, S; Plunkett, W | 1 |
| Joshi, SS; Pavletic, ZS; Wang, P | 1 |
| Bar, M; Cohen, NS; del Prete, S; Flamm, M; Garrett, TJ; Heitjan, D; Hesdorffer, CS; Lonberg, M; March, R; Mears, JG; Nichols, G; Oster, MW; Savage, DG; Talbot, S; Taub, RN | 1 |
| De Braekeleer, M; Herry, A; Le Bris, MJ; Morel, F; Morice, P | 1 |
| Kovacs, MJ; Wells, T | 1 |
| Bosanquet, AG; Daniel, PT; Dörken, B; Güner, D; Hermann, S; Sturm, I | 1 |
| Boudová, L; Cerná, K; Jindra, P; Karas, M; Koza, V; Lysák, D; Svojgrová, M; Vozobulová, V | 1 |
| Brand, R; Corradini, P; Deliliers, GL; Dreger, P; Finke, J; Hansz, J; Martino, R; Michallet, M; Milligan, D; Niederwieser, D; Russell, N; Van Biezen, A | 1 |
| Ajchenbaum-Cymbalista, F; DeCaprio, JA; Delmer, A; Sanhes, L; Tang, R | 1 |
| Pettitt, AR | 1 |
| Cortes, JE; Giles, FJ; Kantarjian, HM; Keating, AR; Keating, MJ; O'Brien, SM; Shi, GG; Thomas, D | 1 |
| Agura, E; Anasetti, C; Blume, K; Chauncey, T; Hegenbart, U; Heimfeld, S; Maloney, D; Maris, MB; McSweeney, P; Niederwieser, D; Petersdorf, E; Pulsipher, M; Sandmaier, BM; Slattery, J; Storb, R; Storer, B; Stuart, M; Woolfrey, A | 1 |
| Annunziata, M; Copia, C; D'Amico, MR; De Simone, M; Ferrara, F; Palmieri, S; Pocali, B; Schiavone, EM; Vecchio, LD | 1 |
| Beyer, J; Bornhauser, M; Ehninger, G; Fauser, AA; Held, TK; Hensel, M; Ho, AD; Hoffken, K; Kiehl, M; Kienast, J; Kroger, N; Neubauer, A; Sayer, HG; Scheffold, C; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zander, AR | 1 |
| Okamoto, S | 1 |
| Burrows, A; Edenfield, WJ; Ekstrand, J; Lucas, M; Myhand, RC; Nelson, DA; Waselenko, JK | 1 |
| Callea, V; Cutrona, G; Ferrarini, M; Ferraris, AM; Mangiola, M; Morabito, F; Oliva, BM; Rapezzi, D; Rossi, E; Spriano, M; Stelitano, C; Zupo, S | 1 |
| Castagna, L; Santoro, A; Sarina, B | 1 |
| Azar, N; Bastit, D; Belhadj, K; Cazin, B; Delmer, A; Diviné, M; Feugier, P; Grosbois, B; Leprètre, S; Maloisel, F; Maloum, K; Manhès, G; Michallet, M; Tournilhac, O; Travade, P; Villard, F; Villemagne, B | 1 |
| Black, JH; Fleming, DR; Frankel, AE; Gartenhaus, R; Hall, PD; Leftwich, C; Powell, BL | 1 |
| Bentley, P; Fegan, C; Hooper, L; Hoy, T; Milligan, D; Pepper, C; Pratt, G; Starczynski, J; Thomas, A | 1 |
| Figgitt, DP; Plosker, GL | 1 |
| Huhn, D | 1 |
| Oscier, D | 1 |
| Cheson, BD | 2 |
| Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S | 1 |
| Brito, C; Cayota, A; Dighiero, G; Gabús, R; Landoni, AI; Oppezzo, P; Pritsch, O; Robello, C; Tiscornia, AC; Vuillier, F | 1 |
| Addison, E; Folarin, NI; Ganeshaguru, K; Hoffbrand, AV; Jones, DT; Lowdell, MW; Mehta, AB; North, JM; Wickremasinghe, RG | 1 |
| Brando, B; Cafro, AM; Cairoli, R; D'Avanzo, G; Farioli, R; Intropido, L; Montillo, M; Morra, E; Pungolino, E; Rossi, V; Scarpati, B; Tedeschi, A; Veronese, S | 1 |
| Bergmann, M; Emmerich, B; Fingerle-Rowson, G; Goede, V; Hallek, M; Schmitt, B; Schweighofer, C; Wendtner, CM | 1 |
| Begleiter, A; Gibson, SB; Hu, X; Johnston, JB; Kabore, AF; Kropp, DM; Kuschak, B; Paul, JT; Strutinsky, J | 1 |
| Stiefelhagen, P | 1 |
| Battle, TE; Dong, DA; Fisher, DC; Frank, DA; Freedman, AS; Friedberg, JW; Gribben, JG; Jurgens, R; Kim, H; Li, S; Neuberg, D; Noonan, K; Stephans, K; Takvorian, T | 1 |
| Ferry-Dumazet, H; Mamani-Matsuda, M; Marit, G; Molimard, M; Mossalayi, MD; Moynet, D; Reiffers, J | 1 |
| Baccarani, M; Fanin, R; Gentile, M; Mandelli, F; Marin, L; Mauro, FR; Stefoni, V; Tura, S; Vegna, ML; Zaja, F; Zinzani, P | 1 |
| Fricová, M; Guman, T; Kafková, A; Stecová, N; Tóthová, E | 1 |
| Kiewe, P; Knauf, W; Körper, S; Rieger, K; Seyfert, S; Thiel, E | 1 |
| Braester, A; Elmalah, Y; Quitt, M | 1 |
| Erba, HP | 1 |
| Adil, SN; Khurshid, M; Sajid, R; Usman, M | 1 |
| Byrd, JC; Flinn, IW; Grever, MR; Hackbarth, ML; Harbison, J; Heerema, NA; Lin, T; Lozanski, G; Lucas, D; Lucas, M; Moran, M; Proffitt, JH; Smith, L; Webb, J | 1 |
| Bairey, O; Berrebi, A; Lugassy, G; Polliack, A; Rahimi-Levene, N; Shpilberg, O; Shtalrid, M; Shvidel, L | 1 |
| Paydas, S | 1 |
| Barry, T; Ben Alon, D; Ben Dor, D; Blumental, R; Ducach, A; Lugassy, G; Nemets, A | 1 |
| Imagawa, J; Imamura, N; Katayama, Y; Kimura, A; Nimi, H; Simomura, T | 1 |
| Bongarzoni, V; Buffolino, S; Cimino, G; Montanaro, M; Niscola, P; Scaramucci, L | 1 |
| Gartenhaus, RB; Nabhan, C; Tallman, MS | 1 |
| Chen, JB; Kaushal, GP; Kurten, RC; Lacy, HM; Schichman, SA; Zent, CS | 1 |
| Binet, JL | 2 |
| Leporrier, M | 1 |
| Eichhorst, BF; Hallek, M | 1 |
| Boogaerts, MA | 1 |
| Albert, S; Bhogal, B; Black, MM; Oyama, N; Powell, AM; Sakuma-Oyama, Y | 1 |
| Coyle, L; Hsiao, E; Huynh, T; Mansberg, R; Roach, P | 1 |
| Nicolle, A; Proctor, SJ; Summerfield, GP | 1 |
| Grdisa, M | 1 |
| Boniver, J; de Leval, L; De Prijck, B; Du, MQ; Harris, NL; Isaacson, P; Vivario, M; Zhou, Y | 1 |
| Ferrajoli, A; O'Brien, SM | 1 |
| Alizadeh, AA; Arthur, DC; Chuang, EY; Davis, RE; Fowler, DH; Marti, GE; Mitchell, JB; Rosenwald, A; Staudt, LM; Wiestner, A; Wilson, WH | 1 |
| Appelbaum, FR; Byrd, JC; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, K; Schiffer, CA; Shepherd, L | 1 |
| Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Christopherson, RI; Mulligan, SP; Wilson, PK | 1 |
| Disel, U; Ergin, M; Paydas, S; Yavuz, S | 1 |
| Andreeff, M; Beran, M; Ferrajoli, A; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Tsimberidou, AM; Wierda, WG | 1 |
| Asch, J; Ford, CD; Petersen, FB; Pulsipher, M | 1 |
| Bowen, A; Catovsky, D; Hendry, L; Matutes, E; Swansbury, J | 1 |
| D'Arena, G; Di Renzo, N; Iodice, G; Pizza, V; Tartarone, A; Vigliotti, ML; Volpe, G | 1 |
| Dmoszyńska, A; Hellmann, A; Komarnicki, M; Kowal, M; Kuliczkowski, K; Kłoczko, J; Lewandowski, K; Piszcz, J; Roznowski, K; Skotnicki, AB; Wegrzyn, J; Wołowiec, D | 1 |
| Cheang, M; Gibson, SB; Haney, N; Hu, X; Johnston, JB; Kropp, DM; Neufeld, NJ; Paul, JT | 1 |
| Delavault, P; Fegan, CD; Hambly, RM; Pepper, CJ; Thurston, DE | 1 |
| Bone, ND; Geyer, SM; Kaufmann, SH; Kay, NE; Lee, YK; Narayanan, VL; Sausville, EA; Shanafelt, TD; Strege, AK | 1 |
| Binet, JL; Cass, CE; Dabbagh, L; Delmer, A; Dumontet, C; Galmarini, CM; Glubrecht, D; Graham, KA; Hanson, J; Jewell, LD; Joy, AA; Lai, R; Lang, T; Mackey, JR; Merle-Béral, H; Young, JD | 1 |
| Carew, JS; Dunner, K; Huang, P; Keating, MJ; McConkey, DJ; Nawrocki, ST; Wierda, WG; Xu, RH | 1 |
| Bengtzen, S; Lehmann, S; Merup, M; Mollgard, L; Nahi, H; Paul, C; Selivanova, G; Wiman, KG | 1 |
| Batár, P; Kiss, A; Méhes, L; Rejto, L; Telek, B; Udvardy, M | 1 |
| Celsing, F; Jondal, M; Morales, AA; Olsson, A; Osorio, LM; Osterborg, A | 1 |
| Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Huber-Ruano, I; Marcé, S; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M; Villamor, N | 1 |
| Briones, J; Forné, I; Juarez, C; Martinez-Gallo, M; Martinez-Lostao, L; Rodriguez-Sanchez, JL; Sierra, J | 1 |
| Aleskog, A; Höglund, M; Larsson, R; Laurell, A; Lindhagen, E; Nilsson, K; Nygren, P; Roos, G; Rosenquist, R; Sundström, C; Thunberg, U; Tobin, G | 1 |
| Majumdar, G; Ramachandran, A | 1 |
| Gibson, SB; Haney, N; Hu, X; Johnston, JB; Kabore, AF; Kropp, D | 1 |
| Briones, J; Ferrer, B; Forné, I; Juarez, C; Martinez-Gallo, M; Martinez-Lostao, L; Rodriguez-Sanchez, JL; Sierra, J | 1 |
| Catovsky, D; Del Giudice, I; Matutes, E; Osuji, N; Parry-Jones, N; Swansbury, J | 1 |
| Ayyildiz, O; Bolaman, Z; Isikdogan, A; Muftuoglu, E | 1 |
| Dziecioł, J; Kłoczko, J; Lemancewicz, D; Piszcz, J | 1 |
| Bellas, C; Catovsky, D; Matutes, E; Pocock, C; Santon, A; Shah, G; Thornton, PD; Wotherspoon, AC | 1 |
| Nichols, GL; Skerrett, DL | 1 |
| Robak, T | 1 |
| Byrd, JC; Grever, MR; Lin, TS | 1 |
| Albitar, M; Beran, M; Cortes, J; Do, KA; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; Lerner, S; O'Brien, S; Thomas, D; Wen, S; Wierda, W | 1 |
| Albitar, M; Andreeff, M; Cortes, J; Detry, MA; Faderl, S; Giles, F; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; Lynn, A; O'Brien, S; Plunkett, W; Thomas, D; Wierda, W | 1 |
| Jindra, P; Koza, V; Lysak, D; Schutzova, M; Steinerova, K; Vozobulova, V | 1 |
| Jindra, P; Koza, V; Lysák, D; Steinerová, K; Vozobulová, V | 1 |
| Agirre, X; Calasanz, MJ; Giraldo, P; Larráyoz, MJ; Odero, MD; Rubio-Felix, D; Rubio-Martinez, A; Valgañón, M | 1 |
| Arbiser, J; Battle, TE; Frank, DA | 1 |
| Agura, E; Al-Ali, H; Blume, KG; Bredeson, C; Bruno, B; Chauncey, TR; Hegenbart, U; Langston, A; Leis, J; Loken, MR; Maloney, DG; Maris, MB; McSweeney, P; Pulsipher, M; Radich, JP; Sandmaier, BM; Sorror, ML; Storb, R; Storer, BE; Stuart, MJ | 1 |
| Fong, D; Gastl, G; Kaiser, A; Spizzo, G; Tzankov, A | 1 |
| Coiffier, B; Michallet, AS; Michallet, M; Salles, G | 1 |
| Czock, D; Hertenstein, B; Keller, F; Kielstein, JT; Radermacher, J; Stadler, M | 1 |
| Richards, S | 1 |
| Burger, JA; Burger, M; Fujii, N; Hartmann, T; Kipps, TJ; Krome, M; Rawluk, J; Tamamura, H | 1 |
| Dührsen, U; Frey, UH; Nückel, H; Röth, A; Siffert, W | 1 |
| Beyer, M; Darabi, K; Debey, S; Endl, E; Hallek, M; Jensen, M; Knolle, PA; Kochanek, M; Popov, A; Schultze, JL; Thomas, RK; von Bergwelt-Baildon, M | 1 |
| Molica, S; Ribatti, D; Tucc, L; Vacca, A | 1 |
| Bond, R; Brown, M; Campbell, P; Grigg, AP; Ritchie, D; Scarlett, J; Seymour, JF; Tam, C; Underhill, C | 1 |
| Goor, KM; Huijgens, PC; Schaafsma, MR; van Agthoven, M | 1 |
| Chim, CS; Leung, WH; Tsang, SF | 1 |
| Adler, SS; Enschede, SH; Gregory, SA; Porter, C; Rao, R; Shammo, JM; Venugopal, P | 1 |
| Hirschman, R; Mastan, A; Ng, R; Rashid, K; Sager, D | 1 |
| Baba, Y; Fujimaki, K; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Takabayashi, M; Takasaki, H; Yamaji, S | 1 |
| Kwong, YL; Lam, CC; Ma, ES | 1 |
| Berger, C; Bernstein, ZP; Chanan-Khan, A; Czuczman, MS; Donohue, K; Klippenstein, D; Koryzna, A; Miller, KC; Mohr, A; Takeshita, K; Wallace, P; Zeldis, JB | 1 |
| Jacobs, MI; Mantha, S; Savage, DG | 1 |
| Hamblin, TJ | 1 |
| Bornkessel, A; Hahnfeld, S; Weyers, W; Ziemer, M | 1 |
| Bontemps, F; Cardoen, S; Offner, F; Van den Neste, E | 1 |
| Carew, JS; Dunner, K; Huang, P; Keating, MJ; Krupnik, YV; McConkey, DJ; Nawrocki, ST | 1 |
| Aulitzky, W; Borchmann, P; Elter, T; Engert, A; Gramatzki, M; Hallek, M; Hasan, I; Jensen, M; Josting, A; Rech, J; Reiser, M; Schinköthe, T; Schnell, R; Schulz, H; Staib, P; Stützer, H; Trelle, S | 1 |
| Abbott, BL | 1 |
| Batár, P; Telek, B; Uvardy, M | 1 |
| Appelbaum, FR; Boldt, DH; Budd, GT; Dakhil, SR; Dobin, SM; Elias, L; Foon, KA; Gundacker, H; Head, DR; Hussein, MA | 1 |
| Bergmann, M; Brittinger, G; Busch, R; Döhner, H; Eichhorst, BF; Emmerich, B; Hallek, M; Hensel, M; Hopfinger, G; Jäger, U; Pasold, R; Schweighofer, C; Siehl, S; Steinbrecher, C; Stilgenbauer, S; Wendtner, CM | 1 |
| Ernemann, U; Hebart, H; Herrlinger, U; Kanz, L; Knop, S | 1 |
| Barbarotto, E; Corallini, F; di Iasio, MG; Melloni, E; Secchiero, P; Tiribelli, M; Zauli, G | 1 |
| Amadori, S; Bruno, A; Buccisano, F; Cantonetti, M; Capelli, G; Consalvo, MA; Del Poeta, G; Del Principe, MI; Gattei, V; Gianní, L; Lo Coco, F; Maurillo, L; Mazzone, C; Venditti, A | 1 |
| Adam, K; Bergmann, J; Buchheidt, D; Hehlmann, R; Hummel, M; Reiter, S | 1 |
| Byrd, JC; Diehl, LF; Flinn, IW; Garrett-Mayer, E; Goodman, SN; Grever, MR; Kasamon, YL; Lucas, MS | 1 |
| Carney, DA; Estrov, Z; Garcia-Prieto, C; Harris, DM; Huang, P; Jin, Z; Kang, Y; Keating, MJ; Kondo, S; Liu, J; Lou, C; Pelicano, H; Xu, RH; Yu, W; Zhou, Y | 1 |
| Byrd, JC; Caligiuri, MA; Grever, MR; Gribben, JG; Heerema, NA; Lampson, B; Larson, RA; Lozanski, G; Lucas, DM; Peterson, BL | 1 |
| Cortes, J; Do, KA; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Lerner, S; O'brien, S; Ravandi-Kashani, F; Thomas, D; Wang, X; Wierda, W | 1 |
| Bukin, M; Jabłońska, E; Kiersnowska-Rogowska, B; Parfieńczyk, A; Puzewska, W; Rogowski, F | 1 |
| Abramenko, I; Bazyka, D; Bebeshko, V; Bilous, N; Chumak, A; Kryachok, I | 1 |
| Fay, M; Murphy, PT; Nolan, A; O'Donnell, R; Quinn, J; Swords, R | 1 |
| Khurshid, M; Syed, NN | 1 |
| Faria, JR; Faria, RM; Kerbauy, J; Oliveira, JS; Yamamoto, M | 1 |
| Castro, ED; Coelho, AM; Linden, R; Maia, RC; Silva, KL; Vasconcellos, DV | 1 |
| Higashihara, M; Horie, R; Motoji, T; Okamura, T; Shoda, M; Taira, M; Umezawa, K; Utsunomiya, A; Watanabe, M; Watanabe, T | 1 |
| Alberto, MF; Fernández-Calotti, P; Gamberale, R; Geffner, J; Giordano, M; Sánchez-Avalos, J | 1 |
| Aguado, JM; Díaz-Pedroche, C; Folgueira, D; Giménez-Mesa, E; Lizasoain, M | 1 |
| Ikeda, Y; Murase, T; Nishida, H; Park, JW; Ueno, H; Yano, T | 1 |
| Andreeff, M; Kojima, K; Konopleva, M; McQueen, T; O'Brien, S; Plunkett, W | 1 |
| Kay, NE | 1 |
| Cairoli, R; Colosimo, A; Intropido, L; Miqueleiz, S; Montagna, M; Montillo, M; Morra, E; Nichelatti, M; Regazzi, M; Ricci, F; Scarpati, B; Tedeschi, A; Veronese, S | 1 |
| Benetatos, L; Bourantas, KL; Hatzimichael, E; Vassou, A | 1 |
| Carney, D; Januszewicz, EH; Lin, KI; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M | 1 |
| Byrd, JC; Croce, CM; De Lay, MD; Edwards, RB; Grever, MR; Johnson, AJ; Lucas, DM; Muthusamy, N; Smith, LL | 1 |
| Hanamura, A; Hayakawa, M; Naito, K | 1 |
| Alexopoulou, A; Archimandritis, AJ; Dourakis, SP; Karayiannis, P; Pandelidaki, H | 1 |
| Bohlius, J; Greil, R; Pall, G; Richards, S; Schwarzer, G; Steurer, M | 2 |
| Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Laurenti, L; Leone, G; Piccioni, P; Piccirillo, N; Sica, S; Tarnani, M | 1 |
| Byrd, JC; Esseltine, DL; Faderl, S; Flinn, IW; Gribben, J; Keating, MJ; O'Brien, S; Rai, K; Sheng, S | 1 |
| Elter, T; Engert, A; Hallek, M | 1 |
| Audouin, J; Compérat, E; Delmer, A; Diebold, J; Le Tourneau, A; Molina, TJ | 1 |
| Choudhury, A; Kiaii, S; Lundin, J; Mellstedt, H; Mozaffari, F; Osterborg, A; Rezvany, R | 1 |
| Everett, PC; Lerner, A; Makkinje, A; Meyers, JA; Rabbi, M | 1 |
| Keating, MJ; Moufarij, MA; Plunkett, W; Sampath, D | 1 |
| Dmoszyńska, A; Giannopoulos, K; Roliński, J | 1 |
| Benedetti, F; Boccadoro, M; Chisesi, T; De Blasio, A; Drandi, D; Gallamini, A; Ladetto, M; Locasciulli, A; Majolino, I; Tarella, C | 1 |
| Carter, WH; Cragg, L; Feldman, EJ; Grant, S; Honeycutt, C; Millenson, MM; Murgo, AJ; Padavic-Shaller, K; Ramakrishnan, V; Roberts, JD; Roboz, GJ; Smith, MR; Thune, R | 1 |
| Campo, E; Gaya, A; Martinez, A; Mercadal, S; Nomdedeu, B; Rozman, M; Salamero, O | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Tiongson, LP; Younes, A | 1 |
| Bianchi, M; Castiglioni, MG; Mechelli, S; Pandolfo, C; Scatena, P | 1 |
| Busch, R; Eichhorst, BF; Emmerich, B; Hallek, M; Schweighofer, C; Wendtner, CM | 1 |
| Alyea, EP; Antin, JH; Brown, JR; Cutler, C; Fisher, DC; Gribben, JG; Ho, V; Kim, HT; Lee, SJ; Li, S; Milford, EL; Ritz, J; Soiffer, RJ; Stephans, K | 1 |
| Anhalt, GJ; Cummins, DL; Meyerle, JH; Mimouni, D; Owens, N; Tzu, J | 1 |
| Flinn, IW; Kasamon, YL | 1 |
| Kay, NE; O'Brien, S; Rai, KR | 1 |
| Cebula, B; Linke, A; Robak, P; Robak, T; Smolewski, P | 1 |
| Celsing, F; Hansson, L; Karlsson, C; Lundin, J | 1 |
| Bakke, AC; Braziel, RM; Fan, G; Gatter, KM; Huang, JZ; Leis, JF; Maziarz, RT; Zhong, Y | 1 |
| Avcu, F; Cetin, T; Kubar, A; Nevruz, O; Safali, M; Tastan, HB; Ural, AU | 1 |
| Appelbaum, FR; Bennett, JM; Dewald, GW; Flinn, IW; Grever, MR; Hussein, MA; Larson, RA; Moore, DF; Neuberg, DS; Paietta, EM; Tallman, MS | 1 |
| Bociek, RG; Boyd, TE; Chanan-Khan, AA; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Pavletic, S; Rai, KR; Seymour, JF; Skotnicki, A | 1 |
| Algüneş, C; Demir, M; Ongören, S; Pala, FS; Pamuk, GE; Soysal, T; Tabakcioğlu, K; Turgut, B; Vural, O | 1 |
| O' Brien, S | 1 |
| Borthakur, G; Cortes, JE; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Thomas, DA; Wierda, WG | 1 |
| Algarotti, A; Bernasconi, P; Boni, M; Brusamolino, E; De Amici, M; Giardini, I; Lazzarino, M; Orlandi, E; Paulli, M; Perfetti, V; Tenore, AM; Vanelli, L; Zibellini, S | 1 |
| Busch, R; Eichhorst, BF; Hallek, M; Herschbach, P; Kuhn-Hallek, I; Obwandner, T | 1 |
| Bunker, CB; Chapman, A; Dearden, CE; Dungarwalla, M; Field-Smith, A; Jameson, C; Matutes, E; Riley, U | 1 |
| Hashimoto, T; Hull, CM; Ishii, N; Leiferman, KM; Taintor, AR; Zone, JJ | 1 |
| Amadori, S; de Fabritiis, P; Del Poeta, G; Fratoni, S; Maurillo, L; Niscola, P; Palombi, M; Piccioni, D; Principe, MI | 1 |
| Admirand, J; Bueso-Ramos, C; Champlin, RE; Giralt, S; Keating, MJ; Khouri, IF; Korbling, M; Lee, MS; Lima, de M; O'Brien, S; Saliba, RM; Samuels, BI | 1 |
| Bilgrami, S; Mahipal, A | 1 |
| León-Mateos, A; Sánchez-Aguilar, D; Toribio, J | 1 |
| Alinari, L; Andritsos, L; Baiocchi, RA; Byrd, JC; Lapalombella, R; Lin, TS | 1 |
| Byrd, JC; Grever, M; Jacob, ST; Kutay, H; Lucas, DM; Majumder, S; Motiwala, T; Neuberg, DS; Smith, DS | 1 |
| Cascavilla, N; D'Arena, G | 1 |
| Delavault, P; Fegan, C; Hartley, JA; Lowe, H; Pepper, C; Thurieau, C; Thurston, DE | 1 |
| Barge, RM; Beaumont, F; Falkenburg, JH; Hoogendoorn, M; Jedema, I; Marijt, EW; van Luxemburg-Heijs, SA; Willemze, R | 1 |
| Kay, NE; Shanafelt, TD | 1 |
| Bezares, RF; Bosanquet, AG; Brito-Babapulle, V; Catovsky, D; Child, JA; Davis, Z; Dearden, CE; Dyer, M; Else, M; Hamblin, T; Hamilton, MS; Hillmen, P; Matutes, E; Milligan, DW; Oscier, D; Pettitt, AR; Richards, S; Smith, AG; Wade, R | 1 |
| Anderson, VR; Perry, CM | 1 |
| Hillmen, P; Rawstron, AC; Sayala, HA | 1 |
| Byrd, JC; Lee, RJ; Muthusamy, N; Wu, J; Zhao, X | 1 |
| Celsing, F; Choudhury, A; Derkow, K; Jondal, M; Norberg, M; Okvist, A; Olsson, A; Osorio, LM; Osterborg, A; Rosenquist, R; Tobin, G | 1 |
| Christopherson, RI; Henrich, S | 1 |
| Baou, M; Naresh, K; Wagner, SD; Willimott, S | 1 |
| Mirabelli, R; Molica, S; Montillo, M; Morra, E; Ribatti, D; Ricci, F; Tedeschi, A; Vacca, A; Veronese, S | 1 |
| Decker, T; Fend, F; Götze, KS; Hoffmann, D; Peschel, C; Schätzl, HM | 1 |
| Bacchu, S; Fegan, C; Neal, J | 1 |
| Biderman, BV; Kolosheĭnova, TI; Kolosova, LIu; Kovaleva, LG; Lorie, IuIu; Nikitin, EA; Risinskaia, NA; Salogub, GN; Stadnik, EA; Sudarikov, AB; Tsyba, NN; Zaritskiĭ, IuA | 1 |
| Baer, MR; Barcos, M; Claydon, MA; Conroy, JM; Nowak, NJ; Sait, SN | 1 |
| Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C | 1 |
| Bowen, DA; Call, TG; Habermann, TM; Hoyer, JD; Jelinek, DF; Kay, NE; Maddocks-Christianson, K; Reinalda, M; Schwager, S; Shanafelt, TD; Slager, SL; Zent, CS | 1 |
| Mulligan, SP | 1 |
| Browning, M; Faderl, S; Ferrajoli, A; Kantarjian, H; Khouri, I; Lerner, S; O'Brien, S; Tam, CS; Tsimberidou, AM; Wierda, WG | 1 |
| Huisman, CA; Laros-van Gorkom, BA; Schipperus, MR; Wijermans, PW | 1 |
| Li, SX; Liu, Y; Lu, XC; Zhu, HL | 1 |
| Dyer, MJ; Gesk, S; Kennedy, DB; Majid, A; Siebert, R; Tsoulakis, O; Walewska, R | 1 |
| Austen, B; Baker, C; Dyer, M; Gardiner, A; Majid, A; Moss, PA; Oscier, D; Powell, JE; Siebert, R; Skowronska, A; Stankovic, T; Taylor, AM | 1 |
| Heiskanen, J; Itälä, M; Jantunen, E; Juvonen, E; Koistinen, P; Koivunen, E; Kuittinen, T; Nousiainen, T; Remes, K; Siitonen, T; Silvennoinen, R; Volin, L | 1 |
| Garratty, G; Petz, LD | 1 |
| Byrd, JC; Flynn, JM | 1 |
| Dabrowska, M; Dzieciol, J; Kloczko, J; Lemancewicz, D; Piszcz, JA; Rusak, M | 1 |
| Byrd, J; Cheney, C; Chu, P; Hariharan, K; Molina, A; Pathan, NI | 1 |
| Catovsky, D; Dearden, C; Else, M; Hamblin, T; Milligan, D; Richards, S; Wade, R | 1 |
| Avalos, JS; Cañones, C; Chianelli, M; Fernández Calotti, P; Galmarini, CM; Gamberale, R; Giordano, M; Rosenstein, R; Saénz, D | 1 |
| Debey, S; Hallek, M; Kofler, D; Königs, S; Pallasch, CP; Schultze, JL; Schulz, A; Schwamb, J; Ultsch, A; Wendtner, CM | 1 |
| Barbarotto, E; Celeghini, C; Corallini, F; Fadda, R; Grill, V; Mischiati, C; Rimondi, E; Vaccarezza, M | 1 |
| Abella, E; Altés, A; Asensi, A; Aymerich, M; Bertazzoni, P; Bosch, F; Briones, J; Escoda, L; Ferrer, A; Font, L; Gardella, S; Giné, E; González, M; González-Barca, E; Montserrat, E; Muntañola, A; Pérez-Ceballos, E; Rozman, M; Sayas, MJ; Villamor, N | 1 |
| Alexandrescu, DT; Wiernik, PH | 1 |
| Browning, ML; Faderl, S; Ferrajoli, A; Keating, MJ; LaPushin, R; O'Brien, SM; Wierda, WG | 1 |
| Brown, JR; Estrov, Z; Ferrajoli, A; Fiorentino, A; Garcia-Manero, G; Kantarjian, HM; Keating, MJ; Kipps, TJ; Kurzrock, R; Lerner, S; O'Brien, S; Plunkett, W; Ravandi-Kashani, F; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Bearden, JD; Greco, FA; Hainsworth, JD; Raefsky, E; Saez, RA; Spigel, DR; Vazquez, ER | 1 |
| Chen, L; Lü, SQ; Ni, X; Song, XM; Wang, JM; Xu, XQ; Yang, JM; Zhang, WP | 1 |
| Andrýs, C; Belada, DZ; Krejsek, J; Malý, J; Siroký, O; Smolej, L; Zák, P | 1 |
| Asslaber, D; Greil, R; Hamacher, F; Heyder, C; Holler, C; Merkel, O; Papak, C; Prokesch, A; Scheideler, M; Stöcher, M; Tinhofer, I; Trajanoski, Z | 1 |
| Gandhi, V; Jewell, RC; Keating, MJ; Lerner, S; O'Brien, S; Plunkett, W; Rodriguez, CO; Tam, C | 1 |
| Catovsky, D; Dearden, CE; Dungarwalla, M; Evans, SO; Matutes, E; Riley, U | 1 |
| Bengtzen, S; Concha, H; Lehmann, S; Merup, M; Möllgård, L; Nahi, H; Paul, C; Selivanova, G; Svensson, A; Wiman, KG | 1 |
| Christian, BA; Lin, TS | 1 |
| Banerji, V; Gibson, SB; Hu, X; Johnston, JB; Mendoza, FJ; Sun, J | 1 |
| Cortes, J; Do, KA; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S; Tam, CS; Thomas, DA; Wen, S; Wierda, W | 1 |
| Coiffier, B; Rioufol, C | 1 |
| Calvo-Villas, JM; Sicilia, F; Umpierrez, AM; Urcuyo, BM | 1 |
| Gill, S; Grigg, A; Ritchie, D; Szer, J | 1 |
| Ashique, A; Begleiter, A; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L | 1 |
| del Villar, V; López, L; Pascual, T | 1 |
| Bourquard, P; Emberger, JM; Exbrayat, C; Fégueux, N; Lavabre-Bertrand, C; Lavabre-Bertrand, T; Navarro, M; Poncelet, P; Rousset, T; Taïb, J | 1 |
| Juliusson, G | 2 |
| Estey, E; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, W; Robertson, LE | 1 |
| Cabanillas, F; Dimopoulos, M; Gandhi, V; Gregoire, V; Kantarjian, H; Keating, MJ; Li, YY; McLaughlin, P; O'Brien, S; Robertson, LE | 1 |
| Bosanquet, AG; Catovsky, D; Crotty, GM; McCann, SR; Mills, MJ | 1 |
| Cacciola, E; Di Raimondo, F; Giustolisi, R; Impera, S; Milone, G; Palumbo, GA; Romeo, MA | 1 |
| Paolini, R; Petracca, GE; Ramazzina, E; Rimondi, AP; Zamboni, S; Zennaro, R | 1 |
| Andreeff, M; Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE | 1 |
| Byrd, JC; Diehl, LF; Freiman, J; Hertler, AA; Kweder, SL; Weiss, RB | 1 |
| Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE | 1 |
| Andreeff, M; Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, LE | 1 |
| Brugiatelli, M; Callea, I; Callea, V; Iacopino, P; Messina, G; Morabito, F; Nobile, F; Rodinò, A | 1 |
| Leoni, P; Montillo, M; Tedeschi, A | 2 |
| Hiddemann, W; Pott-Hoeck, C | 1 |
| Gouldesbrough, DR; Macheta, MP; Parapia, LA | 1 |
| O'Brien, RK; Sparling, TG | 1 |
| Briz, M; Cabrera, JR; Díez, JL; Fernández, MN; Forés, R; Herrero, M; Regidor, C; Sanjuán, I | 1 |
| del Giglio, A; Keating, M; O'Brien, S | 1 |
| Appleton, AL; Hamilton, PJ; Jackson, GH; Maung, ZT; Turner, GE; Wood, AC | 1 |
| Keating, MJ; O'Brien, S; Plunkett, W; Robertson, LE; Wright, SJ | 1 |
| Cass, Y; Dann, EJ; Gillis, S; Polliack, A; Rochlemer, RR | 1 |
| Catovsky, D; Cunningham, D; Ellis, PA; Emmett, E; Hickish, T; Hill, M; Matutes, E; Mercieca, J; Milan, S; O'Brien, ME | 1 |
| Benner, A; Bentz, M; Cabot, G; Coy, J; Diehl, D; Döhner, H; Fischer, K; Galle, PR; Hansen, K; Hunstein, W; Lichter, P; Poustka, A; Schlenk, R; Stilgenbauer, S; Volkmann, M | 1 |
| Alfarano, A; Bergui, L; Caligaris-Cappio, F; De Leo, AM; Gottardi, D; Stacchini, A | 1 |
| Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Pierce, S; Robertson, B | 1 |
| Juliusson, G; Liliemark, J | 3 |
| Piro, L; Saven, A | 1 |
| Hopkins, JA; Howe, D; Johnson, SA; Phillips, MJ; Richardson, DS | 1 |
| Girmenia, C; Mauro, FR; Rahimi, S | 1 |
| Canellakis, ZN; Costin, D; Degar, B; Drygas, JC; Mani, M; Morse, L; Newcomb, EW; Potmesil, M; Rosenberg, CR; Silber, R | 1 |
| Bosly, A; Brousset, P; Delannoy, A; Pris, J; Riga-Huguet, F; Schlaifer, D | 1 |
| Aguilera, A; Liaño, F; Montalban, C | 1 |
| Bendandi, M; Buzzi, M; Farabegoli, P; Martinelli, G; Ottaviani, E; Salvucci, M; Tosi, P; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Dean, MG; Mulligan, SP | 1 |
| Buzzi, M; Farabegoli, P; Fortuna, A; Martinelli, G; Tosi, P; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Bruijn, JA; van Groningen, K; van Royen, EA; Wijermans, PW | 1 |
| Berman, E; Kempin, S; Spiess, T; Weiss, M | 1 |
| Bendandi, M; Tabanelli, M; Tura, S; Zinzani, PL | 1 |
| Chubb, S; Ford, R; Hittelman, WN; Meyn, RE; Plunkett, W; Robertson, LE; Story, M | 1 |
| Delannoy, A; Ferrant, A; Hanique, G | 1 |
| Lemon, RH; Piro, LD; Saven, A | 1 |
| Larson, RA; Spielberger, RT; Stock, W | 1 |
| Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Robertson, LB | 1 |
| Leporrier, M; Reman, O; Troussard, X | 1 |
| Clauvel, JP; Jaccard, A; Oksenhendler, E | 1 |
| Chamone, DF; Deisseroth, AB; Del Giglio, A; Ford, RJ; Johnston, D; Keating, M; Manning, J; O'Brien, S; Saya, H | 1 |
| Huh, Y; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, W; Robertson, L | 1 |
| Gandhi, V | 1 |
| Buckley, C; Hoffbrand, AV; Smith, OP | 1 |
| Collins, KA; Davda, RK; Kitchens, CS | 1 |
| Gandhi, V; Keating, MJ; Plunkett, W; Robertson, LE | 1 |
| Cabanillas, F; Gandhi, V; Gregoire, V; Keating, MJ; McLaughlin, P; O'Brien, S; Plunkett, W; Robertson, LE; Yang, L | 1 |
| Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Kemena, A; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, L | 1 |
| Cacciola, E; Di Raimondo, F; Giustolisi, R; Kantarjian, H; Keating, MJ; O'Brien, S; Robertson, LB | 1 |
| Cleveland, KO; Gelfand, MS | 1 |
| Rai, KR | 3 |
| Bergmann, L; Fenchel, K; Hoelzer, D; Jahn, B; Mitrou, PS | 1 |
| Benfenati, D; Bocchia, M; Cavo, M; Cirio, TM; Gozzetti, A; Lauria, F; Raspadori, D; Rondelli, D; Zaja, F; Zinzani, PL | 1 |
| Gandhi, V; Keating, MJ; Kemena, A; Plunkett, W | 2 |
| Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Lerner, S; O'Brien, S; Robertson, LE; Smith, T | 1 |
| Abdallah, JM; Cohen, RB; Foss, F; Gray, JR | 1 |
| Hopkins, J; Howe, D; Johnson, SA; Phillips, MJ; Richardson, D | 1 |
| Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Feldman, EJ; Keating, MJ | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
| Pawelski, S | 1 |
| Bergmann, L; Diehl, V; Engert, A; Fenchel, K; Hoelzer, D; Mitrou, PS; Pralle, H; Wijermans, P | 1 |
| Keating, MJ; Lerner, S; O'Brien, S; Robertson, LE; Seymour, JF | 1 |
| de Marie, S; Leenders, A; Sonneveld, P | 1 |
| Copplestone, JA; Craig, V; Curtis, D; Hamblin, TJ; Hamon, MD; Myint, H; Orchard, J; Oscier, DG; Prentice, AG | 1 |
| Algora, M; Briz, M; Cabrera, R; Díez, JL; Fernández, MN; Forés, R; Herrero, M; Regidor, C; Sanjuán, I | 1 |
| Calleja, E; Gabrilove, J; Menzel, T; Rahman, Z; White, K; Wieder, R; Wilson, EL | 1 |
| Denny, AW; Huh, YO; Keating, MJ; Nelson, JA; Plunkett, W; Robertson, LE | 1 |
| Maclean, R; Meiklejohn, D; Soutar, R | 1 |
| Brown, RD; Gibson, J; Joshua, DE; Luo, XF; Petersen, AJ; Pope, B; Schutz, L; Wiley, JS | 1 |
| Catovsky, D; Murphy, RL | 1 |
| Alcorta, I; Briones, J; Pereira, A | 1 |
| Bachelez, H; Bazarbachi, A; Dehen, L; Delmer, A; Dubertret, L; Zittoun, R | 1 |
| Emmerich, B; Hiddemann, W; Johnson, S; Juliusson, G; Löffler, H; Osby, E; Smith, AG; Wyld, PJ | 1 |
| Geisen, F; Konwalinka, G; Michlmayr, G; Schirmer, M | 1 |
| Williamson, LM; Wimperis, JZ; Wood, ME; Woodcock, B | 1 |
| Saven, A | 2 |
| Falkson, CI; Falkson, G; Hocepied, AM | 1 |
| Hakimian, D; Tallman, MS | 1 |
| Gjedde, SB; Hansen, MM | 1 |
| Catovsky, D; Glynne, P; Hamblin, M; Matthey, F; Mehta, J; Middleton, G; Powles, R; Prendiville, J; Singhal, S; Treleaven, J; Zomas, A | 1 |
| Keating, MJ; Wright, SJ | 1 |
| Bosch, F; Briones, J; Colomer, D; Esteve, J; Hadjieu, E; López-Guillermo, A; Montserrat, E; Rozman, C; Urbano-Ispizua, A | 1 |
| Chandra, J; Keating, M; McConkey, DJ; McDonnell, TJ; Plunkett, W; Reed, JC; Wright, S | 1 |
| Lärfars, G; Samuelsson, J; Udén-Blohmé, AM | 1 |
| Błasinka-Morawiec, M; Ceglarek, B; Dmoszynska, A; Durzynski, T; Dwilewicz-Trojaczek, J; Grieb, P; Hansz, J; Hellmann, A; Kasznicki, M; Komarnicki, M; Konopka, L; Kopec, I; Kotlarek-Haus, S; Krykowski, E; Lewandowski, K; Maj, S; Mazur, G; Potemski, P; Płuzanska, A; Robak, T; Sikorska, A; Skotnicki, AB; Urasinski, I; Zaucha, JM; Zdziarska, B | 1 |
| Bayle, C; Cartron, J; Lambert, T; Rudent, A; Tchernia, G; Tertian, G | 1 |
| Lipton, JH; Pierratos, A; Tisler, A | 1 |
| Adam, Z; Hejlová, N; Vorlícek, J | 1 |
| Al-Katib, A; Gabrilove, JL; König, A; Lynen, S; Menzel, T; Raveche, E; Rosén, A; Wrazel, L | 1 |
| Kantarjian, H; Keating, MJ; O'Brien, S | 1 |
| Byrnes, JJ; Frankfurt, OS; Villa, L | 1 |
| Bowen, AL; Catovsky, D; Dyer, MJ; Emmett, E; Matutes, E; Zomas, A | 1 |
| Bourantas, KL; Briasoulis, E; Christou, L; Konstantinidou, P; Panteli, A; Tsiara, S | 1 |
| Dighiero, G | 1 |
| Aziz, M; Levin, M; Opitz, L | 1 |
| Andersson, BS; Champlin, RE; Giralt, S; Keating, MJ; Khouri, IF; Körbling, M; Lerner, S; Mehra, RC; O'Brien, S; Palmer, JL; Przepiorka, D; van Besien, K; Vriesendorp, HM | 1 |
| Brisou, P; de Jaureguiberry, JP; Gisserot, O; Hequet, O; Jaubert, D; Muzellec, Y | 1 |
| Alcala, A; Arias-Sampedro, J; Bosch, F; Fernandez, MN; Garcia-Conde, J; Guardia, R; Lopez-Lorenzo, JL; Manso, F; Martin, A; Montserrat, E; Odriozola, J; Oyarzabal, FJ; Prieto, E | 1 |
| Hiddemann, W; Pott, C | 1 |
| Bergmann, L | 1 |
| Hilgenfeld, E; Jäger, U; Knauf, WU; Mitterbauer, M; Wilfing, A | 1 |
| Arning, M; Schneider, W; Südhoff, T | 1 |
| Catovsky, D; Dyer, MJ; Emmett, E; Hale, G; Kelsey, SM; Mackay, HJ; Newland, AC; Thornton, P; Waldmann, H | 1 |
| Ballin, A; Davidovitz, Y; Meytes, D | 1 |
| Frewin, RJ; Provan, D; Smith, AG | 1 |
| Cusack, JC; Keating, MJ; Lerner, S; Pollock, RE; Seymour, JF | 1 |
| Bendandi, M; Benni, M; Cavo, M; de Vivo, A; Magagnoli, M; Rondelli, D; Tura, S; Zamagni, E; Zinzani, PL | 1 |
| Emilia, G; Ferrara, L; Gandini, G; Longo, G; Torelli, U | 1 |
| Magagnoli, M; Ottaviani, E; Pellacani, A; Tosi, P; Tura, S; Zinzani, PL | 1 |
| Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Talpaz, M | 1 |
| Alfarano, A; Aragno, M; Bergui, L; Caligaris-Cappio, F; Circosta, P; De Leo, AM; Gottardi, D; Gregoretti, MG; Stacchini, A | 1 |
| Soda, R; Tada, A; Takahashi, K; Takeuchi, M | 1 |
| Antich Rojas, J; Balaguer, H; Cladera, A | 1 |
| Begleiter, A; Daeninck, P; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L; Williams, G | 1 |
| Berrebi, A; Klepfish, A; Shtarlid, M; Shvidel, L; Sigler, E | 1 |
| Baccarani, M; Marin, L; Rogato, A; Russo, D; Silvestri, F; Zaja, F | 1 |
| Andreeff, M; Armitage, RJ; Clodi, K; Consoli, U; Palmer, JL; Snell, V; Thomas, EK; Younes, A; Zhao, S | 1 |
| Beal, CL; Byrd, JC; Chaffin, DJ; Vick, DJ | 1 |
| Losonczy, H | 1 |
| Byrd, JC; Diehl, LF; Freiman, J; Kweder, SL; Weiss, RB | 1 |
| Amoroso, V; Baccarani, M; Beltrami, CA; Damiani, D; Di Loreto, C; Fanin, R; Infanti, L; Mariuzzi, L; Russo, D; Salmaso, F; Silvestri, F; Zaja, F | 1 |
| Baudet, S; Binet, JL; Blanc, C; Issaly, F; Mentz, F; Merle-Beral, H | 1 |
| Cheson, BD; Frame, JN; Quashu, N; Sorensen, JM; Vena, D | 1 |
| Clauvel, JP; Eftekhari, P; Lassoued, K; Oksenhendler, E; Scieux, C | 1 |
| Alfinito, F; Bonelli, P; Chiurazzi, F; Costantini, S; Defrance, T; Lamberti, A; Romano, MF; Tassone, P; Tuccillo, F; Turco, MC; Venuta, S | 1 |
| Leach, M; Parsons, RM; Reilly, JT; Winfield, DA | 2 |
| O'Brien, S | 1 |
| Keating, MJ | 1 |
| Bellucci, R; Cordone, I; de Fabritiis, P; De Propris, MS; Foà, R; Lisci, A; Mauro, FR; Sala, R | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE | 1 |
| Bromidge, TJ; Howe, DJ; Johnson, SA; Rule, SA; Turner, DL | 1 |
| Azar, N; Binet, JL; Dighiero, G; Gabarre, J; Gonzalez, H; Leblond, V; Sutton, L; Vernant, JP | 1 |
| Anderlini, P; Andersson, B; Champlin, R; Claxton, D; Donato, M; Gajewski, J; Gee, A; Giralt, S; Ippoliti, C; Keating, M; Khouri, IF; Körbling, M; O'Brien, S; Przepiorka, D; Ueno, N; von Wolff, B | 1 |
| Miller, M | 1 |
| Kim, HS; Niihara, Y; Yospur, L | 1 |
| Hamblin, TJ; Myint, H; Orchard, JA; Oscier, DG | 1 |
| Anaissie, EJ; Kantarjian, H; Keating, MJ; Kontoyiannis, DP; Lerner, S; O'Brien, S; Robertson, L | 1 |
| Callea, I; Console, G; Filangeri, M; Messina, G; Morabito, F; Sculli, G | 1 |
| Byrd, JC; Diehl, LF; Flinn, IW; Fuchs, EJ; Grever, MR; Lehman, TA; Nguyen, PL; Sausville, E; Shinn, C; Waselenko, JK | 1 |
| Huang, P; Plunkett, W; Robertson, LE; Wright, S | 1 |
| Cawley, M; Kaplan, B; Narasihman, P; Taha, HM; Venkatesh, L | 1 |
| Azgui, Z; Baudet, S; Brefort, K; Chretien, MC; Dujarric, C; Maloum, K; Mentz, F; Merle-Béral, H; Sevin, O; Vinsobre, MF | 1 |
| Filangeri, M; Morabito, F; Oliva, B; Sculli, G | 1 |
| Berrebi, A; Klepfish, A; Shimoni, A; Shtalrid, M; Shvidel, L; Sigler, E | 1 |
| Koski, T; Vilpo, J; Vilpo, L | 2 |
| Asfoura, J; Butty, H; Cortese, F; Doyle, M; Rutecki, G | 1 |
| Karadogan, I; Timuragaoglu, A; Undar, L | 1 |
| Bergmann, L; Hoelzer, D; Jäger, E; Käfer, G; Mitrou, PS; Pfreundschuh, M; Reinhardt, U; Rummel, MJ | 1 |
| Brugiatelli, M; Callea, V; Iuliano, F; Kropp, MG; Levato, D; Molica, S; Morabito, F; Nobile, F; Oriana, V; Stelitano, C | 1 |
| Elliott, MA; Hammack, JE; Hoyer, JD; Letendre, L; Li, CY | 1 |
| Albertini, P; Magagnoli, M; Ottaviani, E; Pellacani, A; Tosi, P; Tura, S; Zinzani, PL | 1 |
| Al-Katib, AM; Beck, FW; Dutcher, BS; Hamdy, N; Limvarapuss, C; Mohammad, RM; Wall, NR | 1 |
| Frank, DA; Mahajan, S; Ritz, J | 1 |
| Camerone, G; Epis, R; Marruchella, A; Tondini, M | 1 |
| Zingman, BS | 1 |
| Bravery, CA; Hoffbrand, AV; Lewin, J; Mehta, AB; Mengubas, K; Owens, DL; Riordan, FA; Wickremasinghe, RG | 1 |
| Emmanouilides, C; Kunkel, L; Rasti, S; Rosen, P; Territo, M | 1 |
| Friedenberg, WR; Hogan, TF; Marx, JJ; Mazza, JJ; Musser, C; Rodvold, KA; Rushing, DA; Spencer, SK; Tewksbury, DA | 1 |
| Bouabdallah, R; Cohen-Valensi, R; Coso, D; Costello, R; Gastaut, JA; Nezri, M; Sainty, D | 1 |
| Kalaycio, M; Sen, K | 1 |
| Dreger, P; Emmerich, B; Hallek, M; Montserrat, E; Schmitt, B; Wendtner, CM; Wilhelm, M | 1 |
| Bosanquet, AG; Johnson, SA; Richards, SM | 1 |
| Fiser, J; Jindra, P; Koza, V; Svojgrová, M; Vozobulová, V | 1 |
| Demeter, J; Lehoczky, D; Varga, F | 1 |
| Costello, C; Shah, S; Stern, SC | 1 |
| Magagnoli, M; Pellacani, A; Tosi, P; Tura, S; Visani, G; Zinzani, PL | 1 |
| Bellosillo, B; Colomer, D; Gil, J; Montserrat, E; Pons, G; Villamor, N | 1 |
| Cawley, JC; Pettitt, AR; Sherrington, PD | 2 |
| Baccarani, M; Marin, L; Ramello, M; Russo, D; Silvestri, F; Zaja, F | 1 |
| Bolgert, F; Camporo, P; Gonzalez, H; Leblond, V | 1 |
| Beinert, T; Hallek, M; Langelotz, C; Mergenthaler, HG; Possinger, K; Schmid, P; Schweigert, M; Sezer, O | 1 |
| Ahsan, G; Jones, R; Schey, S | 1 |
| Catovsky, D; Ribeiro, I; Tsatalas, C | 1 |
| Barrett, J; Cheson, BD; Freidlin, B; Vena, DA | 1 |
| Bentley, P; Davies, S; Hidalgo de Quintana, J; Hoy, T; Pepper, C; Thomas, A | 1 |
| Grau, E; Pastor, E; Real, E; Sandra, S | 1 |
| Faure, I; Leng, B; Mercié, P; Pellegrin, JL; Viallard, JF | 1 |
| Arcaini, L; Astori, C; Baldanti, F; Bernasconi, C; Furione, M; Gerna, G; Lazzarino, M; Orlandi, E; Pagnucco, G; Paulli, M; Viglio, A | 1 |
| Gandhi, V; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Plunkett, W; Robertson, LE; Santini, V; Seymour, JF | 1 |
| Calvo Villas, J; Ramírez Sánchez, M; Sicilia Guillén, F | 1 |
| Bauer, O; Golfier, S; Klein, A; Miera, O; Schriever, F | 1 |
| Battista, R; Bendandi, M; Cellini, C; Ciccone, F; De Renzo, A; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Magagnoli, M; Marra, R; Mazza, P; Moretti, L; Ricciuti, F; Ronconi, F; Stefoni, V; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Lamberti, A; Romano, MF; Turco, MC; Venuta, S | 1 |
| Bowyer, JD; Gregson, RM; Horn, EH; Johnson, EM | 1 |
| Ahmad, I; Al-Katib, AM; Beck, FW; Liu, KZ; Mantsch, HH; Mohammad, RM; Wall, NR | 1 |
| Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S | 1 |
| Freireich, EJ; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S; Robertson, LE; Smith, TL | 1 |
| Chastang, C; Chevret, S; Leporrier, M | 1 |
| Chatterjee, R; Goldstone, A; Haines, GA; Morris, ID; Perera, DM | 1 |
| Andreeff, M; Clodi, K; Consoli, U; Jiang, S; Kliche, KO; Schenk, T; Snell, V; Weidner, D; Zhao, S | 1 |
| Apperley, JF; Belhabri, A; Björkstrand, B; Dreger, P; Hamon, M; Kimby, E; Michallet, M; Milpied, N; Remes, K; Santini, G; Tanguy, ML; Thiébaut, A | 1 |
| Bosanquet, AG; Bosanquet, MI | 1 |
| Barth, S; Diehl, V; Engert, A; Oberhäuser, F; Pfitzner, T; Schinköthe, T; Schulz, H; Wittor, H | 1 |
| Cerretti, R; Coluzzi, S; Foa, R; Giannarelli, D; Girelli, G; Mandelli, F; Mauro, FR | 1 |
| Haznedar, R; Sucak, GT; Yağci, M | 2 |
| Catovsky, D; Dearden, CE; Matutes, E | 1 |
| Beer, M; Byrd, JC; Grever, MR; Lucas, MA; Waselenko, JK | 1 |
| Kipps, TJ | 1 |
| Ambinder, RF; Byrd, JC; Diehl, LF; Flinn, IW; Grever, MR; Jamison, J; Morrison, C; Murphy, T; Piantadosi, S; Seifter, E; Vogelsang, G | 1 |
| Cawley, JC; Pettitt, AR | 1 |
| Huang, P; Keating, MJ; Plunkett, W; Sandoval, A; Van Den Neste, E | 1 |
| Byrd, JC; Rai, KR | 1 |
| Cervantes, F; Cervera, A; Cid, J; Ferrer, I; Montserrat, E; Muñoz, E; Revilla, M | 1 |
| Akhter, S; Ambrus, JL; Donahue, T; Islam, A; Sands, AM; Vladutiu, AO | 1 |
| Amaranto, P; Capria, S; Cimino, G; Cordone, I; de Fabritiis, P; Foa, R; Mandelli, F; Mauro, F; Meloni, G; Proia, A; Rapanotti, C; Reato, G; Vignetti, M | 1 |
| Baccarani, M; Capello, D; Fanin, R; Gaidano, G; Patriarca, F; Zaja, F | 1 |
| Glenn, M; Golde, DW; Maslak, P; Noy, A; Rahman, Z; Scheinberg, DA; Weiss, MA; Zelenetz, A | 1 |
| Gabeeva, NG; Kaplanskaia, IB; Kremenetskaia, AM; Moiseeva, TN; Pivnik, AV; Samoĭlova, RS; Varlamova, EIu; Zybunova, EE | 1 |
| Astori, C; Bernasconi, C; Bernasconi, P; Boni, M; Calatroni, S; Caresana, M; Cavigliano, P; Giglio, S; Lazzarino, M; Orlandi, E; Pagnucco, G | 1 |
| Albertini, P; Bendandi, M; Magagnoli, M; Rondelli, D; Stefoni, V; Tani, M; Tura, S; Zinzani, PL | 1 |
| Abdel-Raheem, MM; Gross, GG; Jamil, MG; Potti, A | 1 |
| Adachi, S; Carrera, CJ; Carson, DA; Chao, Q; Cottam, HB; Genini, D; Leoni, LM; Rose, DW | 1 |
| Bigazzi, C; Bocchia, M; Lauria, F; Lenoci, M; Marotta, G; Tozzi, M | 1 |
| Appelbaum, FR; Cheson, BD; Elias, L; Hines, J; Kolitz, J; Larson, RA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L; Threatte, GA | 1 |
| Binet, JL; Dighiero, G | 1 |
| Acquaah-Mensah, GK; Biswal, SS; Datta, K; Kehrer, JP | 1 |
| Johnson, SA; Thomas, W | 1 |
| del Mar Castellanos, M; Gardella, S; Mata, MI; Ortiz, MR | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Claviez, A; Dreger, P; Glass, B; Humpe, A; Schmitz, N; Schoch, R; Seyfarth, B; Suttorp, M; von Neuhoff, N | 1 |
| Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Beran, M; Cortes, J; Giles, FJ; Kantarjian, HM; Keating, M; Koller, CA; Lerner, S; O'Brien, SM | 1 |
| Bruzzone, BM; Cataldi, A; Franceschini, R; Icardi, G; Tenconi, GL | 1 |
| Bone, N; Han, L; Kay, NE; Williams, G | 1 |
| Filippa, D; Glenn, M; Keenan, JR; Maslak, P; Noy, A; Rahman, ZU; Verma, R; Weiss, M; Zelenetz, AD | 1 |
| Weiss, MA | 1 |
| Barosi, G; Liberato, LN; Marchetti, M | 1 |
| Copur, MS; Ledakis, P; Muhvic, J | 1 |
| Mounter, P; Proctor, SJ; Summerfield, GP | 1 |
| Celik, I; Erman, M; Tekuzman, G | 1 |
| Hendrick, A | 1 |
| Balázs, M; Kappelmayer, J; Karászi, E; Kiss, A; Mezei, G; Rák, K; Rejtó, L; Telek, B; Udvardy, M; Ujj, G | 1 |
| Joshi, SS; Pavletic, ZS; Vu, UE; Wang, X | 1 |
| Chatterjee, R; Goldstone, AH; Kottaridis, PD; McGarrigle, H | 1 |
| Byrd, JC; Flinn, IW; Grever, MR; Lehman, T; Lucas, D; Sausville, E; Shinn, C; Willis, CR | 1 |
| Allen, J; Amagai, M; Carmichael, AJ; Dean, D; Frith, P; Gooptu, C; Hashimoto, T; Littlewood, TJ; Lyon, CC; MacWhannell, A; Oliwiecki, S; Wojnarowska, F | 1 |
| Cacciola, E; Di Raimondo, F; Giustolisi, R; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S | 1 |
| Cazin, B; Chevret, S; Delabarre, F; Leporrier, M; Levy, V; Porcher, R | 1 |
| Emmerich, B; Hallek, M; Schmitt, B; Stein, H | 1 |
| Hallek, M; Schmitt, B | 1 |
| Bentley, P; Fegan, C; Hoy, T; Pepper, C; Thomas, A | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Martell, RE; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Derigs, HG; Fischer, T; Huber, C; Kolbe, K; Kreiter, S; Schneider, PM; Schuler, M; Ullmann, AJ; Winkelmann, N | 1 |
| Brittinger, G; Busch, R; Döhner, H; Emmerich, B; Fostitsch, HP; Franke, A; Freund, M; Hallek, M; Herold, M; Hiddemann, W; Knauf, W; Kröber, A; Kuse, R; Nerl, C; Schmitt, B; Schriever, F; Sezer, O; Thiel, E; Wendtner, CM; Wilhelm, M | 1 |
| Bassan, R; Di Gaetano, N; Erba, E; Golay, J; Introna, M; Rambaldi, A; Xiao, Y | 1 |
| Eigler, A; Emmerich, B; Endres, S; Loher, F; Meinhardt, G; Siegmund, B; Welsch, J | 1 |
| Cortes, J; Giles, F; Kantarjian, H; Keating, M; Koller, C; Loscertales, J; O'Brien, S; Thomas, D | 1 |
| Rouger, P; Wautier, JL | 1 |
| Battista, C; Broccia, G; Capalbo, S; Castoldi, G; Cuneo, A; Leoni, P; Liso, V; Molica, S; Montillo, M; Pogliani, E; Specchia, G | 1 |
| Gabrilove, JL | 1 |
| Keating, MJ; Nowak, BJ; Plunkett, W; Yamauchi, T | 1 |
| Anderlini, P; Cabanillas, FF; Champlin, RE; Donato, ML; Gajewski, JL; Giralt, SA; Hagemeister, FB; Ippoliti, C; Khouri, IF; Korbling, M; Lee, MS; McLaughlin, P; Okoroji, GJ; Saliba, RM; Younes, A | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Levesque, MC; Moore, J; Silber, R; Smith, KL; Weinberg, JB | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 1 |
| Chevret, S; Mahé, C | 1 |
| Imamura, N | 1 |
| Champain, K; Csermak, K; Ganeshaguru, K; Gordon, M; Hart, SM; Hoffbrand, AV; Jones, DT; Man, A; Mehta, AB; Prentice, HG; Virchis, AE; Wickremasinghe, RG | 1 |
| Albitar, M; Keating, MJ; O'Brien, S | 1 |
| Casanova, B; de la Fuente, MT; Garcia-Gila, M; Garcia-Marco, J; Garcia-Pardo, A; Moyano, JV; Sanz, L; Silva, A | 1 |
| Carter, C; Hillmen, P; Kennedy, B; Lucas, G; Rawstron, A; Ryan, M; Speed, K | 1 |
| Mounter, PJ; Proctor, SJ; Summerfield, GP; Taylor, PR | 1 |
| Hulkkonen, J; Hurme, M; Kivekäs, I; Vilpo, J; Vilpo, L | 1 |
| Byrd, JC; Flynn, JM; Howard, RS; Perkins, JG | 1 |
| Albitar, M; Binet, JL; Brettman, L; Byrd, J; Flinn, I; Hillmen, P; Jain, V; Keating, MJ; Rai, KR; Santabarbara, P; Wacker, B | 1 |
| Clausen, NT; Hansen, PB; Larsen, CR | 1 |
| Castells, G; Escoda, L; Marés, R; Richart, C; Saumoy, M; Ugarriza, A | 1 |
| Dwyer, KM; Firkin, F; Hill, PA; Lee, P; Murphy, BF | 1 |
| Barton, P; Bryan, S; Davenport, C; Fry-Smith, A; Hyde, C; Song, F; Wake, B | 1 |
| Barth, S; Borchmann, P; Diehl, V; Engert, A; Oberhäuser, F; Pfitzner, T; Reiser, M; Schinköthe, T; Schulz, H; Tur, M; Wessels, J | 1 |
| Voutsadakis, IA | 1 |
| Cerretti, R; De Propriis, MS; Foa, R; Gentile, M; Giannarelli, D; Guarini, A; Mancini, F; Mauro, FR | 1 |
| Amir, G; Berrebi, A; Cohen, Y; Da'as, N; Libster, D; Polliack, A | 1 |
| Kasznicki, M; Robak, T | 1 |
| Bosanquet, AG; Bosanquet, MI; Daniel, PT; Dörken, B; Essmann, F; Head, DJ; Sturm, I; Wieder, T | 1 |
| Diehl, V; Voliotis, D | 1 |
| Brando, B; Cafro, AM; Cairoli, R; Montillo, M; Morra, E; Oreste, P; Pungolino, E; Rossi, V; Tedeschi, A; Veronese, S | 1 |
| Anaissie, E; Elting, L; Kantarjian, H; Keating, M; Kontoyiannis, DP; Robertson, LE | 1 |
| Elmhorn-Rosenborg, A; Juliusson, G; Liliemark, J | 1 |
| Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Robertson, L | 1 |
| Butler, JJ; Hirsch-Ginsberg, C; Huh, YO; Kantarjian, H; Keating, MJ; Pugh, WC; Robertson, LE; Stass, S | 1 |
| Phyliky, RL; Tefferi, A | 1 |
| Crowley, S; Dahut, WL; Frame, JN | 1 |
| Ali Ege, M; Amadori, S; Caruso, R; D'Adamo, F; Girelli, G; Maurillo, L; Mauro, FR; Picardi, A; Tosti, S | 1 |
| Gandhi, V; Plunkett, W | 1 |
| Gandhi, V; Keating, M; Kemena, A; Plunkett, W; Shewach, DS | 1 |
| Lawrence, HJ; Perez, EA; Sanders, C | 1 |
| Bastion, Y; Bryon, PA; Coiffier, B; Dumontet, C; Espinouse, D | 1 |
| Schilling, PJ | 1 |
| Gribbin, TE | 1 |
| Catovsky, D; Davis, CL; Lister, TA; Mehta, AB; Ranson, M; Rohatiner, AZ; Rule, S; Smith, OP; Whelan, JS | 1 |
| Bladé, J; Cervantes, F; Marín, P; Montserrat, E; Rozman, C; Rozman, M | 1 |
154 review(s) available for fludarabine and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2020 |
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Vidarabine | 2020 |
How I treat autoimmune hemolytic anemia.
Topics: Aged; Algorithms; Anemia, Hemolytic, Autoimmune; Coombs Test; Erythrocyte Transfusion; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Serologic Tests; Splenectomy; Vidarabine | 2017 |
FCR achieves long-term durable remissions in patients with
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Remission Induction; Rituximab; Time Factors; Vidarabine | 2017 |
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Vidarabine | 2018 |
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 12; Cyclin D1; Cyclophosphamide; Disease Progression; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Rituximab; Treatment Outcome; Trisomy; Vidarabine | 2018 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine | 2018 |
The changing paradigm of chronic lymphocytic leukemia management.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Rituximab; Vidarabine | 2013 |
Fludarabine: a review of the clear benefits and potential harms.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Vidarabine | 2013 |
Fulminant hepatitis due to human adenovirus.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Aged; Antibodies, Monoclonal, Murine-Derived; Biopsy; Female; Hepatitis, Viral, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Liver; Rituximab; Vidarabine | 2014 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine | 2014 |
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine | 2014 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrophenols; Phytochemicals; Piperazines; Protein Kinase Inhibitors; Quercetin; Sulfonamides; Vidarabine | 2014 |
A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Nitrogen Mustard Compounds; Pentostatin; Physical Fitness; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2015 |
Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Richter syndrome: an aggressive transformation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clone Cells; Cyclophosphamide; Disease Progression; Doxorubicin; Hospice and Palliative Care Nursing; Humans; Hypercalcemia; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Male; Neoplastic Stem Cells; Organoplatinum Compounds; Palliative Care; Prednisone; Prognosis; Risk Factors; Rituximab; Salvage Therapy; Syndrome; Vidarabine; Vincristine | 2015 |
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers; CD5 Antigens; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Cyclophosphamide; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2015 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Chlorambucil; Clinical Trials as Topic; Comorbidity; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2015 |
[Acquired pure red cell aplasia in a patient with B cell chronic lymphocytic leukemia after fludarabine therapy].
Topics: Aged; Antineoplastic Agents; Cyclosporine; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Red-Cell Aplasia, Pure; Treatment Outcome; Vidarabine | 2015 |
Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Practice Guidelines as Topic; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Prognosis; Rituximab; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2016 |
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides; Vidarabine | 2016 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Pentostatin in chronic lymphocytic leukemia.
Topics: Adenosine Deaminase Inhibitors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 2008 |
[Chronic lymphocytic leukemia and the related disorders].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chromosome Aberrations; Gene Rearrangement; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Recombination, Genetic; Rituximab; Time Factors; Vidarabine | 2008 |
Treatment of fludarabine-refractory chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Salvage Therapy; Stem Cell Transplantation; Vidarabine | 2009 |
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retreatment; Transplantation, Homologous; Vidarabine | 2009 |
Pentostatin treatment combinations in chronic lymphocytic leukemia.
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Forecasting; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Pentostatin; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2009 |
Update in the management of chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Congresses as Topic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Patient Selection; Vidarabine | 2009 |
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Recurrence; Rituximab; Vidarabine | 2009 |
Tumor lysis syndrome following chlorambucil therapy for chronic lymphocytic leukemia: case report and review of the literature.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Risk Factors; Tumor Lysis Syndrome; Vidarabine | 2009 |
State-of-the-art treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Combined Modality Therapy; Cytostatic Agents; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Rituximab; Salvage Therapy; Thionucleotides; Transplantation, Homologous; Vidarabine | 2009 |
Cutaneous Richter's syndrome, prognosis, and clinical, histological and immunohistological patterns: report of four cases and review of the literature.
Topics: Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD5 Antigens; Cell Transformation, Viral; Epstein-Barr Virus Infections; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Ki-1 Antigen; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Skin Neoplasms; Vidarabine | 2010 |
Advances in the treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drugs, Investigational; Forecasting; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Rituximab; Salvage Therapy; Vidarabine | 2006 |
Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.
Topics: Antineoplastic Agents; Clinical Trials as Topic; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Salvage Therapy; Vidarabine | 2010 |
[Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].
Topics: Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2010 |
Chemoimmunotherapy of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Disease Progression; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Failure; Vidarabine | 2010 |
Ofatumumab in the treatment of chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cyclophosphamide; Evidence-Based Medicine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Rituximab; Treatment Outcome; Vidarabine | 2010 |
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Mice; Rituximab; Vidarabine | 2010 |
The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; United Kingdom; Vidarabine | 2010 |
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Approval; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Randomized Controlled Trials as Topic; Rituximab; United States; United States Food and Drug Administration; Vidarabine | 2011 |
Refractory chronic lymphocytic leukemia--new therapeutic strategies.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Survival Analysis; Therapies, Investigational; Vidarabine | 2010 |
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Cytotoxicity, Immunologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Vidarabine | 2011 |
[Specific palatal infiltration in B-cell chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Cyclophosphamide; Diagnosis, Differential; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Mitoxantrone; Palate, Soft; Red-Cell Aplasia, Pure; Rituximab; Vidarabine | 2011 |
[A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Vidarabine | 2011 |
Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality-Adjusted Life Years; Vidarabine | 2011 |
[Practical considerations and questions in the treatment of chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Prognosis; Recurrence; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2011 |
Rituximab in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2011 |
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Topics: Agammaglobulinemia; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2012 |
Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2011 |
The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Salvage Therapy; Vidarabine | 2012 |
The treatment of relapsed refractory chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Vidarabine | 2011 |
Alemtuzumab for patients with chronic lymphocytic leukaemia.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2012 |
A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2012 |
Renal failure secondary to leukemic infiltration of kidneys in CLL--a case report and review of literature.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Delayed Diagnosis; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Lymph Nodes; Male; Renal Dialysis; Rituximab; Vidarabine | 2013 |
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2012 |
Fludarabine in chronic lymphocytic leukemia with membranous nephropathy.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Follow-Up Studies; Glomerulonephritis, Membranous; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proteinuria; Rare Diseases; Risk Assessment; Treatment Outcome; Vidarabine | 2013 |
[Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcosis; Cryptococcus neoformans; Cutaneous Fistula; Cyclophosphamide; Diabetes Mellitus, Type 2; Female; Fungemia; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Neutropenia; Opportunistic Infections; Osteolysis; Osteomyelitis; Rituximab; Vidarabine | 2013 |
Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.
Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases; Prednisone; Tomography, X-Ray Computed; Vidarabine | 2002 |
[Experience with fludarabine treatment and review of the literature].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Remission Induction; Treatment Outcome; Vidarabine | 2002 |
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chlorambucil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Current and developing chemotherapy for CLL.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Survival Rate; Vidarabine | 2002 |
Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2002 |
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphoma; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2002 |
Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Blood Urea Nitrogen; Calcium; Creatinine; Fatal Outcome; Fluid Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Phosphorus; Potassium; Renal Dialysis; Tumor Lysis Syndrome; Uric Acid; Vidarabine | 2003 |
Rituximab in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2003 |
Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bowen's Disease; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Fatal Outcome; Female; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lomustine; Male; Middle Aged; Mitoxantrone; Neoplasms, Multiple Primary; Neoplastic Stem Cells; Prednisone; Prognosis; Reed-Sternberg Cells; Remission Induction; Skin Neoplasms; Splenectomy; Tumor Virus Infections; Vidarabine; Vinblastine; Vincristine | 2003 |
Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature.
Topics: Aging; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 15; Chromosomes, Human, Y; Clone Cells; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pancytopenia; Trisomy; Tumor Cells, Cultured; Vidarabine | 2003 |
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Mechanism of action of purine analogues in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Division; Cladribine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Phosphorylation; Tumor Suppressor Protein p53; Vidarabine | 2003 |
[Evidence-based therapy for chronic leukemia].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Transplantation, Homologous; Vidarabine | 2003 |
Oral fludarabine.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Biological Availability; Clinical Trials as Topic; Half-Life; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2003 |
[Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Combined Modality Therapy; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitrogen Mustard Compounds; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Time Factors; Vidarabine | 2003 |
Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy.
Topics: Antineoplastic Agents; Diagnosis, Differential; DNA, Viral; Fatal Outcome; Humans; Immunosuppression Therapy; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Polymerase Chain Reaction; Vidarabine | 2003 |
Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Synergism; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2004 |
Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2004 |
Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Rituximab; Vidarabine | 2004 |
Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2004 |
Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2004 |
Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience.
Topics: Administration, Oral; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2004 |
Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans.
Topics: Aged; Biopsy, Needle; Fluorescent Antibody Technique, Indirect; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycophenolic Acid; Paraneoplastic Syndromes; Pemphigus; Risk Assessment; Severity of Illness Index; Stomatitis; Treatment Outcome; Vidarabine | 2004 |
Treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2004 |
Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 2004 |
Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Safety; Survival Rate; Treatment Outcome; Vidarabine | 2004 |
[New perspectives in the evolution of prognosis and treatment of chronic lymphocytic leukaemia].
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Mutation; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Recurrence; Remission Induction; Rituximab; Stem Cell Transplantation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Cladribine; Clinical Trials as Topic; Glycoproteins; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Random Allocation; Rituximab; Time Factors; Vidarabine | 2005 |
[News in therapeutic management of chronic lymphoid leukemia].
Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 2005 |
Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Economic assessment on the management of chronic lymphocytic leukaemia.
Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Agents; Chlorambucil; Cost-Benefit Analysis; Health Care Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Vidarabine | 2005 |
Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia (CLL) treated with fludarabine: case report and review of literature.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mycobacterium tuberculosis; Tomography, X-Ray Computed; Tuberculosis; Vidarabine | 2005 |
Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Membrane; Cell Proliferation; Cell Survival; Cladribine; DNA; DNA Damage; DNA Repair; DNA-Directed DNA Polymerase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Models, Biological; Models, Chemical; Nucleosides; RNA; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2005 |
Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Purine Nucleosides; Risk Assessment; Treatment Outcome; Vidarabine | 2006 |
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Cladribine; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vidarabine | 2006 |
Purine antagonists for chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Chlorambucil; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Vidarabine | 2006 |
Fludarabine in chronic lymphocytic leukaemia.
Topics: Administration, Oral; Aged; Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Survival Analysis; Vidarabine | 2006 |
Management of symptomatic, untreated chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Management; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Risk Assessment; Treatment Outcome; Vidarabine | 2007 |
Chronic lymphocytic leukemia: current and emerging treatment approaches.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosomes, Human, Pair 12; Cyclophosphamide; Disease-Free Survival; Drug Screening Assays, Antitumor; Flow Cytometry; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Polymerase Chain Reaction; Risk Factors; Survival Rate; Trisomy; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2006 |
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; CD52 Antigen; Cyclophosphamide; Glycoproteins; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2007 |
Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Vidarabine | 2007 |
Fludarabine: a review of its use in non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine | 2007 |
Chemoimmunotherapy of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Rituximab; Vidarabine | 2007 |
Minimal residual disease assessment in chronic lymphocytic leukaemia.
Topics: Alleles; Antibodies, Monoclonal; Antigens, CD19; CD5 Antigens; Combined Modality Therapy; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Polymerase Chain Reaction; Sensitivity and Specificity; Stem Cell Transplantation; Vidarabine | 2007 |
[Chronic lymphoid leukemia and intravenous immunoglobulins].
Topics: Agammaglobulinemia; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multicenter Studies as Topic; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome; Vidarabine | 2007 |
Antibody therapy for chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drugs, Investigational; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Pentostatin; Rituximab; Vidarabine | 2008 |
Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Cladribine; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1994 |
Clinical experience with fludarabine in leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 1994 |
The expanding role of fludarabine in hematologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 1995 |
Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Chlorambucil; Chromosome Aberrations; Cladribine; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Vidarabine | 1995 |
The role of fludarabine in hematological malignancies.
Topics: Adult; Aged; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Nucleoside analogs in treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Survival Rate; Vidarabine | 1993 |
Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL).
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Cell Division; DNA Repair; Drug Resistance; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Prognosis; Proliferating Cell Nuclear Antigen; Vidarabine | 1993 |
Fludarabine for treatment of adult acute myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Molecular Structure; Multicenter Studies as Topic; Radiation-Sensitizing Agents; Remission Induction; Tumor Cells, Cultured; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
Fludarabine in the treatment of lymphoproliferative malignancies.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoproliferative Disorders; Vidarabine | 1993 |
[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Remission Induction; Vidarabine | 1995 |
Key issues in the treatment of chronic lymphocytic leukaemia (CLL)
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; Hematopoietic Cell Growth Factors; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Risk Factors; Vidarabine | 1995 |
Current results and prospective trials of cladribine in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prospective Studies; Vidarabine | 1996 |
The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia.
Topics: Alkylation; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1996 |
[Treatment of chronic lymphatic leukemia].
Topics: Antineoplastic Agents; Cladribine; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Vidarabine | 1996 |
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Purine Nucleosides; Vidarabine; Waldenstrom Macroglobulinemia | 1996 |
Adverse and beneficial immunological effects of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Cladribine; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Purine Nucleosides; Vidarabine | 1996 |
Purine analogs in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1997 |
Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Recurrence; Remission Induction; Vidarabine | 1997 |
Is there a place for 2-CDA in the treatment of B-CLL?
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thrombocytopenia; Vidarabine | 1997 |
Prophylactic strategies to meet infectious complications in fludarabine-treated CLL.
Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Granulocyte Colony-Stimulating Factor; Humans; Immunoglobulins, Intravenous; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Opportunistic Infections; Salvage Therapy; Vidarabine | 1997 |
Complications in the treatment of CLL with purine analogues.
Topics: Anemia, Hemolytic, Autoimmune; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Purine Nucleosides; Vidarabine | 1997 |
[Current principles of diagnosis and treatment of chronic lymphocytic B-cell leukemia].
Topics: Alkylating Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1998 |
Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Vidarabine | 1998 |
Clinical challenges in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Splenectomy; Vidarabine | 1998 |
Chronic lymphocytic leukemia in the next decade: where do we go from here?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1998 |
Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk-adapted therapy.
Topics: Bacterial Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 1999 |
Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Eosinophilia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1999 |
CD40 and B chronic lymphocytic leukemia cell response to fludarabine: the influence of NF-kappaB/Rel transcription factors on chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; CD40 Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Oncogene Proteins v-rel; Tumor Cells, Cultured; Vidarabine | 2000 |
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Remission Induction; Vidarabine | 2000 |
Chronic lymphocytic leukemia.
Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; CD79 Antigens; Chromosome Aberrations; Chromosomes, Human; Cladribine; Combined Modality Therapy; Cytokines; Female; Genes, Immunoglobulin; Genes, p53; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Stem Cells; Prognosis; Risk Factors; Vidarabine | 2000 |
Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Vidarabine | 1999 |
Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 2000 |
Novel treatment strategies in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pentostatin; Randomized Controlled Trials as Topic; Sex Factors; Vidarabine | 2001 |
[Chronic lymphocytic leukemia. 2. Therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; Chlorambucil; Dose-Response Relationship, Radiation; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunization, Passive; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Risk Factors; Splenectomy; Steroids; Transplantation, Autologous; Vidarabine | 2001 |
[Drug-induced hemolytic anemia].
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Cephalosporins; Cyclosporine; Hemolytic-Uremic Syndrome; Humans; Isoantibodies; Leukemia, Lymphocytic, Chronic, B-Cell; Methyldopa; Procainamide; Purpura, Thrombocytopenic; Quinine; Rho(D) Immune Globulin; Thrombocytopenia; Vidarabine | 2001 |
Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies.
Topics: Angiogenesis Inhibitors; Apoptosis; Cytokines; Fibroblast Growth Factor 2; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2001 |
[Chronic lymphocytic leukemias].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prognosis; Sex Factors; Survival Rate; Vidarabine | 2001 |
Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2002 |
Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cost of Illness; Cost-Benefit Analysis; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical; Treatment Outcome; United Kingdom; Vidarabine | 2002 |
Fludarabine-induced eosinophilia: case report.
Topics: Antineoplastic Agents; Eosinophilia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Vidarabine | 2002 |
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Nucleosides; Survival Rate; Treatment Failure; Vidarabine | 2002 |
Challenges in treating hematologic malignancies.
Topics: Anemia; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epoetin Alfa; Erythropoietin; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Prognosis; Quality of Life; Recombinant Proteins; Vidarabine | 2002 |
A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities.
Topics: 2-Chloroadenosine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Chlorambucil; Deoxyadenosines; Dose-Response Relationship, Drug; Histocompatibility Testing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prednisone; Prognosis; Survival Rate; Vidarabine | 1992 |
New purine analogues for the treatment of chronic B-cell malignancies.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1991 |
[Treatment with cyclosporin A of the anemia associated with chronic lymphatic leukemia].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclosporins; Erythropoiesis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Red-Cell Aplasia, Pure; T-Lymphocytes, Regulatory; Thrombocytopenia; Vidarabine | 1990 |
247 trial(s) available for fludarabine and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Female; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Myelopoiesis; Myeloproliferative Disorders; Neoplasms, Second Primary; Sulfonamides; Vidarabine | 2022 |
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Cyclophosphamide; Cytokines; Humans; Inflammation; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Rituximab; T-Lymphocytes; Vidarabine | 2022 |
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Rituximab | 2023 |
Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Progression-Free Survival; Remission Induction; Vidarabine | 2020 |
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Predictive Value of Tests; Rituximab; Vidarabine | 2019 |
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Gene Expression Profiling; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Risk Assessment; Risk Factors; Rituximab; Texas; Time Factors; Transcriptome; Treatment Outcome; Vidarabine | 2019 |
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
Topics: Antibodies, Monoclonal, Humanized; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Vidarabine | 2020 |
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Baculoviral IAP Repeat-Containing 3 Protein; Biomarkers, Tumor; Cohort Studies; Cyclophosphamide; Extracellular Signal-Regulated MAP Kinases; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Signaling System; Mutation; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2020 |
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prospective Studies; Rituximab; Vidarabine | 2020 |
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Survival Rate; Vidarabine | 2020 |
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Induction Chemotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Purines; Rituximab; Treatment Outcome; Vidarabine | 2021 |
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Topics: Adult; Aged; Antigens, CD19; Cell Proliferation; Cyclophosphamide; Cytokine Release Syndrome; Female; Humans; Immunotherapy, Adoptive; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Progression-Free Survival; T-Lymphocytes; Treatment Outcome; Vidarabine | 2021 |
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease Progression; Endpoint Determination; Female; Humans; Immunosuppression Therapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2021 |
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine | 2021 |
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2021 |
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2021 |
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Rituximab; Treatment Outcome; Vidarabine | 2021 |
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 17; Cyclophosphamide; DNA Mutational Analysis; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2018 |
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
Topics: Adolescent; Adult; Aged; Antigens, CD20; Cyclophosphamide; Dose-Response Relationship, Drug; Female; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Hematologic Diseases; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Rituximab; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Vidarabine | 2018 |
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2018 |
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Registries; Retrospective Studies; Rituximab; Survival Rate; Sweden; Vidarabine | 2019 |
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Survival Rate; Vidarabine | 2019 |
Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oncology Nursing; Risk Factors; Rituximab; Survival Rate; Vidarabine | 2019 |
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Vidarabine | 2013 |
Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cohort Studies; Female; Humans; Immunotherapy; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Metabolic Clearance Rate; Middle Aged; Rituximab; Time Factors; Treatment Outcome; Vidarabine | 2013 |
In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cladribine; Cyclophosphamide; DNA Fragmentation; Electrophoresis, Agar Gel; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Vidarabine | 2013 |
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Phosphoproteins; Prognosis; Prospective Studies; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2013 |
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2013 |
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cyclophosphamide; Cytochrome P-450 CYP2B6; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pharmacogenetics; Prognosis; Remission Induction; Vidarabine | 2013 |
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Administration Schedule; Fatigue; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Nausea; NF-kappa B; Pneumonia; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Vidarabine | 2014 |
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine | 2014 |
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Quality of Life; Retreatment; Treatment Outcome; Vidarabine | 2014 |
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Time Factors; Vidarabine; Withholding Treatment | 2014 |
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2014 |
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Focal Adhesion Kinase 1; Gene Expression; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Proportional Hazards Models; Recurrence; Retrospective Studies; Rituximab; RNA, Messenger; RNA, Neoplasm; Vidarabine | 2014 |
How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prospective Studies; Risk Factors; Rituximab; Treatment Outcome; Vidarabine | 2014 |
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Vidarabine | 2014 |
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Combinations; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Rituximab; Survival Analysis; Treatment Failure; Vidarabine; Vincristine | 2014 |
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Yttrium Radioisotopes | 2015 |
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Rituximab; Sweden; Vidarabine | 2015 |
Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Cells, Cultured; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Treatment Outcome; Vidarabine | 2015 |
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Thalidomide; Vidarabine | 2015 |
An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arrhythmias, Cardiac; B-Lymphocytes; Biomarkers; Cardiotoxicity; Complement System Proteins; Cytokines; Drug Resistance, Neoplasm; Electrocardiography; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Retreatment; Treatment Outcome; Vidarabine | 2015 |
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergr
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; CpG Islands; Cyclophosphamide; DNA Methylation; DNA Mutational Analysis; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2015 |
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine | 2015 |
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Recurrence; Survival Analysis; Treatment Failure; Vidarabine | 2015 |
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Retreatment; Vidarabine | 2015 |
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Preference; Rituximab; Vidarabine | 2015 |
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrroles; Recurrence; Retreatment; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2015 |
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Smith-Magenis Syndrome; Survival Rate; Vidarabine | 2015 |
Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Darbepoetin alfa; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Treatment Outcome; Vidarabine | 2016 |
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Rituximab; Vidarabine | 2015 |
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retreatment; Treatment Outcome; Vidarabine | 2015 |
Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Inositol Polyphosphate 5-Phosphatases; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphoric Monoester Hydrolases; Prognosis; Proportional Hazards Models; Transcriptome; Vidarabine | 2015 |
The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2016 |
[Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2016 |
Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Case-Control Studies; Cell Transformation, Neoplastic; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Registries; Risk Assessment; Risk Factors; Vidarabine | 2016 |
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; International Agencies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine | 2016 |
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Topics: Bridged Bicyclo Compounds, Heterocyclic; DNA-Activated Protein Kinase; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Proteins; Nuclear Proteins; Purines; Pyrazines; Quinazolinones; Sulfonamides; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured; Vidarabine | 2016 |
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medication Adherence; Middle Aged; Quality of Life; Rituximab; Sex Factors; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2017 |
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Rituximab; Survival Rate; Vidarabine | 2016 |
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Protocols; Cyclophosphamide; Drug Dosage Calculations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Research Design; Time Factors; Treatment Outcome; United Kingdom; Vidarabine | 2016 |
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine | 2017 |
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Treatment Outcome; Vidarabine | 2017 |
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2017 |
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Topics: Administration, Oral; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neutropenia; Remission Induction; Vidarabine | 2008 |
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Immune Tolerance; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Recurrence; Vidarabine | 2008 |
Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease-Free Survival; Flow Cytometry; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2008 |
[Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Vidarabine | 2008 |
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cell Cycle; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Inactivation, Metabolic; Infusions, Intravenous; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Piperidines; Protein Kinase Inhibitors; Recurrence; Salvage Therapy; Treatment Outcome; Tumor Lysis Syndrome; Uridine Diphosphate Glucuronic Acid; Vidarabine | 2009 |
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Treatment Outcome; Vidarabine | 2009 |
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Genes, Immunoglobulin Heavy Chain; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Receptors, Fc; Rituximab; Survival Analysis; Vidarabine; Young Adult | 2009 |
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etanercept; Female; Humans; Immunoglobulin G; Infusions, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Tumor Necrosis Factor; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Tumor Necrosis Factor-alpha; Vidarabine | 2009 |
Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2009 |
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Vidarabine | 2009 |
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents, Alkylating; Chlorambucil; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Survival Rate; Vidarabine | 2009 |
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Topics: Administration, Cutaneous; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclin-Dependent Kinase Inhibitor p21; DNA Mutational Analysis; Drug Resistance, Neoplasm; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Signal Transduction; Treatment Failure; Tumor Suppressor Protein p53; Vidarabine | 2009 |
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cell Separation; Cyclophosphamide; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Pilot Projects; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2010 |
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Thionucleotides; Vidarabine | 2009 |
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Vidarabine | 2010 |
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
Topics: Adult; Aged; Alemtuzumab; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Bone Marrow Diseases; CD52 Antigen; Cohort Studies; Cytomegalovirus Infections; Feasibility Studies; Female; Glycoproteins; Humans; Hypotension; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Survival Analysis; Vidarabine | 2009 |
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genes, p53; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Somatic Hypermutation, Immunoglobulin; Survival Analysis; Tumor Suppressor Protein p53; Vidarabine; Young Adult; ZAP-70 Protein-Tyrosine Kinase | 2009 |
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD52 Antigen; Cyclophosphamide; Disease Progression; Epidemiologic Methods; Female; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prognosis; Rituximab; Vidarabine | 2010 |
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Rituximab; Vidarabine | 2010 |
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Quality of Life; Retreatment; Rituximab; Vidarabine | 2010 |
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2010 |
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Cytogenetic Analysis; Female; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
[Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mitoxantrone; Myeloablative Agonists; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2010 |
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Apoptosis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Phosphoric Monoester Hydrolases; Purine Nucleosides; Purine-Nucleoside Phosphorylase; Pyrimidinones; Severity of Illness Index; Vidarabine | 2010 |
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Vidarabine | 2010 |
Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Plasma; Rituximab; Salvage Therapy; Vidarabine | 2011 |
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neoplasm, Residual; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2010 |
TP53 mutation and survival in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multivariate Analysis; Mutation; Prognosis; Proportional Hazards Models; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2010 |
A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.
Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Rituximab; Thrombocytopenia; Vidarabine | 2010 |
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Rituximab; Severity of Illness Index; Treatment Outcome; Vidarabine | 2010 |
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Rad51 Recombinase; Recombination, Genetic; Treatment Outcome; Vidarabine | 2011 |
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2011 |
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Proportional Hazards Models; Recurrence; Rituximab; Time Factors; Treatment Outcome; Vidarabine | 2011 |
Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2011 |
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Disease-Free Survival; Genes, Immunoglobulin Heavy Chain; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; London; Mutation; Proportional Hazards Models; Risk Assessment; Risk Factors; Rituximab; Survival Rate; Time Factors; Treatment Outcome; United States; Vidarabine | 2011 |
[Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2011 |
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; DNA Mutational Analysis; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Proportional Hazards Models; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine | 2011 |
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Salvage Therapy; Smith-Magenis Syndrome; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2011 |
Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cytomegalovirus Infections; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Vidarabine | 2011 |
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Middle Aged; Prospective Studies; Rituximab; Vidarabine | 2011 |
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Risk Factors; Rituximab; Smith-Magenis Syndrome; Thrombocytopenia; Vidarabine | 2011 |
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Survival Rate; Time Factors; Vidarabine | 2011 |
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Time Factors; United States; Vidarabine | 2011 |
Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Quality-Adjusted Life Years; Rituximab; Survival Rate; Vidarabine | 2012 |
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Nitrogen Mustard Compounds; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2011 |
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Vidarabine | 2011 |
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Salvage Therapy; Vidarabine; Virus Activation | 2012 |
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Rituximab; Treatment Outcome; Vidarabine | 2012 |
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; North America; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vidarabine | 2011 |
Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; Vidarabine; Vomiting | 2012 |
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Computer Simulation; Cyclophosphamide; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Retrospective Studies; Rituximab; Vidarabine | 2012 |
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Prognosis; Prospective Studies; Rituximab; Survival Rate; Vidarabine | 2012 |
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Time Factors; Vidarabine | 2012 |
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Cell Line, Tumor; Combined Modality Therapy; Complement Activation; Complement C3b; Complement C4b; Complement System Proteins; Cyclophosphamide; Cytotoxicity, Immunologic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Opsonin Proteins; Rituximab; Vidarabine | 2012 |
[Clinical study on efficiency of fludarabine-based regimen for the patients with chronic lymphocytic leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2012 |
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Vidarabine | 2012 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Recurrence; Risk; Rituximab; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine; Whole-Body Irradiation | 2013 |
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Chromosomes, Human, Pair 12; Cyclophosphamide; Education, Medical, Continuing; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Middle Aged; Phosphoproteins; Prognosis; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Trisomy; Tumor Suppressor Protein p53; Vidarabine | 2013 |
Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2013 |
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Cyclophosphamide; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Protein Serine-Threonine Kinases; Survival Analysis; Tumor Suppressor Proteins; United Kingdom; Vidarabine | 2012 |
Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bendamustine Hydrochloride; Chemotherapy, Adjuvant; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Survival Analysis; Treatment Outcome; Vidarabine | 2013 |
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Creatinine; Disease-Free Survival; Female; Hematologic Tests; Humans; Kidney Function Tests; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neutrophils; Vidarabine | 2002 |
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine | 2002 |
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors; Vidarabine | 2002 |
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Vidarabine | 2002 |
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, T-Cell; Male; Neutropenia; Opportunistic Infections; Pilot Projects; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine | 2002 |
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cerebral Hemorrhage; Chills; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Time Factors; Vidarabine | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Vidarabine | 2002 |
Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Bryostatins; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Vidarabine | 2002 |
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Patient Selection; Survival Rate; Time Factors; Vidarabine | 2003 |
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Follow-Up Studies; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2003 |
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Radiation-Protective Agents; Sepsis; Survival Rate; Vidarabine | 2003 |
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Antigens Class I; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Acute; Lymphocyte Transfusion; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Tissue Donors; Vidarabine; Whole-Body Irradiation | 2003 |
Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2003 |
Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.
Topics: Adult; Antigens, CD34; Cyclophosphamide; Female; Hematologic Diseases; Hematologic Neoplasms; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutrophils; Peripheral Blood Stem Cell Transplantation; Platelet Count; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Rate; Vidarabine | 2003 |
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Diphtheria Toxin; Drug Resistance, Neoplasm; Female; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Recombinant Fusion Proteins; Time Factors; Tomography, Emission-Computed; Treatment Outcome; Vidarabine | 2003 |
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; STAT1 Transcription Factor; Survival Analysis; Trans-Activators; Treatment Outcome; Vidarabine | 2004 |
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Disease Progression; Drug Administration Schedule; Female; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 2003 |
Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vidarabine | 2003 |
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Radiation, Ionizing; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2004 |
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Vidarabine | 2004 |
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Nucleoside Transport Proteins; RNA, Messenger; Treatment Outcome; Vidarabine | 2005 |
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Staging; Neutropenia; Patient Selection; Recurrence; Treatment Outcome; Vidarabine | 2005 |
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vidarabine | 2005 |
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2005 |
Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2005 |
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Remission Induction; Retrospective Studies; Thrombocytopenia; Vidarabine | 2006 |
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Probability; Prognosis; Prospective Studies; Risk Assessment; Rituximab; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2005 |
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosphamide; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Follicular; Male; Middle Aged; Vidarabine | 2005 |
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD34; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus Infections; Feasibility Studies; Female; Ganciclovir; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Treatment Outcome; Vidarabine | 2006 |
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Thalidomide; Treatment Failure; Tumor Necrosis Factor-alpha; Vidarabine | 2007 |
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome; Vidarabine | 2006 |
Preclinical assessment of curcumin as a potential therapy for B-CLL.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Curcumin; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; NF-kappa B; NF-kappaB-Inducing Kinase; PPAR gamma; Protein Serine-Threonine Kinases; Rolipram; Signal Transduction; Tumor Cells, Cultured; Vidarabine; Vincristine | 2007 |
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Adducts; DNA Repair; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Vidarabine | 2006 |
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Vidarabine | 2006 |
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vidarabine | 2006 |
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Multivariate Analysis; Remission Induction; Respiratory Tract Infections; Risk Factors; Survival Rate; Vidarabine | 2007 |
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Male; Middle Aged; Neoplasms, Second Primary; Prognosis; Vidarabine | 2007 |
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotides, Antisense; Proportional Hazards Models; Recurrence; Thionucleotides; Time Factors; Treatment Failure; Treatment Outcome; Vidarabine | 2007 |
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Nausea; Quality of Life; Surveys and Questionnaires; Vidarabine; Vomiting | 2007 |
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biomarkers, Tumor; Chi-Square Distribution; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Statistics, Nonparametric; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2007 |
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Vidarabine | 2007 |
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Platelet Endothelial Cell Adhesion Molecule-1; Vidarabine | 2007 |
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Coombs Test; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome; Vidarabine | 2008 |
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2008 |
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Salvage Therapy; Vidarabine | 2008 |
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Research Design; Rituximab; Statistics, Nonparametric; Survival Analysis; Syndrome; Treatment Outcome; Vidarabine | 2008 |
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Rituximab; Survival Rate; Vidarabine | 2008 |
Phase I trial of nelarabine in indolent leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Arabinonucleotides; DNA (Cytosine-5-)-Methyltransferases; Drug Therapy, Combination; Female; Guanosine Triphosphate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Tumor Cells, Cultured; Vidarabine | 2008 |
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Infection Control; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Rituximab; Salvage Therapy; Vidarabine | 2008 |
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2008 |
Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fatal Outcome; Female; Humans; Ifosfamide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pilot Projects; Prednisolone; Prednisone; Remission Induction; Staining and Labeling; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Vidarabine; Vinca Alkaloids; Vincristine | 1995 |
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Rate; Vidarabine | 1995 |
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
Topics: Adult; Aged; CD4 Lymphocyte Count; Female; Humans; Immunity, Cellular; Immunoglobulin G; Interferon Type I; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recombinant Proteins; Skin; Survival Analysis; Vidarabine | 1995 |
[Treatment with fludarabine of chronic refractory lymphoid leukemia].
Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Vidarabine | 1995 |
Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma--the Jerusalem experience.
Topics: Adult; Aged; Bone Marrow Transplantation; Combined Modality Therapy; Female; Humans; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1994 |
Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B-Lymphocytes; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; T-Lymphocytes; Vidarabine | 1994 |
Absence of minimal residual disease detectable by FACS, Southern blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine.
Topics: Aged; Antineoplastic Agents; Blotting, Southern; DNA, Neoplasm; Flow Cytometry; Gene Rearrangement; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Remission Induction; Vidarabine | 1994 |
Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
Topics: Antineoplastic Agents; B-Lymphocytes; Camptothecin; Cell Survival; Cells, Cultured; Chlorambucil; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1994 |
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Topics: Antineoplastic Agents; Cladribine; Drug Resistance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1993 |
Chronic lymphocytic leukemia--correlation of response and survival.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Survival Rate; Vidarabine | 1993 |
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Gastrointestinal Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 1993 |
Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Prednisone; Remission Induction; Survival Rate; Vidarabine; Vincristine | 1993 |
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
Topics: Adult; Aged; Antineoplastic Agents; Arabinonucleotides; Female; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Vidarabine | 1993 |
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD4 Antigens; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisone; Prognosis; Regression Analysis; Survival Analysis; Time Factors; Treatment Outcome; Vidarabine | 1993 |
When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)? The French Cooperative Group on C.L.L.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multivariate Analysis; Neoplasm Staging; Peptichemio; Prednisone; Sex Factors; Vidarabine; Vincristine | 1993 |
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vidarabine | 1993 |
Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; CD4 Lymphocyte Count; Female; Humans; Immunosuppression Therapy; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Platelet Count; Survival Analysis; Vidarabine | 1995 |
Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.
Topics: Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cladribine; Combined Modality Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Survival Analysis; Vidarabine | 1995 |
Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Topics: Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Prospective Studies; Remission Induction; Survival Rate; Time Factors; Vidarabine | 1996 |
A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Sleep Wake Disorders; Thrombocytopenia; Vidarabine | 1996 |
Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Vidarabine | 1996 |
[Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Vidarabine | 1996 |
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Vidarabine | 1996 |
Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Female; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Vidarabine | 1997 |
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fever; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neutropenia; Vidarabine | 1997 |
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4 Lymphocyte Count; Disease Progression; Disease-Free Survival; Female; Fever; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisolone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 1998 |
Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate; Vidarabine | 1999 |
Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Vidarabine | 1998 |
Multi-drug resistance in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dexamethasone; Doxorubicin; Drug Resistance, Multiple; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine; Vincristine | 1999 |
Autologous transplantation with peripheral blood stem cells in chronic lymphocytic leukemia. A phase III, randomized, multicenter study. GIMEMA. Gruppo Italiano per le Malattie Ematologiche dell'Adulto. GITMO-Gruppo Italiano Trapianto di Midollo Osseo.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophosphamide; Drug Therapy; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Phenotype; Pilot Projects; Prospective Studies; Statistics as Topic; Survival Rate; Toxicity Tests; Transplantation, Autologous; Vidarabine | 1999 |
A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia. EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chlorambucil; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Pilot Projects; Vidarabine | 1999 |
Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study.
Topics: Adult; Antineoplastic Agents; Base Sequence; Combined Modality Therapy; Disease-Free Survival; DNA Primers; Female; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 1999 |
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1999 |
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vidarabine | 2000 |
Measures of treatment effectiveness on tumour response and survival: a multi-state model approach.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Vidarabine | 2000 |
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2000 |
Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine | 2000 |
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cross-Over Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Analysis; Vidarabine | 2000 |
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Staging; Neutropenia; Rituximab; Vidarabine | 2000 |
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Flow Cytometry; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine | 2001 |
Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine | 2001 |
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Ontario; Respiratory Tract Infections; Skin Diseases, Infectious; Treatment Outcome; United States; Vidarabine | 2001 |
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome; Vidarabine | 2001 |
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
Topics: Aged; Anemia; Antineoplastic Agents; Cyclosporine; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Splenectomy; Thrombocytopenia; Vidarabine | 2001 |
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Rituximab; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine | 2001 |
Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Resistance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2002 |
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Demography; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine | 2002 |
[Fludarabine as primary therapeutic drug in chronic lymphatic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate; Treatment Outcome; Vidarabine | 2002 |
Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2002 |
Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Topics: 2-Chloroadenosine; Adult; Antineoplastic Agents; Cladribine; Deoxyadenosines; Drug Resistance; Female; Haptoglobins; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Remission Induction; Vidarabine | 1992 |
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine; Vidarabine Phosphate | 1991 |
735 other study(ies) available for fludarabine and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice, Inbred BALB C; Oxazolidinones; Stereoisomerism; Structure-Activity Relationship | 2014 |
Small-molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): synthesis and biological evaluation.
Topics: Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Cytochrome P-450 Enzyme Inhibitors; Heme; Humans; Imidazoles; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Molecular; Sequence Homology, Amino Acid; Structure-Activity Relationship; Vitamin D3 24-Hydroxylase | 2014 |
SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured | 2015 |
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; DNA Mutational Analysis; Female; Gene Expression Regulation, Leukemic; Genomics; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Rituximab; RNA Splicing; Vidarabine | 2021 |
Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines.
Topics: Antimalarials; Antineoplastic Agents; Apoptosis; Artemisinins; Biomarkers; Cell Proliferation; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1; Vidarabine | 2021 |
Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Rituximab; Treatment Outcome; Vidarabine | 2022 |
Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2022 |
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2023 |
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2023 |
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2023 |
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; East Asian People; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prospective Studies; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2023 |
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine | 2023 |
del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.
Topics: Chromosome Aberrations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Prognosis; Receptors, TNF-Related Apoptosis-Inducing Ligand; Vidarabine | 2023 |
Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Variable Region; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mutation; Neoplasm, Residual; Prognosis; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2019 |
Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia.
Topics: Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Retrospective Studies; Rituximab; Vidarabine | 2019 |
[Effect of miR-214 on Fludarabine Resistance in Chronic Lymphocytic Leukemia].
Topics: Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Phosphatidylinositol 3-Kinases; Vidarabine | 2019 |
Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Line, Tumor; Dendrimers; Drug Development; Heterografts; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Neoplasms, Experimental; Polypropylenes; Tissue Distribution; Trisaccharides; Vidarabine | 2020 |
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vidarabine | 2019 |
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy.
Topics: Adult; Aged; Cyclophosphamide; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Rituximab; Treatment Outcome; Vidarabine | 2019 |
A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2020 |
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease Management; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2020 |
Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
Topics: Antigens, CD; Antineoplastic Agents; B-Lymphocytes; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Receptors, Cell Surface; Vidarabine | 2020 |
DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy.
Topics: Bendamustine Hydrochloride; DNA Methylation; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Suppressor Protein p53; Vidarabine | 2020 |
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine.
Topics: Adult; Aged; Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Neoplasm Transplantation; Polyethylene Glycols; Treatment Outcome; Tumor Microenvironment; Vidarabine | 2020 |
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Pharmacological; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mass Spectrometry; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Piperidines; Purines; Quinazolinones; Vidarabine | 2020 |
Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Multiple, Fungal; Drug Substitution; Fatal Outcome; Febrile Neutropenia; Female; Filgrastim; Fluconazole; Humans; Immunocompromised Host; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperacillin, Tazobactam Drug Combination; Purines; Quinazolinones; Recurrence; Rituximab; Scedosporium; Triazoles; Valacyclovir; Vidarabine | 2020 |
Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL.
Topics: Animals; Cell Line, Tumor; Dendrimers; Drug Delivery Systems; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred NOD; Neoplasms, Experimental; Pilot Projects; Polypropylenes; Trisaccharides; Vidarabine | 2020 |
HuR Affects Proliferation and Apoptosis of Chronic Lymphocytic Leukemia Cells via NF-
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Chlorambucil; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Humans; I-kappa B Kinase; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; TNF Receptor-Associated Factor 1; Tumor Necrosis Factor-alpha; Up-Regulation; Vidarabine | 2020 |
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Vidarabine | 2021 |
Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies.
Topics: Adult; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Prednisone; Prognosis; Retrospective Studies; Rituximab; Vidarabine | 2020 |
Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Edema; Cyclophosphamide; Demyelinating Diseases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Steroids; Vidarabine | 2021 |
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine | 2020 |
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Vidarabine | 2020 |
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chlorambucil; Cohort Studies; Denmark; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Risk Assessment; Survival Analysis; Vidarabine | 2021 |
Syngeneic leukemia models using lentiviral transgenics.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Viral; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Immunocompetence; Lentivirus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Oncogenes; Transplantation, Isogeneic; Vidarabine | 2021 |
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Prognosis; Rituximab; Survival Rate; Telomere Homeostasis; Tumor Suppressor Protein p53; Vidarabine | 2022 |
Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Vidarabine | 2021 |
MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2021 |
Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Quality-Adjusted Life Years; Rituximab; Vidarabine | 2017 |
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bayes Theorem; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrazoles; Pyrimidines; Vidarabine | 2017 |
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
Topics: Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Sulfonamides; Vidarabine | 2017 |
Blockage of Wnt/β-Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro-Preliminary Study.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cluster Analysis; Dendrimers; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nanoparticles; Tumor Stem Cell Assay; Vidarabine; Wnt Signaling Pathway | 2017 |
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.
Topics: Antineoplastic Agents; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Risk; Vidarabine | 2017 |
Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Retrospective Studies; Vidarabine | 2018 |
Reply to S. Opat et al.
Topics: Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2017 |
Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support.
Topics: Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2017 |
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Vidarabine | 2018 |
The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Carrier Proteins; Caspase 7; CRADD Signaling Adaptor Protein; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; NF-kappa B; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Up-Regulation; Vidarabine | 2018 |
Efficacy of Rituximab for Patients with Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2017 |
Coexistence of t(2;14;11)(p16.1;q32;q23) and t(14;19)(q32;q13.3) chromosome translocations in a patient with chronic lymphocytic leukemia: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 2; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Translocation, Genetic; Vidarabine | 2017 |
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine | 2018 |
DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Progression; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mutation; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Vidarabine | 2018 |
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prospective Studies; Rituximab; Vidarabine | 2018 |
Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2018 |
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retreatment; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2018 |
MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; DNA Damage; Female; Follow-Up Studies; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Prognosis; Receptors, Antigen, B-Cell; Repressor Proteins; Rituximab; Signal Transduction; Survival Rate; Vidarabine | 2019 |
Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Disease Susceptibility; Female; Flow Cytometry; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation; Sirolimus; Treatment Outcome; Vidarabine | 2019 |
Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Line, Tumor; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Spleen; Survival Rate; Transcription Factor Brn-3A; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Ubiquitination; Vidarabine | 2018 |
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2019 |
Telomere length predicts for outcome to FCR chemotherapy in CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Telomere; Vidarabine | 2019 |
Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; DNA Damage; Female; Gene Expression Regulation, Leukemic; Humans; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minichromosome Maintenance Complex Component 7; RNA, Messenger; Up-Regulation; Vidarabine; Virus Replication | 2019 |
Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytochrome P-450 CYP2B6; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Pharmacogenomic Testing; Pharmacogenomic Variants; Vidarabine | 2020 |
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2019 |
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Rituximab; Survival Rate; Vidarabine | 2019 |
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Patient Selection; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Treatment Outcome; Vidarabine | 2019 |
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs.
Topics: Adenine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Heme Oxygenase-1; Histone Deacetylase 1; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Nude; Middle Aged; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyridines; Random Allocation; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine; Xenograft Model Antitumor Assays | 2019 |
High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fas Ligand Protein; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prognosis; Treatment Outcome; Vidarabine | 2019 |
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Mutation; Predictive Value of Tests; Prognosis; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2019 |
Outcomes in critically ill chronic lymphocytic leukemia patients.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Hospital Mortality; Humans; Intensive Care Units; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Rituximab; Treatment Outcome; Vidarabine | 2013 |
[Subcutaneous panniculitis-like T-cell lymphoma following treatment with rituximab and cyclophosphamide].
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Transformation, Neoplastic; Cyclophosphamide; Diagnosis, Differential; Gene Rearrangement, T-Lymphocyte; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell, Cutaneous; Male; Mitomycin; Neoplasms, Second Primary; Panniculitis; Rituximab; Subcutaneous Tissue; T-Lymphocytes; Vidarabine | 2013 |
Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Caspase 3; Caspase 9; Cladribine; Cyclophosphamide; Down-Regulation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proteasome Inhibitors; Rituximab; Sirolimus; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vidarabine | 2013 |
Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Arachidonic Acid; Cell Line, Tumor; Docosahexaenoic Acids; Doxorubicin; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, B-Cell; Lipid Peroxidation; Malondialdehyde; Organ Specificity; Reactive Oxygen Species; Vidarabine; Vincristine; Vitamin E | 2013 |
The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; Female; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; Mitochondrial Membrane Transport Proteins; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2013 |
Efficacy of oral fludarabine in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2013 |
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2013 |
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Bcl-2-Like Protein 11; Beclin-1; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysosomal-Associated Membrane Protein 2; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Ubiquitin-Activating Enzymes; Vidarabine | 2013 |
[Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2013 |
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Treatment Outcome; Vidarabine | 2013 |
The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; DNA Breaks, Double-Stranded; Gene Expression Regulation, Leukemic; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proliferating Cell Nuclear Antigen; Signal Transduction; Transcriptional Activation; Tumor Suppressor Protein p53; Vidarabine | 2013 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine | 2013 |
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Female; Humans; Immune Tolerance; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Neoadjuvant Therapy; Pancytopenia; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2013 |
A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine | 2011 |
Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
Topics: Adult; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Drug Synergism; Enzyme Activation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Tumor Cells, Cultured; Up-Regulation; Valproic Acid; Vidarabine | 2014 |
First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Comorbidity; Creatinine; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multivariate Analysis; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Rituximab; Vidarabine | 2013 |
Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine | 2014 |
[Ultra high risk chronic lymphocytic leukemia - characteristics and treatment options].
Topics: Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2013 |
Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cells, Cultured; Female; Gene Expression; Humans; Immunity, Cellular; Interleukin-17; Kaplan-Meier Estimate; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; T-Lymphocytes, Regulatory; Th17 Cells; Treatment Outcome; Vidarabine | 2013 |
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Public Health Surveillance; Registries; Salvage Therapy; Sweden; Treatment Outcome; Vidarabine | 2014 |
Richter syndrome: chronic lymphocytic leukemia transformation into Hodgkin's disease.
Topics: Antineoplastic Agents; Antiviral Agents; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Vidarabine | 2013 |
Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Recurrence, Local; Rituximab; Vidarabine | 2013 |
Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Treatment Outcome; Vidarabine | 2014 |
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?
Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2014 |
Cyclophosphamide for CLL: to be or not CYP2B activated?
Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cyclophosphamide; Cytochrome P-450 CYP2B6; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 2013 |
Second malignancies in chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chlorambucil; Combined Modality Therapy; Ear Neoplasms; Early Diagnosis; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Neoplasms, Second Primary; Risk; Rituximab; Skin; Skin Neoplasms; Vidarabine | 2014 |
Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boron Compounds; Caspase 3; Caspase 9; Cell Death; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Gossypol; Humans; Intracellular Membranes; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mitochondria; Neoplasm Staging; Permeability; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2014 |
Multifocal central nervous system demyelination and Lhermitte's phenomenon secondary to combination chemotherapy for chronic lymphocytic leukaemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Hamartoma Syndrome, Multiple; Hereditary Central Nervous System Demyelinating Diseases; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Rituximab; Vidarabine | 2014 |
A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Case-Control Studies; Cyclin-Dependent Kinase 9; Drug Synergism; HEK293 Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Transcription, Genetic; Vidarabine | 2014 |
Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Merkel Cell; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Merkel cell polyomavirus; Neoplasms, Multiple Primary; Polyomavirus Infections; Rituximab; Skin Neoplasms; Tumor Virus Infections; Vidarabine | 2014 |
Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cyclophosphamide; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2014 |
Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Immunohistochemistry; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Pleural Effusion; Treatment Outcome; Tumor Lysis Syndrome; Vidarabine | 2014 |
Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2014 |
Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Bone Marrow Cells; CD40 Antigens; Cell Cycle; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Female; Gene Deletion; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Naphthoquinones; Nitrogen Mustard Compounds; Stromal Cells; Survivin; Toll-Like Receptor 9; Vidarabine | 2014 |
Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Vidarabine | 2014 |
Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Comorbidity; Cyclophosphamide; Databases, Factual; Disease Management; Doxorubicin; Ethnicity; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medicare; Practice Patterns, Physicians'; Prednisone; Rituximab; SEER Program; Socioeconomic Factors; Treatment Outcome; United States; Vidarabine; Vincristine | 2014 |
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Germany; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Office Visits; Prednisone; Prospective Studies; Registries; Rituximab; Vidarabine | 2015 |
Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Bone Marrow Cells; Cells, Cultured; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Primary Cell Culture; Stromal Cells; Time Factors; Vidarabine | 2014 |
The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
Topics: Aged; Amyloid Precursor Protein Secretases; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Receptor, Notch1; Tetrahydronaphthalenes; Tumor Cells, Cultured; Valine; Vidarabine | 2015 |
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Female; Genes, Immunoglobulin; Genes, p53; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Prospective Studies; Receptor, Notch1; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2014 |
Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Male; Middle Aged; Multivariate Analysis; Peptide Hydrolases; Pilot Projects; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases; Vidarabine | 2015 |
Small lymphocytic lymphoma presenting as bulky renal incidentaloma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Humans; Kidney; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Rituximab; Tomography, X-Ray Computed; Vidarabine | 2014 |
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2014 |
Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Membrane; Down-Regulation; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Matrix Metalloproteinase 9; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Transcription, Genetic; Up-Regulation; Vidarabine | 2014 |
Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Outcome Assessment, Health Care; Prednisone; Rituximab; SEER Program; Survival Analysis; United States; Vidarabine; Vincristine | 2015 |
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Therapy; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2015 |
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Rituximab; Vidarabine | 2014 |
Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
Topics: B-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Oxidative Phosphorylation; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Vidarabine | 2014 |
Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Time Factors; Vidarabine; Virus Activation | 2015 |
[Detection of p53 gene deletion in Xinjiang patients with chronic lymphocytic leukemia by fluorescence in situ hybridization and its clinical significance].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2014 |
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Vidarabine | 2015 |
The impact of SF3B1 mutations in CLL on the DNA-damage response.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cohort Studies; DNA Damage; DNA Mutational Analysis; Doxorubicin; Flow Cytometry; Gene Deletion; Gene Expression Regulation, Leukemic; Genome, Human; Histones; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phosphoproteins; Piperazines; Prognosis; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Tumor Suppressor Protein p53; Vidarabine | 2015 |
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; CD40 Ligand; Cell Hypoxia; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrogen Mustard Compounds; Nitrophenols; Oxygen; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides; Vidarabine | 2015 |
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Gene Expression Regulation, Leukemic; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Multivariate Analysis; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2015 |
[Elderly chronic lymphocytic leukemia combined with invasive aspergillosis infection in one case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Rituximab; Vidarabine | 2015 |
Pathological fractures in a patient with chronic lymphatic leucaemia without disease progression.
Topics: Accidental Falls; Allopurinol; Antineoplastic Agents; Bone Marrow; Female; Femur; Fractures, Bone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Osteolysis; Pelvis; Positron-Emission Tomography; Radiography; Rituximab; Sacrum; Sodium Bicarbonate; Treatment Outcome; Vidarabine | 2015 |
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2015 |
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Topics: Acrylonitrile; Aniline Compounds; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Coculture Techniques; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Stromal Cells; Tumor Microenvironment; Vidarabine | 2015 |
[Chronic lymphatic leukemia].
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Rituximab; Vidarabine | 2015 |
[Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2015 |
Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Enzyme Inhibitors; Female; Growth Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MAP Kinase Signaling System; Middle Aged; Oxides; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Vidarabine | 2015 |
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Remission Induction; Rituximab; Vidarabine | 2015 |
Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.
Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Count; Cell Lineage; Cyclophosphamide; Female; Flow Cytometry; GPI-Linked Proteins; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Neoplastic Cells, Circulating; Receptors, Cell Surface; Receptors, IgG; Rituximab; Vidarabine | 2015 |
The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia.
Topics: Antigens, CD19; Antineoplastic Agents; Apoptosis; Blood Cells; Bone Marrow Cells; Caspase 3; CD5 Antigens; Cell Line, Tumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine | 2015 |
ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Survival; Cells, Cultured; Drug Synergism; Female; Flow Cytometry; Heterocyclic Compounds, 1-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Potential, Mitochondrial; Middle Aged; Reactive Oxygen Species; Vidarabine | 2015 |
Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Administration Schedule; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Phosphoproteins; Receptor, Notch1; Recurrence; Remission Induction; Retrospective Studies; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2015 |
Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Biological Assay; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gamma Rays; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multiplex Polymerase Chain Reaction; Mutation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Sensitivity and Specificity; Tumor Suppressor Protein p53; Vidarabine | 2015 |
An atypical case of bilateral posterior scleritis in a patient with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Eye Neoplasms; Fluorescein Angiography; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Rituximab; Scleritis; Vidarabine | 2015 |
Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myelin-Associated Glycoprotein; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Retrospective Studies; Severity of Illness Index; Vidarabine | 2015 |
Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 9; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunoglobulin Heavy Chains; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mutation; Tumor Suppressor Protein p53; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2016 |
Leukaemia cutis after starting bendamustine: cause or coincidence?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Erythema Nodosum; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Rituximab; Skin; Vidarabine | 2015 |
Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Second Primary; Prognosis; Recurrence; Remission Induction; Retreatment; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
Topics: Adenine; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Cyclophosphamide; Cytokines; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Vidarabine | 2015 |
The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; BRCA1 Protein; Cell Line, Tumor; Chromatography, Liquid; Cyclin D1; DNA Damage; DNA Repair; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; NF-kappa B p52 Subunit; Nucleolin; Phosphoproteins; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; Signal Transduction; Tandem Mass Spectrometry; Tumor Suppressor Protein p53; Vidarabine | 2015 |
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Prednisolone; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Rituximab; Survival Rate; Vidarabine | 2016 |
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Female; Follow-Up Studies; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Statistical; Quality-Adjusted Life Years; Rituximab; Treatment Outcome; Vidarabine | 2016 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2016 |
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Separation; Cyclophosphamide; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exome; Humans; Immunoprecipitation; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Neoplasm Recurrence, Local; Ribosomal Proteins; Rituximab; Transfection; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Role of Tumor Necrosis Factor-Producing Mesenchymal Stem Cells on Apoptosis of Chronic B-lymphocytic Tumor Cells Resistant to Fludarabine-based Chemotherapy.
Topics: Adipose Tissue; Adult; Antineoplastic Agents; Apoptosis; Cells, Cultured; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mesenchymal Stem Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Vidarabine | 2015 |
Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations.
Topics: Antibodies, Monoclonal, Humanized; CD40 Antigens; Heterografts; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2016 |
An unusual manifestation in a patient with Neurofibromatosis type 1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cyclophosphamide; Diagnosis, Differential; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neurofibromatosis 1; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Agents; DNA Transposable Elements; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutagenesis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins B-raf; Transcription Factors; Tumor Cells, Cultured; Vidarabine | 2016 |
Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bayes Theorem; Chlorambucil; Contraindications; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2016 |
Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Female; Germany; Health Care Surveys; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
Topics: Age Factors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cells, Cultured; Drug Synergism; Female; Humans; Immunoblotting; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Mice, Inbred NZB; Neoplasms, Experimental; NF-kappa B; Proto-Oncogene Proteins c-akt; Rotenone; Signal Transduction; Tumor Cells, Cultured; Vidarabine | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.
Topics: Antineoplastic Agents; Aphidicolin; Apoptosis; Cladribine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2016 |
Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cost-Benefit Analysis; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Markov Chains; Meta-Analysis as Topic; Middle Aged; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Treatment Outcome; United Kingdom; Vidarabine | 2016 |
Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays.
Topics: Aged; Aged, 80 and over; Antimetabolites; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dendrimers; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polypropylenes; Trisaccharides; Vidarabine | 2017 |
[SYNERGISTIC ACTIVITY OF DEGUELIN AND FLUDARABINE IN PRIMARY CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) AND IN A CLL MURINE MODEL].
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Primary Cell Culture; Rotenone; Tumor Cells, Cultured; Vidarabine | 2014 |
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Mitosis; Mutation; Nucleosides; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Increased IL-10/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Female; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Interleukin-10; Interleukin-17; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nuclear Receptor Subfamily 1, Group F, Member 3; Prognosis; Rituximab; T-Lymphocytes, Regulatory; Th17 Cells; Vidarabine | 2016 |
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
Topics: Adult; Aged; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine | 2017 |
TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.
Topics: Adult; Aged; Apoptosis; Apoptosis Regulatory Proteins; Cell Survival; Female; Glycolysis; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphoric Monoester Hydrolases; Prognosis; RNA, Messenger; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine; Young Adult | 2016 |
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
Topics: Animals; Apoptosis; Cell Line, Tumor; Clinical Trials as Topic; Dioxoles; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 2017 |
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Recurrence; Vidarabine | 2017 |
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cohort Studies; Disease Management; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Neoplasm Invasiveness; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine | 2017 |
PPI-G4 Glycodendrimers Upregulate TRAIL-Induced Apoptosis in Chronic Lymphocytic Leukemia Cells.
Topics: Adult; Apoptosis; Cell Line, Tumor; Dendrimers; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligonucleotide Array Sequence Analysis; Polypropylenes; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Vidarabine | 2017 |
Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D3; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Repressor Proteins; Vidarabine | 2017 |
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
Topics: bcl-X Protein; Caspases; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Thiazoles; Tumor Cells, Cultured; Vidarabine | 2008 |
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
Topics: Antineoplastic Agents; Caspase 3; Cell Death; Cytochromes c; Drug Resistance, Neoplasm; Glutathione; Glutathione Peroxidase; Humans; In Vitro Techniques; Isothiocyanates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Oxidation-Reduction; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Vidarabine | 2008 |
Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Research Design; Treatment Outcome; Vidarabine | 2008 |
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Biomarkers, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulin Heavy Chains; In Vitro Techniques; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Prognosis; Proto-Oncogene Proteins c-bcl-2; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2008 |
Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Single-Blind Method; Vidarabine | 2008 |
Epstein-Barr virus reactivation is a potentially severe complication in chronic lymphocytic leukemia patients with poor prognostic biological markers and fludarabine refractory disease.
Topics: Adult; Aged; Biomarkers, Tumor; Drug Resistance, Neoplasm; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Vidarabine; Virus Activation | 2008 |
Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calorimetry, Differential Scanning; Cell Survival; Cells, Cultured; Cladribine; Cyclophosphamide; DNA Damage; Drug Combinations; Drug Monitoring; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myeloid Cell Leukemia Sequence 1 Protein; Phase Transition; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2009 |
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; Benzothiazoles; Chlorambucil; Female; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitochondria; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Toluene; Transcription, Genetic; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Massive swelling of the cervical region: an uncommon manifestation of B cell chronic lymphocytic leukemia.
Topics: Adipose Tissue; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lipectomy; Lipomatosis, Multiple Symmetrical; Lymph Nodes; Middle Aged; Neck; Vidarabine | 2008 |
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Myeloablative Agonists; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytomegalovirus Infections; Diagnosis, Differential; Disease Progression; Epstein-Barr Virus Infections; Female; Genome, Viral; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Monitoring, Physiologic; Vidarabine | 2008 |
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; B-Lymphocytes; Cell Communication; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gossypol; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Stromal Cells; Tumor Cells, Cultured; Vidarabine | 2009 |
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Equilibrative-Nucleoside Transporter 2; Female; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphoric Monoester Hydrolases; Tumor Cells, Cultured; Vidarabine | 2008 |
Thalidomide induces phosphorylation of histone H2AX and increases rate of apoptosis caused by fludarabine in malignant lymphocytes of chronic lymphocytic leukemia in short-term cell cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Culture Techniques; Drug Synergism; Fluorescent Antibody Technique; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Phosphorylation; Thalidomide; Tumor Cells, Cultured; Vidarabine | 2009 |
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Recurrence; Vidarabine | 2009 |
[First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment].
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cyclophosphamide; Drug Costs; Frail Elderly; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloablative Agonists; Opportunistic Infections; Risk Factors; Rituximab; Vidarabine | 2009 |
Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Blotting, Western; Cladribine; Drug Synergism; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Confocal; Middle Aged; Reactive Oxygen Species; Tumor Cells, Cultured; Valproic Acid; Vidarabine | 2009 |
Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Gene Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2009 |
Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
Topics: Antineoplastic Agents; Apoptosis; Cell Communication; Cell Division; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Hedgehog Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligodeoxyribonucleotides, Antisense; Signal Transduction; Stromal Cells; Transcription Factors; Vidarabine; Zinc Finger Protein GLI1 | 2008 |
Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine | 2009 |
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Rituximab; Treatment Outcome; Vidarabine | 2009 |
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Flow Cytometry; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymerase Chain Reaction; Remission Induction; Rituximab; Vidarabine | 2009 |
The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
Topics: Antineoplastic Agents; CD40 Ligand; Cytoprotection; DNA; Drug Synergism; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Prognosis; Sesquiterpenes; Vidarabine | 2008 |
Dasatinib induces a response in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Dasatinib; Female; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Jejunal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Rituximab; src-Family Kinases; Thiazoles; Tomography, X-Ray Computed; Vidarabine | 2009 |
Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity.
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Cell Line, Tumor; Chlorambucil; Cytotoxins; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Formazans; Glucosyltransferases; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Chemical; Molecular Structure; Tetrazolium Salts; Vidarabine | 2009 |
Chronic lymphocytic leukaemia: current first-line therapy.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2009 |
Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.
Topics: Adrenal Cortex Hormones; Annexin A5; Apoptosis; Chlorambucil; Down-Regulation; Flow Cytometry; Gene Expression Regulation, Enzymologic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Plasmids; Prognosis; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Syk Kinase; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2009 |
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
Topics: ADAM Proteins; Antineoplastic Agents; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; DNA Mutational Analysis; Gene Expression Regulation, Neoplastic; Genes, Immunoglobulin Heavy Chain; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lipoprotein Lipase; Mutation; Remission Induction; Treatment Outcome; Vidarabine | 2009 |
Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Chlorambucil; Cladribine; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Prognosis; Time Factors; Tumor Cells, Cultured; Vidarabine | 2009 |
Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pancytopenia; Vidarabine | 2009 |
A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Conflict of Interest; Cost-Benefit Analysis; Cross-Over Studies; Cyclophosphamide; Disease-Free Survival; Drug Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Practice Guidelines as Topic; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Vidarabine | 2009 |
Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Receptors, Tumor Necrosis Factor; Risk Factors; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha; Vidarabine | 2009 |
Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2009 |
Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bendamustine Hydrochloride; Cyclophosphamide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Mitochondria; Nitrogen Mustard Compounds; Nuclear Proteins; Proto-Oncogene Proteins; Purine Nucleosides; Pyrimidinones; Rituximab; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2009 |
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Caspase 3; Cell Line, Tumor; Curcumin; Gene Expression Profiling; Humans; Immunoglobulin Variable Region; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Oxazines; Phosphorylation; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Syk Kinase; Vidarabine | 2009 |
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality of Life; Survival Analysis; Technology Assessment, Biomedical; Vidarabine | 2009 |
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
Topics: Animals; CD4-Positive T-Lymphocytes; CD40 Antigens; CD8-Positive T-Lymphocytes; Clone Cells; Cytotoxicity, Immunologic; Female; Flow Cytometry; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Mice; Middle Aged; Minor Histocompatibility Antigens; Myeloablative Agonists; NIH 3T3 Cells; T-Lymphocytes; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; bcl-X Protein; Biphenyl Compounds; Dexamethasone; Doxorubicin; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Mimicry; Nitrophenols; Piperazines; Prognosis; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Vidarabine | 2009 |
Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; DNA Mutational Analysis; Frameshift Mutation; Gene Expression Regulation, Leukemic; Genes, p53; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Neoplasm Proteins; Prognosis; Rituximab; Survival Analysis; Tumor Suppressor Protein p53; Vidarabine | 2009 |
Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cell Survival; Cells, Cultured; Cladribine; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclophosphamide; Drug Synergism; Female; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Vidarabine | 2009 |
Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Feasibility Studies; Humans; Immunotherapy; Infections; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2009 |
Renal dysfunction due to leukemic infiltration of kidneys in a case of chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Middle Aged; Prednisolone; Renal Dialysis; Renal Insufficiency; Ultrasonography; Vidarabine | 2010 |
Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Death; Cladribine; Cohort Studies; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2009 |
Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Disease-Free Survival; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Caspase 8; DNA (Cytosine-5-)-Methyltransferases; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunoblotting; Immunoglobulin Heavy Chains; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microtubules; Middle Aged; Oxazepines; Prognosis; Pyrroles; Tubulin; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2009 |
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.
Topics: Antineoplastic Agents; Blotting, Western; DNA Damage; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gene Silencing; Genes, p53; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 2009 |
Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression.
Topics: Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Cell Survival; Cells, Cultured; Female; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysophospholipids; Male; Middle Aged; Receptors, Lysophosphatidic Acid; Receptors, Purinergic P2; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Vascular Endothelial Growth Factor A; Vidarabine | 2009 |
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Survival; Cells, Cultured; Cladribine; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Cyclophosphamide; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Purines; Roscovitine; Vidarabine | 2010 |
R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2010 |
Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Blotting, Western; Caspase 3; Caspase 9; Cell Separation; Drug Synergism; Enzyme Activation; Female; Flow Cytometry; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Vidarabine | 2010 |
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Cyclophosphamide; Drug Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Risk; Rituximab; Thalidomide; Treatment Outcome; Vidarabine | 2010 |
CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Autoimmunity; CD40 Ligand; Cells, Cultured; Cladribine; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Vidarabine | 2010 |
Progressive multifocal leukencephalopathy and cerebral toxoplasmosis in a patient with CLL.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Humans; Immunocompromised Host; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Rituximab; Toxoplasmosis, Cerebral; Vidarabine; Virus Activation | 2010 |
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.
Topics: Adult; Aged; Antigens, CD19; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cancer Vaccines; CD40 Ligand; CD5 Antigens; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Female; Humans; Hyaluronan Receptors; Immunization; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; T-Lymphocytes, Cytotoxic; Vidarabine | 2010 |
[Correlation of deoxycytidine kinase gene expression with fludarabine resistance in patients with chronic lymphocytic leukemia].
Topics: Aged; Aged, 80 and over; Case-Control Studies; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2010 |
All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.
Topics: Antineoplastic Agents; Autocrine Communication; Cell Membrane; Cytosol; Enzyme Activation; HeLa Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Promyelocytic, Acute; Membrane Transport Proteins; Mitogen-Activated Protein Kinase 3; Protein Transport; rhoA GTP-Binding Protein; Transcription, Genetic; Transforming Growth Factor beta1; Tretinoin; Vidarabine | 2010 |
In defence of the use of modern chemotherapy regimens for the treatment of patients with chronic lymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2009 |
Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
Topics: Aged; Apoptosis; Female; Hemoglobins; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Leukocytes, Mononuclear; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Platelet Count; Vidarabine | 2008 |
Haemophagocytic syndrome and Hodgkin's disease variant of Richter's syndrome after fludarabine for CLL.
Topics: Aged; Antineoplastic Agents; Epstein-Barr Virus Infections; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Male; Vidarabine | 2010 |
Drug-induced immune hemolytic anemia.
Topics: Anemia, Hemolytic; Anti-Bacterial Agents; Antineoplastic Agents; Cefotetan; Ceftriaxone; Coombs Test; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperacillin; Vidarabine | 2010 |
Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunomodulation; Immunotherapy; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Rituximab; Survival Rate; Vidarabine | 2010 |
Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Genes, myc; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Vidarabine | 2010 |
Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.
Topics: ADP-ribosyl Cyclase 1; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Proteins; Cladribine; DNA-Binding Proteins; Enzyme Activation; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Simvastatin; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Fever; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neutropenia; Pneumonia; Treatment Outcome; United States; United States Food and Drug Administration; Vidarabine | 2010 |
LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.
Topics: Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prognosis; Purines; Tumor Necrosis Factor-alpha; Vidarabine | 2010 |
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Female; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Treatment Outcome; Vidarabine | 2011 |
High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine | 2010 |
Auer rod-like inclusions in a low-grade B-cell leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Separation; Cyclophosphamide; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Inclusion Bodies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Electron, Transmission; Middle Aged; Rituximab; Vidarabine | 2010 |
HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus.
Topics: Antineoplastic Agents; Blood Transfusion; Disease Transmission, Infectious; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine; Virus Activation | 2010 |
Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.
Topics: Adult; Aged, 80 and over; Apoptosis; Cells, Cultured; Drug Synergism; fas Receptor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Quercetin; Receptors, Death Domain; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Vidarabine | 2010 |
Effect of FCGR2A and FCGR3A variants on CLL outcome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Genotype; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, IgG; Rituximab; Treatment Outcome; Vidarabine | 2010 |
Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL).
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Czech Republic; Disease Management; Female; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2010 |
Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
Topics: ADP-ribosyl Cyclase 1; Adult; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Proteins; Cladribine; DNA-Binding Proteins; Drug Therapy, Combination; Enzyme Activation; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Membrane Glycoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Resveratrol; Stilbenes; Tumor Suppressor Proteins; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2011 |
The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
Topics: Adjuvants, Immunologic; Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; Cell Communication; Coculture Techniques; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Proteins; Receptors, CXCR4; Rituximab; Stromal Cells; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured; Vidarabine | 2010 |
Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Repair; Drug Synergism; Humans; Hydroxylamines; Leukemia, Lymphocytic, Chronic, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Uracil-DNA Glycosidase; Vidarabine | 2010 |
B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Separation; Coloring Agents; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Phenotype; Recombinant Proteins; Rituximab; Vidarabine | 2010 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Thailand; Vidarabine; Young Adult | 2010 |
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Male; Middle Aged; Myeloablative Agonists; T-Lymphocyte Subsets; T-Lymphocytes; Vidarabine | 2011 |
Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative dis
Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Cell Transformation, Neoplastic; Clone Cells; Epstein-Barr Virus Infections; Fatal Outcome; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Immunoblastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Plasma Cells; Vidarabine | 2010 |
Chronic lymphocytic leukaemia--moving towards cure?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Time Factors; Treatment Outcome; Vidarabine | 2010 |
ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; CD40 Antigens; Cisplatin; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2011 |
Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia.
Topics: Aged; Angiomatosis, Bacillary; Anti-Bacterial Agents; Antineoplastic Agents; Bacteriological Techniques; Bartonella quintana; Drug Therapy; Female; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Microscopy; Osteomyelitis; Treatment Failure; Vidarabine | 2011 |
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Flow Cytometry; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Receptors, CXCR4; Survival Analysis; Tumor Cells, Cultured; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2011 |
Diagnostic and therapeutic challenges.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymph Nodes; Male; Middle Aged; Retinal Neoplasms; Rituximab; Splenomegaly; Tomography, X-Ray Computed; Vidarabine; Vision, Low; Visual Acuity; Vitreoretinopathy, Proliferative; Vitreous Hemorrhage | 2011 |
EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immune System; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 2011 |
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medi
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; European Union; Female; Health Services; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Practice Guidelines as Topic; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Enzyme Activation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proliferating Cell Nuclear Antigen; Proteasome Endopeptidase Complex; Purine Nucleosides; Tumor Suppressor Protein p53; Ubiquitination; Up-Regulation; Vidarabine | 2011 |
DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; ATP Binding Cassette Transporter, Subfamily B; Benzaldehydes; Blotting, Western; Caffeine; Cell Cycle Proteins; Cell Line, Tumor; Chromones; Cyclosporine; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine | 2010 |
Personalizing treatment for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Receptors, CXCR4; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2011 |
Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic 'sensor/effector' compounds.
Topics: Antineoplastic Agents; Apoptosis; Catalysis; Cell Survival; Drug Synergism; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Organic Chemicals; Oxidation-Reduction; Reactive Oxygen Species; Vidarabine | 2011 |
Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Drug Monitoring; Female; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Pilot Projects; Recombinant Proteins; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine | 2011 |
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line; Cell Survival; CHO Cells; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Organoplatinum Compounds; Oxaliplatin; Signal Transduction; Vidarabine | 2011 |
Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Glomerulonephritis, Membranoproliferative; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2011 |
Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Glomerulosclerosis, Focal Segmental; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Rituximab; Vidarabine | 2011 |
Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Clinical Trials as Topic; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2012 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 5; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Translocation, Genetic; Vidarabine | 2011 |
Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Hemianopsia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Rituximab; Vidarabine | 2012 |
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Oligonucleotides; Prognosis; Risk Factors; Rituximab; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2012 |
Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Female; Flow Cytometry; Genes, Immunoglobulin Heavy Chain; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2012 |
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Death; Cell Survival; Cyclophosphamide; Depsipeptides; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Monocytes; Peptides, Cyclic; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Vidarabine | 2012 |
Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; B-Lymphocytes; CD5 Antigens; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Neoplasm, Residual; Reference Values; ROC Curve; Sensitivity and Specificity; Vidarabine | 2011 |
Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.
Topics: Adult; Aged; Aged, 80 and over; CD4-Positive T-Lymphocytes; Cells, Cultured; Coculture Techniques; Flow Cytometry; Forkhead Transcription Factors; Humans; Immunomodulation; Interleukin-2 Receptor alpha Subunit; Interleukin-7 Receptor alpha Subunit; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tumor Necrosis Factor Receptor Superfamily, Member 7; Vidarabine | 2011 |
CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers, Tumor; Cohort Studies; Female; Humans; Lectins, C-Type; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Vidarabine | 2012 |
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 2012 |
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; B-Lymphocytes; Biomarkers, Tumor; Cell Line, Tumor; Female; Humans; Hydrogen Peroxide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphorylation; Proteome; Reactive Oxygen Species; Signal Transduction; Single-Cell Analysis; Vidarabine | 2011 |
Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.
Topics: Antineoplastic Agents; Cell Death; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; Tumor Cells, Cultured; Vidarabine | 2012 |
Fludarabine versus chlorambucil: is the debate over?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Remission Induction; Vidarabine | 2011 |
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Topics: Amino Acid Sequence; Antineoplastic Agents; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Sequence Data; Mutation; Oligonucleotide Array Sequence Analysis; Phosphoproteins; Polymorphism, Single Nucleotide; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Sequence Homology, Amino Acid; Spliceosomes; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjögren syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biopsy; Cyclophosphamide; Drug Therapy, Combination; Eyelids; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Necrobiotic Xanthogranuloma; Paraproteinemias; Rituximab; Sjogren's Syndrome; Treatment Outcome; Vidarabine | 2011 |
Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2012 |
Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Apoptosis; CD40 Ligand; Cell Proliferation; Crotonates; Drug Resistance, Neoplasm; Humans; Hydroxybutyrates; Interleukin-4; Isoxazoles; Janus Kinases; Leflunomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitriles; Signal Transduction; STAT Transcription Factors; Toluidines; Tumor Cells, Cultured; Vidarabine | 2012 |
Anti-CD20: tales of identical twins?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Vidarabine | 2011 |
Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Incidence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Rituximab; Vidarabine | 2012 |
Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purines; Roscovitine; Vidarabine | 2012 |
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biphenyl Compounds; CD40 Antigens; CD40 Ligand; Coculture Techniques; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Mice; Middle Aged; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; NIH 3T3 Cells; Nitrophenols; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Tumor Cells, Cultured; Vidarabine | 2012 |
Fludarabine nucleoside modulates nuclear "survival and death" proteins in resistant chronic lymphocytic leukemia cells.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nuclear Proteins; Nucleosides; Protein Processing, Post-Translational; Vidarabine | 2011 |
Chemotherapy: New FluCam combination therapy has familiar limitations.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Cyclophosphamide; Drug Therapy, Combination; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2011 |
The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzamides; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Protein Serine-Threonine Kinases; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2012 |
Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Annexin A5; Antineoplastic Agents; Apoptosis; Biological Transport; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Primary Cell Culture; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tretinoin; Tritium; Vidarabine | 2012 |
Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.
Topics: Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD18 Antigens; Cell Adhesion; Cell Communication; Coculture Techniques; Culture Media, Conditioned; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Integrin beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Primary Cell Culture; Signal Transduction; Vascular Cell Adhesion Molecule-1; Vidarabine | 2012 |
Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient.
Topics: Antineoplastic Agents; Brain; DNA, Viral; Herpesvirus 7, Human; Humans; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Vidarabine | 2011 |
Individualized fludarabine-based regimen in elderly patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2012 |
[Modern times: back to past, back to future].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multiple Myeloma; Pyrazines; Rituximab; Vidarabine | 2012 |
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Baculoviral IAP Repeat-Containing 3 Protein; Blotting, Western; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; In Situ Hybridization, Fluorescence; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; NF-kappa B; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Vidarabine | 2012 |
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Bone Marrow Cells; Cell Communication; Cell Line; Cell Survival; Coculture Techniques; Culture Media, Conditioned; Cysteine; Cystine; Drug Resistance, Neoplasm; Flow Cytometry; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Organoplatinum Compounds; Oxaliplatin; Reactive Oxygen Species; Stromal Cells; Tumor Cells, Cultured; Vidarabine | 2012 |
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Disease-Free Survival; DNA Mutational Analysis; DNA-Binding Proteins; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Mutation, Missense; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Serine-Threonine Kinases; Rituximab; Tumor Suppressor Proteins; Vidarabine | 2012 |
Risk categories and refractory CLL in the era of chemoimmunotherapy.
Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Forecasting; Genes, p53; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Prognosis; Risk Assessment; Rituximab; Terminology as Topic; Treatment Failure; Vidarabine | 2012 |
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Middle Aged; Neoadjuvant Therapy; Rituximab; Survival Analysis; Time Factors; Vidarabine | 2012 |
N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Proliferation; Drug Synergism; Fenretinide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sulfonamides; Vidarabine | 2012 |
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.
Topics: Abnormal Karyotype; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Fatal Outcome; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Prednisone; Vidarabine; Vincristine | 2013 |
miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
Topics: Antineoplastic Agents; Apoptosis; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Vidarabine | 2012 |
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; CASP8 and FADD-Like Apoptosis Regulating Protein; Cells, Cultured; Cytoprotection; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Resorcinols; Signal Transduction; Survivin; Tumor Microenvironment; Vidarabine | 2012 |
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.
Topics: Animals; Apoptosis; CD40 Antigens; CD40 Ligand; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunophenotyping; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phenotype; Receptor Tyrosine Kinase-like Orphan Receptors; Resorcinols; STAT3 Transcription Factor; Stromal Cells; Vidarabine | 2012 |
Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study.
Topics: Antineoplastic Agents; Apoptosis; Cladribine; DNA, Complementary; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Transcriptome; Tumor Cells, Cultured; Vidarabine | 2012 |
Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Cyclin-Dependent Kinase Inhibitor p21; Cyclophosphamide; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Prognosis; Protein Serine-Threonine Kinases; Randomized Controlled Trials as Topic; Signal Transduction; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2012 |
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
Topics: Antineoplastic Agents; Autophagy; Cell Culture Techniques; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Starvation; Tumor Cells, Cultured; Vidarabine | 2012 |
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Dactinomycin; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Mice, Transgenic; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2012 |
HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Blood Proteins; Cell Nucleus; Cyclophosphamide; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, Antigen, B-Cell; RNA, Messenger; src-Family Kinases; Subcellular Fractions; Substrate Specificity; Vidarabine | 2012 |
The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
Topics: Antineoplastic Agents; Biological Assay; Drug Monitoring; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Patient Selection; Predictive Value of Tests; Prognosis; Random Allocation; Randomized Controlled Trials as Topic; Survival Rate; Vidarabine | 2013 |
Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cyclophosphamide; DNA Probes; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Rituximab; Translocation, Genetic; Vidarabine | 2012 |
Fludarabine and cladribine induce changes in surface proteins on human B-lymphoid cell lines involved with apoptosis, cell survival, and antitumor immunity.
Topics: Antigens, CD; Apoptosis; B-Lymphocytes; Burkitt Lymphoma; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Survival; Cladribine; Drug Resistance, Neoplasm; Flow Cytometry; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Reproducibility of Results; Signal Transduction; Up-Regulation; Vidarabine | 2012 |
Richter syndrome and fludarabine: a controversial relationship.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Vidarabine | 2013 |
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).
Topics: Adult; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Vidarabine | 2013 |
Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.
Topics: Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Immunoprecipitation; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; NF-kappa B; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine | 2012 |
Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Topics: Aged; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcus neoformans; Cyclophosphamide; Drug Therapy, Combination; Fatal Outcome; Flucytosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meningitis, Cryptococcal; Rituximab; Time Factors; Vidarabine | 2013 |
S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Topics: Aged; Animals; Antineoplastic Agents; Cell Cycle Proteins; Female; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Nuclear Proteins; Piperazines; Prognosis; Protein Splicing; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Suppressor Protein p53; Vidarabine | 2012 |
Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Cytogenetics; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Time Factors; Translocation, Genetic; Vidarabine | 2012 |
Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cryoglobulinemia; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2013 |
[Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Flow Cytometry; Hospitals, County; Humans; Hungary; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prednisolone; Remission Induction; Treatment Outcome; Vidarabine; Vincristine | 2012 |
Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomal Proteins, Non-Histone; Female; Humans; Imidazoles; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleoproteins; Oncogene Proteins; Piperazines; Poly-ADP-Ribose Binding Proteins; Prognosis; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2012 |
Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Leukemia specific loss of heterozygosity of MHC in a CLL patient: disease state impacts timing of confirmatory typing.
Topics: Antibodies, Monoclonal, Murine-Derived; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Histocompatibility Testing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Loss of Heterozygosity; Male; Middle Aged; Myeloablative Agonists; Rituximab; Time Factors; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2013 |
Visceral varicella in a patient with chronic lymphocytic leukemia treated with fludarabine: a case report.
Topics: Antineoplastic Agents; Chickenpox; Herpesvirus 3, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine; Virus Activation | 2013 |
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Vidarabine | 2012 |
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cell Line, Tumor; CpG Islands; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Rituximab; RNA, Small Interfering; Thionucleotides; Toll-Like Receptor 9; Vidarabine; Xenograft Model Antitumor Assays | 2013 |
Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Disease-Free Survival; Female; Gene Dosage; Gene Knockdown Techniques; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Prognosis; Risk Factors; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Transcriptome; Up-Regulation; Vidarabine | 2013 |
A non-fatal case of invasive zygomycete (Lichtheimia corymbifera) infection in an allogeneic haematopoietic cell transplant recipient.
Topics: Antifungal Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Mucorales; Mucormycosis; Peripheral Blood Stem Cell Transplantation; Triazoles; Vidarabine | 2013 |
Exacerbation of lymphomatoid papulosis during rituximab therapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphomatoid Papulosis; Male; Middle Aged; Prednisolone; Rituximab; Vidarabine; Vincristine | 2014 |
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, SCID; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Spleen; Syk Kinase; Vidarabine; Xenograft Model Antitumor Assays | 2013 |
In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphotoxin-alpha; MicroRNAs; Prognosis; Toll-Like Receptors; Vidarabine | 2013 |
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Randomized Controlled Trials as Topic; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2013 |
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Cladribine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Vidarabine | 2002 |
Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Count; Cyclophosphamide; Dexamethasone; Enzyme Activation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; Mitoxantrone; Protein Conformation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2002 |
Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation.
Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Case-Control Studies; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Proteins; Ribonucleotide Reductases; Vidarabine | 2002 |
Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cause of Death; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Interstitial; Lymphoproliferative Disorders; Male; Middle Aged; Risk Factors; Vidarabine | 2002 |
Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antiviral Agents; Cyclophosphamide; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Respiratory Syncytial Virus Infections; Ribavirin; Vidarabine | 2002 |
The triterpenoid CDDO induces apoptosis in refractory CLL B cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Caspases; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitric Oxide; Oleanolic Acid; Vidarabine | 2002 |
Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adult; Aged; Aged, 80 and over; Biological Transport; Carrier Proteins; Cell Survival; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes; Male; Melphalan; Membrane Transport Proteins; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured; Vidarabine | 2003 |
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine.
Topics: Female; Guillain-Barre Syndrome; Herpes Zoster; Herpesvirus 3, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Vidarabine; Virus Activation | 2002 |
[Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia].
Topics: Aged; Antineoplastic Agents; Biopsy; Brain; Chronic Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Polymerase Chain Reaction; Vidarabine | 2002 |
[Successful treatment with fludarabine of chronic lymphocytic leukemia associated with nephrotic syndrome].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nephrotic Syndrome; Vidarabine | 2002 |
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Adenoviridae Infections; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2002 |
[Whipple's disease as a complication of chronic lymphocytic leukemia treated with fludarabine].
Topics: Antineoplastic Agents; Fatal Outcome; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Vidarabine; Whipple Disease | 2002 |
CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
Topics: Aged; Aged, 80 and over; Apoptosis; Autocrine Communication; B-Lymphocytes; CD40 Antigens; CD40 Ligand; Female; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha; Up-Regulation; Vidarabine | 2003 |
Immune thrombocytopenia induced by fludarabine successfully treated with rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2003 |
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; Survival Rate; Transplantation Conditioning; Vidarabine | 2002 |
Facial paresis after fludarabine treatment for advanced chronic lymphocytic leukaemia.
Topics: Aged; Facial Paralysis; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Shock, Septic; Vidarabine | 2002 |
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubicin; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Vidarabine; Vincristine | 2003 |
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Pentostatin; Thrombocytopenia; Treatment Outcome; Vidarabine | 2003 |
Bilateral orbital masses in a patient with B-cell chronic lymph.
Topics: Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Orbital Neoplasms; Treatment Outcome; Vidarabine | 2003 |
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Salvage Therapy; Time Factors; Vidarabine | 2002 |
Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.
Topics: Annexin A5; Apoptosis; Apoptosis Regulatory Proteins; Caenorhabditis elegans Proteins; Cell Cycle; Cell Division; Cell Line, Tumor; Coloring Agents; Cyclin D3; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Cyclins; Down-Regulation; Fluorescein-5-isothiocyanate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Vidarabine | 2002 |
Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Time Factors; Vidarabine | 2003 |
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Chlorambucil; Cyclophosphamide; DNA Damage; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gamma Rays; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Risk Factors; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2003 |
Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2003 |
Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase Inhibitors; Caspases; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cyclin D2; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Subcellular Fractions; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vidarabine | 2003 |
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Topics: Adult; Aged; Busulfan; Child; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Probability; Retrospective Studies; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Amino Acid Chloromethyl Ketones; Antibodies; Antibodies, Monoclonal; Antigens, CD; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin A; Immunoglobulin D; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Neprilysin; Palatine Tonsil; Vidarabine | 2003 |
Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2003 |
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Platelet Count; Transplantation, Autologous; Vidarabine | 2004 |
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Case-Control Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Frequency; Genes, bcl-2; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Vidarabine | 2003 |
Oral fludarabine: a viewpoint by Dieter Huhn.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Clinical Trials as Topic; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2003 |
Oral fludarabine: a viewpoint by David Oscier.
Topics: Administration, Oral; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2003 |
Oral fludarabine: a viewpoint by Bruce D. Cheson.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2003 |
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2003 |
Post-transcriptional regulation of inducible nitric oxide synthase in chronic lymphocytic leukemia B cells in pro- and antiapoptotic culture conditions.
Topics: Aged; Aged, 80 and over; Alternative Splicing; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Base Sequence; Caspase 3; Caspases; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Interleukin-4; Isoenzymes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Sequence Data; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; RNA Processing, Post-Transcriptional; RNA, Messenger; Sequence Deletion; Sequence Homology, Nucleic Acid; Signal Transduction; Transcription, Genetic; Vidarabine | 2004 |
Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs.
Topics: Antibiotics, Antineoplastic; Antigens, CD34; Apoptosis; Benzoquinones; Blotting, Western; Bone Marrow Cells; Cell Separation; Chlorambucil; Down-Regulation; Enzyme Inhibitors; Flow Cytometry; HSP70 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinones; Rifabutin; RNA, Messenger; T-Lymphocytes; Time Factors; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes; Male; Middle Aged; Time Factors; Transplantation, Autologous; Vidarabine | 2004 |
Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Chlorambucil; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Protein Binding; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine | 2003 |
[Pressure pain in the left epigastrium: blood picture provides diagnosis. Chronic lymphatic leukemia].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytosis; Lymphocyte Count; Male; Middle Aged; Prednisone; Splenomegaly; Time Factors; Ultrasonography; Vidarabine | 2003 |
Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Albuterol; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Calcium; Cell Line, Tumor; Chlorambucil; Cyclic AMP; Ethanolamines; Female; Formoterol Fumarate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Vidarabine | 2004 |
Fatal fludarabine-induced extensive bone marrow necrosis in a patient with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Diseases; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Vidarabine | 2003 |
Fludarabine induced immune thrombocytopenia in a patient with CD5 positive B cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Vidarabine | 2003 |
45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Prednisone; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Vincristine | 2003 |
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Evaluation; Drug Resistance; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Sequence Deletion; Treatment Outcome; Vidarabine | 2004 |
Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine | 2003 |
Fludarabine-induced hemolytic anemia: successful treatment by rituximab.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Blood Transfusion; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2004 |
Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Cyclophosphamide; Disease Progression; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Second Primary; Syndrome; Time Factors; Vidarabine | 2003 |
[Drug-resistant B cell chronic lymphocytic leukemia safely treated with rituximab to control leukemic cell increment and platelet transfusion dependence].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Hepatomegaly; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytosis; Male; Middle Aged; Platelet Transfusion; Rituximab; Vidarabine | 2004 |
Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Rituximab; Treatment Failure; Vidarabine | 2004 |
Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chlorambucil; Complement System Proteins; Culture Media, Serum-Free; Humans; Immunoglobulin Fab Fragments; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2004 |
Fludarabine in chronic lymphocytic leukemia and other hematological malignancies: progress in treatment. Fludarabine supplement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine | 2004 |
Transient absence of hepatic uptake on gallium-67 scintigraphy following fludarabine therapy.
Topics: Antineoplastic Agents; Citrates; Gallium; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liver; Male; Metabolic Clearance Rate; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Spleen; Time Factors; Vidarabine | 2004 |
High dose chlorambucil in the treatment of lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vidarabine | 2004 |
Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Apoptosis; B-Lymphocytes; Biomarkers, Tumor; Cell Cycle; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Microfilament Proteins; Muscle Proteins; Rituximab; Sensitivity and Specificity; Tumor Protein, Translationally-Controlled 1; Vidarabine | 2004 |
Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection.
Topics: Aged; Antineoplastic Agents; Clone Cells; DNA, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Deletion; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasms, Second Primary; Polymerase Chain Reaction; Reed-Sternberg Cells; Vidarabine | 2004 |
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Treatment Outcome; Vidarabine | 2005 |
Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Ionomycin; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleotides; Pentostatin; Prognosis; Tumor Cells, Cultured; Vidarabine | 2004 |
Fludarabine as the possible cause of acute myelofibrosis.
Topics: Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Primary Myelofibrosis; Vidarabine | 2004 |
Successful reduced-intensity allogeneic transplantation utilizing a fludarabine-based preparative regimen in a patient with chronic lymphocytic leukaemia and a history of fludarabine-associated autoimmune haemolytic anaemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2004 |
Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Fever of Unknown Origin; Filgrastim; Granulocyte Colony-Stimulating Factor; Guillain-Barre Syndrome; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Transplantation, Autologous; Vidarabine | 2004 |
Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cell Survival; Cells, Cultured; Chlorambucil; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasm Staging; Predictive Value of Tests; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2004 |
The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Topics: Apoptosis; B-Lymphocytes; Benzodiazepines; Benzodiazepinones; Case-Control Studies; Caspase 3; Caspases; Cross-Linking Reagents; DNA Damage; DNA Repair; Enzyme Activation; Humans; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrroles; T-Lymphocytes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2004 |
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.
Topics: Adamantane; Apoptosis; B-Lymphocytes; Cells, Cultured; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Hydroquinones; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Vidarabine | 2005 |
Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Mitochondrial Proteins; Nitric Oxide; Nuclear Proteins; Nuclear Respiratory Factor 1; Organelle Biogenesis; Transcription Factors; Tumor Cells, Cultured; Vidarabine | 2004 |
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Synergism; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2004 |
High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Culture Media, Serum-Free; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Oligonucleotide Array Sequence Analysis; Phenotype; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2005 |
Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.
Topics: Antineoplastic Agents; Blotting, Western; Equilibrative-Nucleoside Transporter 2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vidarabine | 2005 |
Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect.
Topics: Aged; Annexin A5; Antigens, CD19; Antineoplastic Agents; Apoptosis; CD5 Antigens; Cell Death; Cell Survival; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Monocytes; Time Factors; Vidarabine | 2004 |
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cladribine; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Idarubicin; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Melphalan; Prednisolone; Survival Analysis; Vidarabine; Vincristine | 2004 |
Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia.
Topics: Acute Kidney Injury; Administration, Oral; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Lysis Syndrome; Vidarabine | 2004 |
Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB.
Topics: Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lysophospholipids; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Lysophosphatidic Acid; Tumor Cells, Cultured; Vidarabine | 2005 |
Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Apoptosis; Cell Survival; DNA-Binding Proteins; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; STAT1 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Tyrphostins; Vidarabine | 2005 |
Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prednisolone; Retreatment; Survival Analysis; Turkey; Vidarabine | 2004 |
The influence of chemotherapy on bone marrow in patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Vidarabine | 2004 |
Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Disease Progression; Female; Herpesvirus 4, Human; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Reed-Sternberg Cells; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2005 |
Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia.
Topics: Antigens, CD34; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Changing the way we think about chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Rituximab; Vidarabine | 2005 |
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF.
Topics: Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Leukemia, Lymphocytic, Chronic, B-Cell; Peripheral Blood Stem Cell Transplantation; Treatment Failure; Vidarabine | 2005 |
p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Female; Genes, p53; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Treatment Outcome; Vidarabine | 2005 |
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Caspases; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Humans; In Vitro Techniques; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lignans; Magnolia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phytotherapy; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2005 |
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Vidarabine; Whole-Body Irradiation | 2005 |
Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine.
Topics: Antineoplastic Agents; Cell Transformation, Viral; Clone Cells; Drug Resistance, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Hodgkin Disease; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Micromanipulation; Middle Aged; Reed-Sternberg Cells; Vidarabine | 2005 |
Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure.
Topics: Acute Kidney Injury; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Renal Dialysis; Vidarabine | 2005 |
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Topics: Actins; Apoptosis; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Chemotaxis; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Molecular Weight; Oligopeptides; Peptides; Receptors, CXCR4; Stromal Cells; Structure-Activity Relationship; Time Factors; Vidarabine | 2005 |
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; B-Lymphocytes; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Caspase 9; Caspases; Cell Aggregation; Cell Survival; Cells, Cultured; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2005 |
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation; Case-Control Studies; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; DNA-Binding Proteins; Forkhead Transcription Factors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Interleukin-10; L-Selectin; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Receptors, Interleukin-2; Receptors, Nerve Growth Factor; Receptors, Tumor Necrosis Factor; T-Lymphocyte Subsets; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vidarabine | 2005 |
Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microcirculation; Middle Aged; Neoplasm, Residual; Neovascularization, Pathologic; Vidarabine | 2005 |
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Disease Susceptibility; Female; Herpesviridae Infections; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia, Pneumocystis; Risk; Rituximab; Vidarabine | 2005 |
Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome; Vidarabine | 2005 |
Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myasthenia Gravis; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2005 |
Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Bone Marrow; Chromosomes, Human, Pair 7; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Monosomy; Neoplasms, Second Primary; Vidarabine | 2005 |
Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia.
Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Diagnosis, Differential; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Vidarabine | 2005 |
Richter's syndrome--the downside of fludarabine?
Topics: Antineoplastic Agents; Epstein-Barr Virus Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Syndrome; Vidarabine | 2005 |
'Specific' cutaneous infiltrate of B-cell chronic lymphocytic leukemia at the site of a florid herpes simplex infection.
Topics: Aged; Antineoplastic Agents; Herpes Zoster; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Neoplasm Staging; Skin Neoplasms; Treatment Outcome; Vidarabine | 2005 |
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; B-Lymphocytes; Brefeldin A; Cells, Cultured; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Golgi Apparatus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Middle Aged; Multiple Myeloma; Protein Transport; Tumor Necrosis Factor Ligand Superfamily Member 13; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vidarabine | 2006 |
Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Disease Management; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prognosis; Rituximab; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
[Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulins; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myeloablative Agonists; Rituximab; Severity of Illness Index; Thrombocytopenia; Treatment Outcome; Vidarabine | 2005 |
Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cerebrospinal Fluid; Drug Evaluation; Female; Humans; Injections, Intravenous; Injections, Spinal; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 2005 |
Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carrier Proteins; Cell Survival; Chlorambucil; Flow Cytometry; Gene Expression; Glycoproteins; Humans; Immunoglobulin G; Interleukin-1; Interleukin-8; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Oligonucleotide Array Sequence Analysis; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2006 |
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Creatinine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Recombinant Proteins; Renal Insufficiency; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Vidarabine | 2005 |
OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channels; Cell Line, Tumor; Cholestenones; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopy, Electron; Mitochondrial Membranes; Saponins; Vidarabine | 2005 |
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Female; Gene Deletion; Genes, Immunoglobulin Heavy Chain; Genetic Predisposition to Disease; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2006 |
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2006 |
Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Case-Control Studies; Cyclophosphamide; Fas Ligand Protein; fas Receptor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Middle Aged; Mitoxantrone; Solubility; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors; Vidarabine | 2005 |
Significance of VH genes mutation status for prognosis of CLL patients.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Flow Cytometry; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 2005 |
Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Hemolysis; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Vidarabine | 2006 |
Fludarabine induced autoimmune haemolytic anaemia in a patient with chronic lymphocytic leukaemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Vidarabine | 2006 |
Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Transcription Factors; Tumor Suppressor Protein p53; Vidarabine | 2006 |
Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Annexin A5; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cytotoxicity Tests, Immunologic; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2006 |
DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; CD40 Antigens; Cell Line, Tumor; Cell Survival; Cyclohexanones; Down-Regulation; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2006 |
The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia.
Topics: Anemia, Hemolytic, Autoimmune; Case-Control Studies; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Vidarabine | 2006 |
[Fever and dyspnea in a patient with chronic lymphatic leukemia under treatment with fludarabine].
Topics: Aged; Antineoplastic Agents; Dyspnea; Female; Fever; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Vidarabine | 2006 |
Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease Progression; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prednisolone; Remission Induction; Risk Factors; Rituximab; Treatment Outcome; Vidarabine | 2006 |
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cells, Cultured; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Transcription, Genetic; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2006 |
Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient.
Topics: Aged; Antifungal Agents; Antineoplastic Agents; Cryptococcosis; Fluconazole; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Male; Opportunistic Infections; Radiography, Thoracic; Tomography, X-Ray Computed; Treatment Outcome; Vidarabine | 2007 |
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2006 |
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
Topics: Animals; Antineoplastic Agents; CD5 Antigens; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Neoplasm Proteins; Proto-Oncogene Proteins; Tumor Cells, Cultured; Vidarabine | 2006 |
[Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisolone; Rituximab; Vidarabine; Vincristine | 2005 |
Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: rituximab as the treatment of choice?
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Rituximab; Treatment Outcome; Vidarabine | 2007 |
Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine.
Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Female; Hepatitis B; Hepatitis B Surface Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phylogeny; Vidarabine | 2006 |
Concomitant Epstein-Barr virus-negative large B-cell lymphoma (Richter syndrome) and Epstein-Barr virus- positive B-cell lymphoproliferation after treatment with fludarabine and cyclophosphamide in a patient with B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epstein-Barr Virus Infections; Fatal Outcome; Herpesvirus 4, Human; Humans; Immunoglobulin A; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Tumor Lysis Syndrome; Vidarabine | 2006 |
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Signal Transduction; T-Lymphocytes; Time Factors; Vidarabine | 2006 |
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; T-Lymphocytes, Regulatory; Thalidomide; Treatment Failure; Tumor Necrosis Factor-alpha; Vidarabine | 2007 |
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Remission Induction; Stem Cells; Treatment Outcome; Vidarabine | 2006 |
Herpes simplex and Epstein-Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Acyclovir; Aged; Antineoplastic Agents; Antiviral Agents; Female; Gene Expression Profiling; Gene Expression Regulation, Viral; Herpesviridae Infections; Herpesvirus 1, Human; Herpesvirus 2, Human; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphadenitis; Vidarabine | 2006 |
Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
Topics: Aged; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2006 |
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Risk; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esophageal Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Cellular; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lichenoid Eruptions; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mucositis; Paraneoplastic Syndromes; Pemphigus; Prednisone; Recurrence; Rituximab; T-Lymphocytes; Vidarabine; Vincristine | 2007 |
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Topics: Alemtuzumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cladribine; Etodolac; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Purines; Rituximab; Spectrometry, Fluorescence; Vidarabine | 2006 |
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Topics: Aged; Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; CD52 Antigen; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Drug Resistance; Glycoproteins; Hemoglobins; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Splenectomy; Treatment Outcome; Vidarabine; Vincristine | 2007 |
Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Deletion; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Toxicity Tests; Treatment Outcome; Vidarabine | 2007 |
Oral fludarabine treatment of cutaneous infiltration in a patient with B-cell chronic lymphocytic leukaemia.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Skin; Treatment Outcome; Vidarabine | 2007 |
17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Chromosome Deletion; Chromosomes, Human, Pair 17; DNA (Cytosine-5-)-Methyltransferases; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine | 2007 |
Advances in CLL.
Topics: Antibodies, Monoclonal; Biomarkers; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Therapy, Combination; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 2007 |
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Red-Cell Aplasia, Pure; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2007 |
Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine.
Topics: Cell Transformation, Neoplastic; Female; Genes, Immunoglobulin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Vidarabine | 2007 |
Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
Topics: Agammaglobulinemia; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Humans; Immunocompromised Host; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Opportunistic Infections; Skin Diseases, Bacterial; Vidarabine | 2007 |
A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Fluorescent Antibody Technique, Direct; Humans; Immunoglobulin A; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Paraneoplastic Syndromes; Pemphigus; Rituximab; Vidarabine | 2007 |
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasms, Second Primary; Rituximab; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2008 |
Acquired hemophilia in chronic lymphocytic leukemia.
Topics: Aged; Autoantibodies; Cyclophosphamide; Factor VIII; Female; Hemophilia A; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Time Factors; Treatment Outcome; Vidarabine | 2007 |
[Ulcers in a patient with chronic lymphocytic leukemia].
Topics: Antimetabolites, Antineoplastic; Ear Diseases; Ear, External; Hand Dermatoses; Herpes Simplex; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Skin Ulcer; Vidarabine | 2007 |
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Topics: B-Lymphocytes; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Models, Biological; Polymerase Chain Reaction; Protein Tyrosine Phosphatases; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Reverse Transcriptase Polymerase Chain Reaction; Sulfites; Vidarabine | 2007 |
Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cross-Linking Reagents; DNA; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrroles; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 2007 |
Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Combination therapies for previously untreated CLL.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Vidarabine | 2007 |
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemistry, Pharmaceutical; Drug Stability; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Mitoxantrone; Solubility; Vidarabine | 2008 |
Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2007 |
Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Genes, p53; Humans; Isoelectric Point; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Mutation; Neoplasm Proteins; Peptide Fragments; Peptide Hydrolases; Phosphorylation; Protein Processing, Post-Translational; Protein Structure, Tertiary; Tumor Suppressor Protein p53; Vidarabine | 2008 |
CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; CD40 Ligand; Cell Proliferation; Cell Survival; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Mice; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine; Tumor Cells, Cultured; Vidarabine | 2007 |
Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.
Topics: Aged; Epstein-Barr Virus Infections; Everolimus; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Vidarabine | 2007 |
Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Opportunistic Infections; Toxoplasmosis, Cerebral; Vidarabine | 2007 |
[Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Treatment Outcome; Vidarabine | 2007 |
Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; DNA-Binding Proteins; Female; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Rituximab; Transcriptional Elongation Factors; Translocation, Genetic; Vidarabine | 2007 |
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prognosis; Purine Nucleotides; Risk Factors; Vidarabine | 2007 |
Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab--double jeopardy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Prognosis; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Male; Middle Aged; Models, Biological; Rituximab; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Aspergillosis; CD52 Antigen; Drug Evaluation; Drug Resistance, Neoplasm; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Records; Netherlands; Opportunistic Infections; Pneumonia, Pneumocystis; Remission Induction; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2007 |
[Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].
Topics: Aged; Amifostine; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Treatment Outcome; Vidarabine | 2007 |
BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-bcl-2; Regulatory Elements, Transcriptional; RNA, Messenger; RNA, Neoplasm; Time Factors; Translocation, Genetic; Vidarabine | 2008 |
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Topics: Aged; Alleles; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Cyclophosphamide; DNA Breaks, Double-Stranded; DNA-Binding Proteins; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine | 2007 |
Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis.
Topics: Adult; Aged; Cohort Studies; Colony-Stimulating Factors; Cyclophosphamide; Female; Finland; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Transplantation, Autologous; Treatment Failure; Vidarabine | 2008 |
Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2007 |
Have we forgotten the purpose of phase III studies?
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD52 Antigen; Chlorambucil; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Research Design; Vidarabine | 2007 |
Cannabinoid receptors expression in bone marrow trephine biopsy of chronic lymphocytic leukaemia patients treated with purine analogues.
Topics: Antineoplastic Agents; B-Lymphocytes; Biopsy; Bone Marrow Cells; Cladribine; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Receptors, Cannabinoid; Vidarabine | 2007 |
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase Inhibitors; Caspases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Mice; Mitochondria; Mitochondrial Proteins; Protease Inhibitors; Receptors, IgE; Signal Transduction; Survival Rate; Tumor Cells, Cultured; Vidarabine; Xenograft Model Antitumor Assays | 2008 |
Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Equilibrative Nucleoside Transporter 1; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Tetradecanoylphorbol Acetate; Vidarabine | 2008 |
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.
Topics: Apoptosis; B-Lymphocytes; Drug Screening Assays, Antitumor; Drug Synergism; Fatty Acids, Nonesterified; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lipid Metabolism; Lipoprotein Lipase; Multigene Family; Neoplasm Proteins; Orlistat; Phospholipases; Proto-Oncogene Proteins c-bcr; Tumor Cells, Cultured; Vidarabine | 2008 |
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Blast Crisis; Cell Cycle; Cell Line, Tumor; Chlorambucil; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperazines; Proto-Oncogene Proteins c-mdm2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Vidarabine | 2008 |
Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.
Topics: Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biomarkers; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Rituximab; Serum Globulins; Vidarabine | 2008 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Thrombocytopenia; Vidarabine | 2007 |
[Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fibroblast Growth Factor 2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vascular Endothelial Growth Factor A; Vidarabine | 2007 |
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Chromosome Deletion; Chromosomes, Human, Pair 17; Drug Resistance, Neoplasm; Enzyme Activation; Female; Free Radical Scavengers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Oxidative Stress; Oxides; Poly(ADP-ribose) Polymerases; Prognosis; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine | 2008 |
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Furans; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Nerve Tissue Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.
Topics: Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Lysophospholipids; Multiple Myeloma; Mutagens; NF-kappa B; RNA, Messenger; Vascular Endothelial Growth Factor A; Vidarabine | 2008 |
Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future.
Topics: Administration, Oral; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Lysis Syndrome; Vidarabine | 2008 |
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Treatment Outcome; Tumor Lysis Syndrome; Urate Oxidase; Vidarabine | 2008 |
Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia.
Topics: Databases, Factual; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine | 2008 |
Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro.
Topics: Antineoplastic Agents; Biological Transport; Bone Marrow; Cell Survival; Cells, Cultured; Chlorambucil; Cladribine; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1995 |
[Fludarabine and fatal hemolytic anemia].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1995 |
CD23 antigen density is related to serum gamma globulin level, bone marrow reticulin pattern, and treatment in B chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Flow Cytometry; Fluorescent Antibody Technique; gamma-Globulins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Prednisolone; Receptors, IgE; Reticulin; Vidarabine; Vincristine | 1994 |
In vitro sensitivity of B-CLL cells to fludarabine and interferons.
Topics: Aged; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cells, Cultured; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Interferon-alpha; Interferon-beta; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1995 |
Remission of leukaemic meningitis after fludarabine.
Topics: Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Meningitis, Aseptic; Remission Induction; Vidarabine | 1995 |
Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Autoimmune Diseases; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Recurrence; Vidarabine | 1995 |
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Bacteremia; Drug Administration Schedule; Female; Fever of Unknown Origin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pneumonia; Remission Induction; Survival Rate; Vidarabine | 1995 |
Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Humans; Interferon-alpha; Interleukin-1; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Necrosis Factor-alpha; Vidarabine | 1995 |
Acute renal failure as a consequence of urine stop flow in a patient with chronic lymphocytic leukemia after treatment with fludarabine.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Renal Insufficiency; Urinary Retention; Vidarabine | 1995 |
Renal failure in a patient with chronic lymphocytic leukaemia treated with fludarabine.
Topics: Acute Kidney Injury; Antineoplastic Agents; Glomerulonephritis, Membranoproliferative; Humans; Kidney Glomerulus; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1995 |
Gentamicin and fludarabine ototoxicity.
Topics: Aged; Antineoplastic Agents; Deafness; Dose-Response Relationship, Drug; Gentamicins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pneumonia; Vidarabine | 1995 |
Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Transfusion Reaction; Vidarabine | 1994 |
Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Purpura, Thrombocytopenic, Idiopathic; Recurrence; T-Lymphocyte Subsets; Vidarabine | 1994 |
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Chromosome Aberrations; Chromosomes, Human, Pair 17; Female; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Sequence Data; Pentostatin; Polymorphism, Single-Stranded Conformational; Survival Rate; Vidarabine | 1995 |
Defective apoptosis due to Bcl-2 overexpression may explain why B-CLL cells accumulate in G0.
Topics: Apoptosis; B-Lymphocytes; Gene Expression Regulation, Leukemic; Humans; Interphase; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 1995 |
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine | 1994 |
2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1994 |
2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1994 |
Late listeriosis after fludarabine plus prednisone treatment.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Male; Opportunistic Infections; Prednisone; Time Factors; Vidarabine | 1994 |
Secondary neoplasms in two patients treated with purine analogues.
Topics: Acute Disease; Aged; Cladribine; Female; Humans; Immunocompromised Host; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melanoma; Neoplasms, Second Primary; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.
Topics: Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Tumor Lysis Syndrome; Vidarabine | 1994 |
Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells.
Topics: Aged; Apoptosis; Cladribine; DNA Damage; Female; Humans; In Vitro Techniques; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Tumor Cells, Cultured; Vidarabine | 1994 |
Fludarabine causing tumour lysis syndrome in chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Tumor Lysis Syndrome; Vidarabine | 1994 |
Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance.
Topics: 2-Chloroadenosine; Aged; Chlorambucil; Drug Resistance; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Time Factors; Vidarabine | 1994 |
Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Survival; Cells, Cultured; Cyclophosphamide; Cytotoxicity, Immunologic; Humans; Immunophenotyping; Interferon-alpha; Interleukin-2; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Tumor Cells, Cultured; Vidarabine | 1994 |
Kaposi's sarcoma in an HIV-negative CLL patient as the cause of thrombocytopenia.
Topics: Aged; Antineoplastic Agents; Biopsy; Blood Platelets; HIV Seronegativity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Radionuclide Imaging; Sarcoma, Kaposi; Skin; Technetium Compounds; Thrombocytopenia; Vidarabine | 1994 |
Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Platelet Count; Recurrence; Vidarabine | 1994 |
Prolonged bone marrow aplasia of refractory prolymphocytoid variant of B-cell chronic lymphocytic leukemia related to fludarabine treatment.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukopenia; Male; Middle Aged; Neutropenia; Vidarabine | 1994 |
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
Topics: Adenosine Triphosphate; Apoptosis; Cladribine; Cycloheximide; Dactinomycin; DNA, Neoplasm; Egtazic Acid; Guanosine Triphosphate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Microscopy, Electron; Puromycin; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Uridine Triphosphate; Vidarabine | 1993 |
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Topics: Antineoplastic Agents; Cladribine; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1993 |
Listeriosis after 2-chlorodeoxyadenosine treatment.
Topics: Aged; Antineoplastic Agents; Cladribine; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Vidarabine | 1993 |
Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Red-Cell Aplasia, Pure; Vidarabine | 1993 |
Cytopenia and fludarabine.
Topics: Adult; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Red-Cell Aplasia, Pure; Vidarabine | 1993 |
Fludarabine and psoriasis.
Topics: Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Psoriasis; Vidarabine | 1994 |
Case report: fatal Staphylococcus aureus sepsis from single-donor platelet transfusion.
Topics: Aged; Antineoplastic Agents; Bacteremia; Blood Donors; Carcinoma, Squamous Cell; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Platelet Transfusion; Skin Neoplasms; Staphylococcal Infections; Staphylococcus aureus; Thrombocytopenia; Vidarabine | 1994 |
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Administration Schedule; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine.
Topics: Aged; Anemia, Hemolytic, Autoimmune; CD4-CD8 Ratio; Coombs Test; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Vidarabine | 1993 |
Listerial brain abscess in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Aged; Antineoplastic Agents; Brain Abscess; Cefotaxime; Drug Therapy, Combination; Gentamicins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Male; Prednisone; Tomography, X-Ray Computed; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 1993 |
Response criteria with fludarabine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1994 |
Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Vidarabine | 1993 |
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia.
Topics: Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Platelet Count; Remission Induction; Vidarabine | 1993 |
Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Brain Diseases; Combined Modality Therapy; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Vidarabine | 1993 |
Complete remission after fludarabine for chronic lymphocytic leukemia.
Topics: Antigens, CD; Antineoplastic Agents; Blotting, Southern; Bone Marrow; DNA, Neoplasm; Drug Administration Schedule; HLA-DR Antigens; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Time Factors; Vidarabine | 1993 |
Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Vidarabine | 1995 |
Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1995 |
Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Polymerase Chain Reaction; Transfusion Reaction; Vidarabine | 1995 |
Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factor 2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Fluorescence; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Tumor Cells, Cultured; Vidarabine | 1996 |
Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
Topics: Adult; Antineoplastic Agents; Cytotoxicity, Immunologic; Flow Cytometry; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocyte Subsets; Tumor Cells, Cultured; Vidarabine | 1996 |
Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1996 |
Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro.
Topics: Antigens, CD19; Apoptosis; B-Lymphocytes; Carrier Proteins; CD5 Antigens; Cladribine; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Neoplasm Proteins; Nucleoside Transport Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; S Phase; Tumor Cells, Cultured; Vidarabine | 1996 |
Transfusion-associated graft-versus-host disease (TA-GVHD) in fludarabine-treated patients: is it time to irradiate blood component?
Topics: Antineoplastic Agents; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Transfusion Reaction; Vidarabine | 1996 |
Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine.
Topics: Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine | 1995 |
2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
Topics: Antineoplastic Agents; Cladribine; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1996 |
Fludarabine treatment and transfusion-associated graft-versus-host disease.
Topics: Antineoplastic Agents; Fatal Outcome; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transfusion Reaction; Vidarabine | 1996 |
Fludarabine treatment and transfusion-associated graft-versus-host disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine | 1996 |
T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; HLA Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Living Donors; Lymphocyte Depletion; Male; Middle Aged; Pancytopenia; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 1996 |
Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role?
Topics: Adult; Antigens, CD; Antineoplastic Agents; Cyclosporine; Flow Cytometry; Follow-Up Studies; Hemoglobins; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Vidarabine | 1995 |
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; DNA, Neoplasm; Endonucleases; Glucocorticoids; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Mitoxantrone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1996 |
Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Count; Cladribine; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Remission Induction; Retreatment; Survival Rate; Treatment Outcome; Vidarabine | 1996 |
Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies.
Topics: Aged; Antineoplastic Agents; Cladribine; Eosinophilia; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Vidarabine | 1996 |
Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Fatal Outcome; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1996 |
Crescentic glomerulonephritis associated with p-ANCA positivity in fludarabine-treated chronic lymphocytic leukaemia.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Antineoplastic Agents; Female; Glomerulonephritis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1996 |
Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.
Topics: Apoptosis; B-Lymphocytes; Cell Line, Transformed; Dactinomycin; DNA Fragmentation; Fibroblast Growth Factor 2; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Vidarabine | 1997 |
Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Melphalan; Middle Aged; Tumor Cells, Cultured; Vidarabine | 1997 |
Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
Topics: Administration, Cutaneous; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Recurrence; Vidarabine | 1997 |
Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1997 |
Chronic lymphocytic leukemia in the elderly population.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prednisone; United States; Vidarabine | 1997 |
Steroid-responsive interstitial pneumonitis after fludarabine therapy.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Cough; Fatal Outcome; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Interstitial; Male; Neoplasm Recurrence, Local; Prednisolone; Prednisone; Respiratory Distress Syndrome; Respiratory Insufficiency; Vidarabine | 1997 |
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.
Topics: Adult; Antineoplastic Agents; Blood Transfusion, Autologous; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 1997 |
Listeriosis after fludarabine treatment for chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Prednisone; Sulfamethoxazole; Trimethoprim; Vidarabine; Vincristine | 1997 |
Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience.
Topics: Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Cause of Death; Drug Evaluation; Fever; Graft vs Host Disease; Hematologic Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Remission Induction; Retrospective Studies; Salvage Therapy; Spain; Survival Analysis; Transfusion Reaction; Treatment Outcome; Vidarabine | 1996 |
In vivo 'purging' of residual disease in CLL with Campath-1H.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Pentostatin; Vidarabine | 1997 |
Flare-up of squamous cell carcinoma of the skin following fludarabine therapy for chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; CD4 Lymphocyte Count; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Skin Neoplasms; Vidarabine | 1997 |
Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 8; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia; Trisomy; Vidarabine | 1997 |
Role of splenectomy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Case-Control Studies; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Neoplasm Staging; Retrospective Studies; Splenectomy; Survival Analysis; Treatment Outcome; Vidarabine | 1997 |
Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia.
Topics: Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1997 |
Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Drug Interactions; Drug Screening Assays, Antitumor; Female; Guanosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Cells, Cultured; Vidarabine | 1997 |
Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations.
Topics: Aged; Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD5 Antigens; Down-Regulation; Female; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymerase Chain Reaction; Tumor Cells, Cultured; Vidarabine | 1997 |
[Successful treatment for advanced and refractory chronic lymphocytic leukemia with fludarabine phosphate].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 1997 |
[Selective aplasia of the red-cell series after fludarabine administration in a patient with chronic B-cell lymphatic leukemia].
Topics: Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Chlorambucil; Cyclophosphamide; Cyclosporine; Doxorubicin; Humans; Hydrocortisone; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methotrexate; Methylprednisolone; Middle Aged; Prednisone; Red-Cell Aplasia, Pure; Vidarabine; Vincristine | 1997 |
P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; bcl-2-Associated X Protein; Chlorambucil; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nuclear Proteins; Polymorphism, Single-Stranded Conformational; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 1997 |
Evans syndrome complicating fludarabine treatment for advanced B-CLL.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Syndrome; Thrombocytopenia; Vidarabine | 1997 |
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Vidarabine | 1997 |
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
Topics: Adult; Apoptosis; Blood Platelets; CD40 Ligand; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fas Ligand Protein; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Membrane Glycoproteins; Up-Regulation; Vidarabine | 1998 |
Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Autoantibodies; Coombs Test; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Temperature; Vidarabine | 1998 |
Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1998 |
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine.
Topics: 2-Chloroadenosine; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Deoxyadenosines; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1998 |
Simple, fast method of detection apoptosis in lymphoid cells.
Topics: Apoptosis; Blood Cell Count; Cells, Cultured; Chlorambucil; Flow Cytometry; Humans; Immunohistochemistry; Interleukin-4; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Reference Values; Scattering, Radiation; Theophylline; Vidarabine | 1998 |
Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tumor Lysis Syndrome; Vidarabine | 1998 |
Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.
Topics: Administration, Inhalation; Adult; Antineoplastic Agents; Antiviral Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Ribavirin; Vidarabine | 1998 |
Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.
Topics: Antibodies, Monoclonal; Apoptosis; CD40 Antigens; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Oligonucleotides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-rel; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 1998 |
Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy.
Topics: Aged; Allantoin; Antimetabolites, Antineoplastic; Diuresis; Drug Evaluation; Female; Humans; Kidney Calculi; Kidney Diseases; Kidney Tubules; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oliguria; Treatment Outcome; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Vidarabine | 1998 |
Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Bone Marrow Cells; Cell Count; Cell Differentiation; Cell Division; Clone Cells; Colony-Forming Units Assay; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Vidarabine | 1998 |
In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues--correlation with clinical course.
Topics: Antineoplastic Agents; Apoptosis; Cladribine; DNA Nucleotidylexotransferase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Phenotype; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1998 |
Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.
Topics: Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Hemolysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Survival Rate; Time Factors; Vidarabine | 1998 |
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Enhancement, Immunologic; Graft vs Host Disease; Graft vs Host Reaction; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine | 1998 |
When prognosis is poor, does false hope add to leukemia patients' pain?
Topics: Adaptation, Psychological; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 1998 |
Chronic lymphocytic leukemia in a patient with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Chronic Disease; Fatal Outcome; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1998 |
Fludarabine and hemolytic anemia in chronic lymphocytic leukemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1998 |
Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Neoplasm Staging; Opportunistic Infections; Prednisone; Retrospective Studies; Risk Factors; Vidarabine | 1998 |
Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine | 1998 |
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Cycle Proteins; Chromosomes, Human, Pair 17; Cyclin-Dependent Kinase Inhibitor p27; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Precursors; Flavonoids; Gene Deletion; Genes, p53; Growth Inhibitors; Humans; In Situ Hybridization, Fluorescence; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Microtubule-Associated Proteins; Neoplasm Proteins; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 1998 |
High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Apoptosis; Chelating Agents; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Egtazic Acid; Enzyme Inhibitors; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Tumor Cells, Cultured; Vidarabine | 1995 |
Fludarabine-related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders.
Topics: Aged; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Humans; Immunosuppressive Agents; Incidence; Infection Control; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Prednisone; Retrospective Studies; Vidarabine | 1998 |
Quantification of apoptosis by the Abbott CD4000 hematology analyzer.
Topics: Apoptosis; Autoanalysis; Cells, Cultured; Female; Flow Cytometry; Hematology; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Theophylline; Vidarabine | 1998 |
In vitro modulation of bcl-2 protein expression, drug-induced apoptosis and cytotoxicity by interleukin-10 in chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Drug Interactions; Drug Screening Assays, Antitumor; Gene Expression Regulation, Leukemic; Humans; Interleukin-10; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 1998 |
Refractory pure red cell aplasia associated with B-CLL: successful treatment with a combination of fludarabine, cyclosporin A and erythropoietin.
Topics: Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Cyclosporine; Erythropoietin; Hemoglobins; Humans; Immunoglobulins, Intravenous; Immunophenotyping; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Red-Cell Aplasia, Pure; Vidarabine | 1999 |
Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cells, Cultured; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1999 |
Chronic lymphocytic leukemia-associated membranous glomerulopathy: remission with fludarabine.
Topics: Antineoplastic Agents; Biopsy; Female; Glomerulonephritis, Membranous; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1999 |
Irreversible renal failure in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Acute Kidney Injury; Antimetabolites, Antineoplastic; Autoantibodies; Erythrocytes; Fatal Outcome; Glomerulonephritis; Humans; Immune Complex Diseases; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Renal Dialysis; Salvage Therapy; Vidarabine | 1999 |
Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Analysis; Vidarabine | 1999 |
Chronic lymphocytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome; Vidarabine | 1999 |
Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Guanosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Cells, Cultured; Vidarabine | 1999 |
Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bryostatins; Cell Division; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured; Vidarabine | 1999 |
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling.
Topics: Alternative Splicing; Antineoplastic Agents; Cyclosporine; Cytokines; DNA-Binding Proteins; Gene Expression Regulation; Humans; Immune Tolerance; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Signal Transduction; STAT1 Transcription Factor; Trans-Activators; Vidarabine | 1999 |
Association between chronic lymphocytic leukemia and sarcoidosis: clinical value of bronchoalveolar lavage.
Topics: Antineoplastic Agents; Bronchoalveolar Lavage Fluid; CD4 Lymphocyte Count; Comorbidity; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Middle Aged; Sarcoidosis; Vidarabine | 1999 |
Fever after cytotoxic therapy of chronic lymphocytic leukemia.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Aztreonam; Candidiasis; Female; Fever; Glycopeptides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Metronidazole; Middle Aged; Monobactams; Vidarabine | 1999 |
Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism.
Topics: Amidohydrolases; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Death; Ceramidases; Enzyme Inhibitors; Gamma Rays; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Myristates; Propanolamines; Protein Biosynthesis; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sphingosine; Vidarabine | 1999 |
Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Vidarabine | 1999 |
Evan's syndrome precipitated by fludarabine therapy in a case of CLL.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Immune Tolerance; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Thrombocytopenia; Vidarabine | 1999 |
Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay.
Topics: Aged; Antineoplastic Agents; Cause of Death; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Survival Rate; Therapeutics; Vidarabine | 1999 |
Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: complete remission of lymphoma with control of autoimmune complications.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Combined Modality Therapy; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transplantation, Autologous; Vidarabine | 1999 |
[Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Treatment Outcome; Vidarabine | 1999 |
Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Vidarabine | 1999 |
In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Leukemic; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1999 |
In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; bcl-X Protein; CD3 Complex; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine | 1999 |
The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Survival; Cladribine; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine | 1999 |
Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Vidarabine | 1999 |
Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP).
Topics: Antineoplastic Agents; Demyelinating Diseases; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Neurotoxicity Syndromes; Vidarabine | 1999 |
Treatment of red cell aplasia in CLL with fludarabine.
Topics: Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Red-Cell Aplasia, Pure; Vidarabine | 1999 |
Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
Topics: Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Pentostatin; Vidarabine | 1999 |
Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chlorambucil; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1999 |
Refractory pure red-cell aplasia associated with B chronic lymphocytic leukemia successfully treated by fludarabine.
Topics: Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Red-Cell Aplasia, Pure; Vidarabine | 1999 |
Successful treatment of lupus with fludarabine.
Topics: Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Male; Middle Aged; Vidarabine | 1999 |
The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Viral; Cyclophosphamide; Dexamethasone; Epstein-Barr Virus Infections; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Opportunistic Infections; Vidarabine; Virus Activation | 1999 |
[Chronic lymphatic leukemia and Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasms, Second Primary; Prednisone; Remission Induction; Vidarabine; Vinblastine | 1999 |
Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclophosphamide; Dexamethasone; DNA Repair; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine | 2000 |
Oochroconis gallopava endophthalmitis in fludarabine treated chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Endophthalmitis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mitosporic Fungi; Opportunistic Infections; Vidarabine | 2000 |
Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
Topics: Aged; Antineoplastic Agents; Biological Transport, Active; Bryostatins; Carrier Proteins; Cladribine; Deoxycytidine Kinase; Dipyridamole; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Male; Membrane Proteins; Nucleoside Transport Proteins; Phosphorylation; Thioinosine; Tumor Cells, Cultured; Vidarabine | 2000 |
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Methotrexate; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate; Vincristine | 2000 |
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Factor Analysis, Statistical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Regression Analysis; Survival Analysis; Vidarabine | 2000 |
Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; DNA Damage; Female; Follicle Stimulating Hormone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Luteinizing Hormone; Male; Middle Aged; Oligospermia; Spermatozoa; Testicular Diseases; Testis; Testosterone; Time Factors; Vidarabine | 2000 |
Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Membrane; DNA Fragmentation; Flow Cytometry; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Phosphatidylserines; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Vidarabine | 2000 |
Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias
Topics: Antineoplastic Agents; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Cladribine; Comorbidity; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pentostatin; Prednisolone; Prognosis; Staining and Labeling; Tumor Cells, Cultured; Vidarabine; Vincristine | 2000 |
A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Cells; Bone Marrow Cells; DNA Primers; DNA, Neoplasm; Gene Duplication; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Hodgkin Disease; Humans; Immunization, Passive; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Oligonucleotide Probes; Polymerase Chain Reaction; Reference Standards; Rituximab; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 2000 |
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
Topics: Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Prednisolone; Probability; Prognosis; Retrospective Studies; Risk Factors; Splenectomy; Survival Analysis; Time Factors; Vidarabine | 2000 |
Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Female; Hepatitis B virus; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Vidarabine; Virus Activation; Virus Replication | 2000 |
Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Pentostatin; Sezary Syndrome; Survival Rate; Vidarabine | 2000 |
Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Membrane; Cell Size; Cells, Cultured; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2000 |
Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Male; Purpura, Thrombocytopenic, Idiopathic; Vidarabine | 2000 |
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Topics: Antineoplastic Agents; DNA Fragmentation; DNA Repair; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; RNA, Neoplasm; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 2000 |
Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium; Calcium Channel Blockers; Calcium Signaling; Chlorambucil; Cisplatin; Cladribine; Cyclosporine; DNA Fragmentation; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nifedipine; Prednisolone; Tumor Cells, Cultured; Verapamil; Vidarabine; Vincristine | 2000 |
Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Membrane; Cell Size; Cladribine; DNA Fragmentation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tumor Suppressor Protein p53; Vidarabine | 2000 |
What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Treatment Failure; Vidarabine | 2000 |
Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Biopsy; Brain; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Stereotaxic Techniques; Vidarabine | 2000 |
CD8 expression on B cells in chronic lymphocytic leukemia: a case report and review of the literature.
Topics: Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Bone Marrow Cells; CD5 Antigens; CD8 Antigens; Fatal Outcome; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, IgE; Vidarabine | 2000 |
Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Treatment Outcome; Vidarabine | 2000 |
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation.
Topics: Antineoplastic Agents; B-Lymphocytes; Clone Cells; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Transplantation, Autologous; Vidarabine | 2000 |
[Fludarabine treatment of chronic lymphoid leukemia].
Topics: Adult; Antineoplastic Agents; Bone Marrow; Disease Progression; Female; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Retrospective Studies; Vidarabine | 2000 |
Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Acute; Neoplasms, Second Primary; Translocation, Genetic; Vidarabine | 2000 |
Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine | 2000 |
Fludarabine therapy in chronic lymphocytic leukemia-associated severe nephrotic syndrome.
Topics: Antineoplastic Agents; Diagnosis, Differential; Female; Glomerulonephritis, Membranous; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nephrotic Syndrome; Proteinuria; Remission Induction; Treatment Outcome; Vidarabine | 2000 |
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Arabinonucleosides; B-Lymphocytes; Cell Survival; Cladribine; Clofarabine; Comet Assay; Deoxyadenosines; DNA Damage; DNA, Mitochondrial; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Potentials; Microinjections; Mitochondria; Time Factors; Tumor Cells, Cultured; Vidarabine | 2000 |
Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2000 |
When and how to treat chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Vidarabine | 2000 |
Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Caspase 3; Caspase Inhibitors; Caspases; Ceramides; Chromatography, Thin Layer; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fumonisins; Glutathione; Humans; Image Processing, Computer-Assisted; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphatidylserines; Sphingomyelins; Tumor Cells, Cultured; Vidarabine | 2000 |
[Progressive multifocal leukoencephalopathy in a patient with chronic lymphatic leukemia treated with fludarabine].
Topics: Aged; Antineoplastic Agents; Biopsy; Brain; Diagnosis, Differential; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Vidarabine | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Red swollen nail folds and nail deformity as presenting findings in chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Fingers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Nails; Nails, Malformed; Skin; Toes; Vidarabine | 2001 |
Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Graft Rejection; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2000 |
Reactivation of hepatitis B virus infection during cytotoxic chemotherapy.
Topics: Acute Disease; Aged; Antineoplastic Agents; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 2001 |
Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD4-Positive T-Lymphocytes; Cells, Cultured; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2001 |
Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Clone Cells; Cyclophosphamide; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Immunoglobulin Heavy Chains; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Lymph Nodes; Neoplasm Proteins; Neoplasm, Residual; Polymerase Chain Reaction; Remission Induction; Sensitivity and Specificity; Treatment Outcome; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Value of Life; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Age Factors; Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Palliative Care; Remission Induction; Vidarabine | 2001 |
Fatal legionella pneumonia after fludarabine treatment in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Fatal Outcome; Humans; Immunocompromised Host; Legionnaires' Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Vidarabine | 2001 |
[Molecular biology examination in chronic lymphocytic leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Time Factors; Vidarabine | 2001 |
Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.
Topics: Antineoplastic Agents; Cytotoxicity, Immunologic; DNA, Antisense; Down-Regulation; Drug Resistance, Neoplasm; Genes, bcl-2; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine | 2000 |
Reversal of fludarabine induced testicular damage in a patient with chronic lymphocytic leukaemia (CLL), by suppression of pituitary-testicular axis using gonadotrophin releasing hormone (GnRH).
Topics: Antineoplastic Agents; Endocrine System; Gonadotropin-Releasing Hormone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pituitary Gland; Sperm Count; Testicular Diseases; Testis; Testosterone; Vidarabine | 2001 |
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Chlorambucil; Drug Resistance, Multiple; Genes, bcl-2; Humans; Interleukin-4; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Prednisone; Proto-Oncogene Proteins c-bcl-2; Spleen; Staurosporine; Thymus Gland; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2001 |
Paraneoplastic pemphigus: an association with fludarabine?
Topics: Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Fluorescent Antibody Technique; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine | 2001 |
Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Prognosis; Retrospective Studies; Survival Analysis; Thymidine Kinase; Treatment Outcome; Vidarabine | 2001 |
[Chronic lymphatic leukemia. 3. The concrete case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Prognosis; Vidarabine | 2001 |
Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Drug Resistance, Neoplasm; Flavonoids; Flow Cytometry; Humans; Lethal Dose 50; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine | 2001 |
Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.
Topics: Adult; Chediak-Higashi Syndrome; Cyclosporine; Fatal Outcome; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; T-Lymphocytes; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Failure; Vidarabine; Whole-Body Irradiation | 2001 |
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Northern; Cisplatin; Complement System Proteins; Cytotoxicity Tests, Immunologic; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Idarubicin; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vidarabine | 2001 |
Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Antineoplastic Agents; Apoptosis; Caspases; Cyclic Nucleotide Phosphodiesterases, Type 4; Down-Regulation; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rolipram; Tumor Cells, Cultured; Vidarabine | 2001 |
Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Retrospective Studies; Treatment Outcome; Vidarabine; Vincristine | 2001 |
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Arabinonucleotides; Clofarabine; Cyclophosphamide; DNA; DNA Repair; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Nucleosides; Time Factors; Vidarabine | 2001 |
Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitric Oxide; Triazenes; Vidarabine | 2001 |
Analysis of recurrent failure times data: should the baseline hazard be stratified?
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rhinitis; Treatment Failure; Vidarabine | 2001 |
Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Topics: 2-Chloroadenosine; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium Channel Blockers; Chlorambucil; Deoxyadenosines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Palatine Tonsil; Protein Kinase C; Staurosporine; Tumor Cells, Cultured; Verapamil; Vidarabine | 2002 |
Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; bcl-X Protein; Drug Resistance, Neoplasm; Female; Fibronectins; Humans; Integrin alpha4beta1; Integrins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Peptide Fragments; Proto-Oncogene Proteins c-bcl-2; Receptors, Lymphocyte Homing; Tumor Cells, Cultured; Vidarabine | 2002 |
High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2002 |
CD80 antigen expression as a predictor of ex vivo chemosensitivity in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; B7-1 Antigen; Deoxyadenosines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2002 |
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Risk Factors; Survival Rate; Vidarabine | 2002 |
Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.
Topics: 2-Chloroadenosine; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nucleosides; Vidarabine | 2002 |
Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine.
Topics: Aged; Diagnosis, Differential; DNA, Viral; Humans; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Polymerase Chain Reaction; Vidarabine | 2002 |
Membranoproliferative glomerulonephritis in association with chronic lymphocytic leukaemia: a report of three cases.
Topics: Adult; Aged; Antineoplastic Agents; Chlorambucil; Drug Therapy, Combination; Female; Glomerular Mesangium; Glomerulonephritis, Membranoproliferative; Humans; Kidney Glomerulus; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Fluorescence; Middle Aged; Paraproteinemias; Prednisolone; Treatment Outcome; Vidarabine | 2002 |
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Topics: Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Computer Systems; DNA, Neoplasm; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neoplastic Cells, Circulating; Polymerase Chain Reaction; Rituximab; Vidarabine | 2002 |
Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Staining and Labeling; Survival Analysis; Vidarabine | 2002 |
Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Follow-Up Studies; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplasms, Second Primary; Rituximab; Time Factors; Vidarabine | 2002 |
Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Chlorambucil; Cladribine; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2002 |
Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Listeriosis; Male; Middle Aged; Prednisone; Retrospective Studies; Vidarabine | 1992 |
Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |
New drugs in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1992 |
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.
Topics: Adult; Aged; Antigens, CD; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; CD5 Antigens; Female; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Gene Rearrangement, B-Lymphocyte, Light Chain; Genes, Immunoglobulin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Male; Middle Aged; Prednisone; Survival Analysis; Vidarabine | 1992 |
Fludarabine and acute tumor lysis in chronic lymphocytic leukemia.
Topics: Acute Kidney Injury; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Lysis Syndrome; Vidarabine | 1992 |
Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1992 |
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Cycle; Cytarabine; Deoxycytidine Kinase; Drug Synergism; G1 Phase; G2 Phase; Humans; Intracellular Fluid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Metaphase; Nucleotides; S Phase; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1992 |
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytarabine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Time Factors; Vidarabine | 1992 |
Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine.
Topics: Antineoplastic Agents; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Pneumonia, Pneumocystis; Tuberculosis; Vidarabine | 1992 |
Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1992 |
Two views of the immunologic effects of fludarabine.
Topics: Antineoplastic Agents; Burkitt Lymphoma; CD4-Positive T-Lymphocytes; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes, Regulatory; Vidarabine | 1991 |
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Synergism; Female; Humans; Hydroxyurea; Infusions, Intravenous; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Vidarabine | 1992 |
Fludarabine approved for use in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1991 |
Fludarabine.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Vidarabine | 1991 |
Fludarabine shows promise for some leukemia patients.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine; Vidarabine Phosphate | 1989 |